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1 Introduction 
1.1 CANCER 
Cancer is one of the most severe health problems in the world. In the United States more than 
1.6 million new cancer cases occurred in 2012 and more than half a million people died from this 
disease (estimated by the American Cancer Society 2012). During the last five years, overall cancer 
incidence rates remained almost stable whereby death rates decreased by 1.8 % per year in men and 
by 1.6 % per year in women. Nevertheless, one in four deaths in the United States is still due to 
cancer. The four leading types of cancer are lung, bronchus, colorectal and prostate for men or 
breast cancer for women. The lifetime probability of developing an invasive cancer is 45 % for men 
and 38 % for women. Cancer cells are characterized by genome instability, which generates the 
genetic diversity that expedites carcinogenesis and tumor cell proliferation; and, inflammation, which 
promotes the multiple hallmark functions of cancer. Tumors exhibit a high level of complexity having 
many distinct cell types, which interact in a heterotypic way. The hallmark functions of cancer 
comprise continuation of proliferative signaling, resistance to cell death, induction of angiogenesis, 
evasion of growth suppressors, enabling of replicative immortality and activation of invasion and 
metastasis [1]. During the last few years, further features have been identified, namely 
reprogramming of energy metabolism and evasion of immune destruction. Most important for the 
survival of tumors is their recruitment of normal cells in order to create a special ‘tumor 
microenvironment’ [2].  
Typical cancer treatment strategies including surgery, chemotherapy and radiotherapy are limited by 
their corresponding serious and often life-threatening side effects, caused by the concurrent killing of 
nonmalignant cells. Furthermore, many tumor cells become resistant to drugs, substantially reducing 
any positive response to the treatment and resulting in a poor prognosis. In addition, surgical 
resection of primary tumors results in high relapse rates due to incomplete removal of tumor cells as 
well as the ineffective control of metastatic disease. Even more life-threatening are tumor stem cells 
since they are the main initiators of tumor cell proliferation and often survive classical treatment 
approaches. Tumor stem cells will often reactivate after therapy leading to a relapse. These facts 
clearly illustrate the strong demand for both more potent and yet more selective, targeted treatment 
options [3,4]. 
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1.2 TARGETED CANCER THERAPY 
Immunotherapeutic approaches have the potential to provide the needed selective, targeted 
treatment options to specifically eliminate malignant cells. Immunotherapy generally involves the 
induction of several mechanisms that interfere with both carcinogenesis and with tumor cell 
proliferation. Active immunotherapy provides a more specialized approach, in which the immune 
system itself is stimulated to remove malignant cells [5,6]. Targeted therapy involves either the direct 
activation or inactivation of (soluble) enzymes, growth factors or surface receptors in signaling 
pathways that are necessary for tumor maintenance and proliferation (e.g. growth factor receptors 
such as EGFR (Epidermal Growth Factor Receptor), Her2, BRAF and Kit) or the indirect targeted 
delivery of effector molecules to tumor cells, leading to growth arrest or remission [7,8]. This may 
involve drugs that penetrate the tumor cell plasma membrane allowing the targeting of intracellular 
tumor antigens, or the use of monoclonal antibodies (mAbs) that target cell surface molecules. Due 
to these different mechanisms of action, the potential of targeted therapies is most promising for the 
treatment of chemoresistant cells. 
Monoclonal antibody therapy (passive immunotherapy) is a rapidly-expanding immunotherapeutic 
treatment platform for cancer. At least 12 therapeutic mAbs for oncologic indications have already 
been approved by the FDA [9] and several more are in clinical development [10]. However, the 
activity of mAbs is limited by their relatively large size, resulting in poor tumor penetration. 
Therefore high doses are needed to effectively compete with serum IgGs, which in turn lead to 
severe side-effects. Furthermore unfavorable Fc receptor polymorphisms can reduce the impact of 
Fc-mediated effector functions. For these reasons, unmodified antibodies are rarely suitable as 
therapeutics [11,12]. 
Several strategies have been developed to enhance the anti-tumor activity of mAbs, including the 
humanization of antibodies [13], the optimization of antibody effector functions [14] and the fusion 
of antibodies to a potent cytotoxic drug. In the early 1900s, Paul Ehrlich considered the idea of a 
‘magic bullet’ forming the basis of the antibody-drug conjugate (ADC); and, immunotoxin (IT) 
concepts in which antibodies or antibody fragments specifically targeting tumor antigens deliver 
cytotoxic payloads and trigger their internalization into abnormal cells [15].  
ADCs usually comprise a full-size antibody chemically linked to a toxin, drug or radionuclide. The 
therapeutic potential of ADCs has been demonstrated in numerous preclinical studies [11,16]. The 
FDA has approved Brentuximab Vedotin, a CD30-directed ADC consisting of the anti-CD30 mAb 
Brentuximab linked to the antimitotic agent monomethyl auristatin E for the treatment of Hodgkin 
lymphoma and anaplastic large cell lymphoma [17]. After binding and internalization this agent binds 
to tubulin which arrests the cell cycle leading to apoptosis of the targeted cells. In 2013, an ADC 
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called Ado-trastuzumab Emtansine (Kadcyla) received FDA approval for treatment of HER2-positive, 
metastatic breast cancer in patients who have already undergone unsuccessful treatment with the 
mAb Trastuzumab (Herceptin) and a taxane. Ado-trastuzumab Emtasine is a conjugate between the 
Trastuzumab portion and a chemotherapeutic molecule called DM1, which attacks the cancer cells 
after Her2 targeting [18]. The FDA also approved Gemtuzumab Ozogamicin (Mylotarg®), a humanized 
anti-CD33 mAb conjugated to calicheamicin for the treatment of acute myeloid leukemia (AML) [19], 
although this has now been withdrawn from the market due to adverse systemic effects.  
1.2.1  Immunotoxins 
ITs comprise an effector domain, which is a naturally-occurring toxin that inhibits protein synthesis or 
induces apoptosis by modifying signal transduction pathways [20,21]. Toxins used in the design of 
conventional highly effective recombinant ITs originate from plants, like Ricin A; or, bacteria, like 
Pseudomonas exotoxin A (ETA) and Diphtheria Toxin (DT). The toxins inhibit protein biosynthesis by 
ADP ribosylation of eukaryotic elongation factor 2, leading to cell death. Cell death-inducing toxins 
use different mechanisms of action than chemotherapeutics. Therefore, ITs are promising for the 
treatment of chemoresistant tumors or residual diseases to achieve for example a ‘chronic’ status of 
the cancer. Furthermore ITs utilize a gentler approach than ADCs which indicates a high potential for 
use in post-remission therapies. In addition, the use of ITs for patients who have endured lengthy 
chemotherapy can result in improved quality of life and better clinical outcomes.  
The first generation of ITs comprised full-size antibodies chemically conjugated to whole-protein 
toxins. These ITs, however, have several drawbacks, including lack of specificity, poor stability, and 
the tendency to be heterogeneous. Improvements were necessary. Investigation of protein structure 
and function showed the presence of discrete cell binding domains within the toxins and led to the 
design of the next generations of ITs. In second generation ITs, these cell binding domains were 
removed, thereby diminishing the binding to normal cells. Third generation ITs were generated via 
recombinant DNA techniques resulting in truncated toxins genetically linked to shorter antibody 
fragments (scFv), leaving only the antigen binding variable domains of an antibody, or natural 
ligands. These improvements yielded ITs having small size and diminished immunogenic response, 
resulting in easier manufacturing, better tumor penetration and increased stability [22].  
The selection of proper target molecules specific for tumor cells is one of the challenges in targeted 
cancer therapy. But, advancements in phage display technology and protein engineering have 
enabled and improved the selection and generation of high-affinity targeting residues [23].  
Early generation ITs have shown promising results in in vitro studies and preclinical tests and have 
also been tested in a small number of clinical trials [24]. The most prominent example is Denileukin 
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Diftitox (Ontak®), a recombinant IT comprising DT and interleukin-2 (IL-2), which has been approved 
by the FDA for the treatment of T-cell lymphoma [25].  
However, the major limitation of clinical deployment of these early generation ITs is that they are 
limited by their immunogenicity since they have non-human components. During long-term cancer 
treatment requiring repeated doses, these components can induce neutralizing antibodies in patients 
with a functional immune system. A murine origin of the binding moiety for example induces a 
human anti-mouse antibody (HAMA) response in some patients. HAMA responses not only reduce 
treatment efficiency, but also have been shown to cause allergic reactions, in extreme cases leading 
to life-threatening complications such as renal failure [26]. 
These issues reduce the therapeutic potential of these early ITs. The complete humanization of ITs is 
therefore an important criterion for the development of fourth-generation molecules called human 
cytolytic fusion proteins (CFPs) [4]. 
1.2.2 Humanization of immunotoxins 
 There are several strategies that can be used to humanize the tumor-selective ligand. For example, 
the effector moiety can be fused to human cytokines or growth factors that target tumor receptors, 
e.g., IL-2, IL-4, EGF (epidermal growth factor), TGFα (tumor growth factor alpha) or the CD30 ligand 
[24]. Recombinant DNA technology can also be used to engineer antibodies for reduced 
immunogenicity. Chimeric antibodies comprising a murine Fab fragment and a human Fc region can 
reduce HAMA responses, because the constant region makes the most significant contribution to 
immunogenicity. Another strategy is the generation of humanized antibodies by grafting murine 
complementarity determining regions (CDR) onto human V-region frameworks, an approach known 
as CDR replacement [27]. Complete humanization is also possible by selecting the V-regions from 
human antibody libraries or using transgenic knock-out mice or rats in which the gene loci for the 
light and heavy antibody chains are replaced by their human counterparts [28]. ScFv antibodies used 
for the production of CFPs can be derived from humanized or human monoclonal antibodies or 
selected directly from a human scFv library [4]. 
There are a number of approaches that can be used to decrease the immunogenic responses of ITs 
caused by the cell-death inducing domains found in bacterial or plant toxins. For example, the T or B 
cell epitopes of ETA can be modified and ITs can be derivated by polyethylene glycol or 
immunosuppressive agents can be co-applied [29,30]. A more favorable approach to achieve 
complete humanization uses human cytolytic proteins, such as enzymes that induce cell death by a 
variety of mechanisms. Pro-apoptotic human proteins that are potentially useful for targeted cancer 
therapy include RNases such as angiogenin as well as death receptor ligands such as sTRAIL (tumor 
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necrosis factor (TNF) -related apoptosis-inducing ligand) and Fas ligand and pro-apoptotic members 
of the Bcl-2 family [31]. In addition, enzymes with tumor suppressive functionality, such as DAPK2 
(death-associated protein kinase 2), allow targeted restoration of tumor suppressor activity in cancer 
cells [4]. Granzymes (serine proteases released by cytoplasmic granules within cytotoxic T 
lymphocytes (CTLs) and natural killer (NK) cells) are another prominent group of human pro-
apoptotic molecules. 
 
1.3 GRANZYMES 
Cytotoxic granules contain a variety of granule-associated proteases. The secretion of cytotoxic 
granules is the primary defense against virally infected and malignant cells. Among these granule-
associated proteases are granzymes, serine proteases, which play a significant role in this defense. 
Five different human granzymes (A, B, H, K and M), each with unique species-dependent expression 
patterns and substrate specificities have been discovered [32,33]. Granzymes promote apoptosis; 
and regulate B-cell proliferation, the cleavage of extracellular matrix proteins, the induction of 
cytokine secretion, the activation of cytokines and the control of viral infections [34]. The main focus 
of this study was granzyme B and granzyme M. 
1.3.1 Granzyme B 
Recombinant granzyme B is the most important and well-studied member of the human granzyme 
family. Its inherent pro-apoptotic activity has been demonstrated in vitro in several proof-of-concept 
studies including Stahnke et al. (AML), Liu et al. (melanoma), Dalken et al. (breast carcinoma) and 
Kanatani et al. (ovarian, breast, endometrial and prostate carcinoma) (Table 9). Granzyme B is also 
the most powerful pro-apoptotic member of the serine proteases stored as a macro-molecular 
complex with the proteoglycan serglycin and the pore forming protein perforin within CTLs and NK 
cells [35]. During NK cell mediated immune surveillance, secretory granules are depleted into the 
immunological synapse formed after specific recognition of abnormal cells via an elaborated 
repertoire of cell surface receptors [36]. The precise mechanism by which granzyme B is taken up 
into cells and released from the endosome into the cytosol is still controversial. Two possible models 
for delivery of granzyme B into target cells, which have been reviewed recently, are an endocytosis 
dependent mechanism of vesicle disruption or a direct pore-mediated delivery of the apoptosis 
inducing cargo. Following the recognition of the target cell, granules release their cytolytic content 
into the immunological synapse that directs granzyme B, most likely by the assistance of perforin, to 
the target cell’s cytosol [37]. Once released, granzyme B recruits multiple signal transduction 
pathways to fulfill its death inducing function. 
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The classical apoptosis induction by granzyme B is comparable to the Fas mediated pathway. It 
involves the cleavage of several executive and downstream caspases and is mediated by both the 
caspase-pathway and the BID (BH3-interacting domain death agonist) -pathway. Direct activation of 
the effector caspase 3 is controlled by the inhibitor of apoptosis protein (IAP) that has to be 
inactivated by e.g. HtrA2/OMI, a pro-apoptotic molecule released from disrupted mitochondria (see 
below). Successful processing of pro-caspase 3 leads to the cleavage of several downstream death 
substrates including the inhibitor of the caspase-activated DNase (CAD) ICAD, poly(ADP ribose) 
polymerase (PARP), DNA-dependent protein kinase (DNA-PK), the nuclear mitotic apparatus protein 
(NuMA) and the nuclear-envelope intermediate-filament protein lamin B. This results in the typical 
morphological changes associated with classical apoptosis, i. e. DNA fragmentation, chromatin 
condensation, membrane blebbing, cell shrinkage and the formation of apoptotic bodies. The 
activation of the BID pathway, either directly by granzyme B or indirectly via the activation of 
caspase-8, leads to the cleavage of mitochondrial BID involving BAX (BCL-2-associated X protein) and 
BAK (BCL-2 antagonist). The translocation of tBID (truncated BID) to the mitochondria results in the 
permeabilization of the outer mitochondrial membrane and thus mitochondrial depolarization and 
the subsequent release of cytochrome c (cyt c) and other pro-apoptotic molecules like endonuclease 
G and HtrA2/OMI. Cyt c presence in the cytosol is crucial for the apoptosome formation by assembly 
to the apoptotic protease activation factor APAF-1 which in turn leads to autocatalytical activation of 
pro-caspase-9 and subsequent processing of the effector caspase-3. In addition to the BID-mediated 
loss of mitochondrial transmembrane potential, granzyme B can directly induce mitochondrial 
depolarization without the assistance of cytosolic mediators, but the exact mechanisms remain 
unclear [4,38]. 
Granzyme B is also known as ‘Asp-ase’ because it cleaves downstream of aspartic or glutamic acid 
residues giving it substrate specificity similar to that of caspases. Consequently, granzyme B can 
directly target and activate the downstream caspase substrates ICAD, PARP, DNA-PK, NuMA and 
lamin B. Taken together, these modes of action show that granzyme B is not only a highly potent 
inducer of apoptosis due to its status as the major mediator of cellular immunity, but also because of 
its ability to induce apoptosis at multiple levels using distinct pathways. Thus granzyme B has the 
potential to circumvent anti-apoptotic mechanisms of the tumor cells, as described below (1.4) [4]. 
Recombinant expression of granzyme B has been proven successful in different expression systems 
of pro- and eukaryotic origin including Escherichia coli (E. coli), Pichia pastoris (P. pastoris), insect 
cells and mammalian cells such as HEK293T, HeLa, Jurkat and COS [4,37]. To be active granzyme B 
requires a free N-terminus. The native enzyme is expressed as an inactive zymogen containing an N-
terminal prepro-leader sequence. The signal peptide is cleaved by a signal peptidase in the 
endoplasmic reticulum to produce an inactive proenzyme with an N-terminal pro-peptide, protecting 
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the cell from the induction of apoptosis, thus the pro-peptide must be removed to generate an active 
protease [39]. In the Golgi apparatus, a mannose-6-phosphate tag is attached which directs 
granzyme B to the cytotoxic granules. Here the pro-peptide is removed by the dipeptidyl peptidase I 
(DPPI) (also known as cathepsin C) [40]. Several strategies have been developed to accomplish the 
correct in vitro or in vivo processing and activation of recombinant granzyme B, including the here 
applied insertion of an enterokinase cleavage site (ECS) upstream of the sequence of the mature 
granzyme B polypeptide, allowing activation after purification by in vitro processing. Secretory 
expression of the active protein in P. Pastoris can be achieved by the direct N-terminal fusion of the 
mature polypeptide to the Saccharomyces cerevisiae (S. cerevisiae) mating factor α prepro-leader 
sequence allowing activation by local Kex2-protease. Secretion and functional in vivo activation by a 
host cell signal peptidase has been achieved in insect cells and COS cells using the native sequence of 
the granzyme B precursor protein with the propeptide deleted, or the genetic fusion of a furin 
recognition motif allowing in vivo processing by endogenous P. pastoris furin-like proteases. In 
addition, in vitro and in vivo activation has been achieved by either co-expression of rat DPPI in COS 
cells or subsequent incubation with bovine spleen DPPI [4]. 
The crystal structure of granzyme B has been elucidated before by two groups [41,42]. As for all 
proteases, the catalytic activity of granzyme B depends on a serine residue at the active site, one of a 
triad of residues corresponding to His57, Asp102 and Ser195 in chymotrypsin. The key residue for 
contact with the P11 substrate residue is Arg226 [34]. The optimal tetrapeptide recognition motif (P4-
P1) is IEPD, which is similar to that of caspase 8 and caspase 9 and thereby reflects their common 
role in the activation of downstream caspases such as caspase-3 [42]. 
1.3.2 Granzyme M 
Granzyme M is classified as ‘Met-ase’ since it cleaves specifically after amino acids with long aliphatic 
side chains such as methionine, leucine, or norleucine at the P1 position1 [43]. It is predominantly 
expressed within NK cells, NKT cells, γd-T cells and CD8+ effector T cells [44,45]. Recently, it was 
shown that granzyme M is involved in TLR4-driven inflammation and endotoxicosis, and as such it 
contributes to the inflammatory response to bacterial lipopolysaccharide by inducing serum 
cytokines such as interferon (IFN) γ, IL-1α, IL-1β and TNF α [46]. However, the exact mechanism 
remains unclear. 
Many groups have reported the cytotoxic efficacy of granzyme M towards tumor cells [47,48]. 
However, the precise molecular mechanism remains controversial in the literature. It has been 
                                                           
1  The active sites in enzymes can be divided in subsides (S) which consist of single amino acids.  
The corresponding positions (P) of the substrate have the same numbering as the subsides they occupy. The 
positions are counted from the point of cleavage. P1 is the primary determinant of specificity. 
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described that granzyme M activates a caspase-dependent pathway involving cleavage of ICAD, 
poly(ADPribose) polymerase (PARP), heat shock protein 75 (HSP 75), survivin and ezrin as well as the 
Fas-associated protein with death domain (FADD), but not Bid [49-52]. Thus, as described for 
granzyme B, classical mechanisms of apoptosis are triggered such as phosphatidyl serine (PS) 
exposure, mitochondrial swelling and loss of mitochondrial transmembrane potential, cyt c release, 
and reactive oxygen species (ROS) production. Other groups did not report those effects, but rather a 
caspase-independent form of cell death which is not blocked by Bcl-2 expression [53-55]. Other 
substrates of granzyme M can be nucleophosmin [54] and α-tubulin leading to a disruption of the 
microtubule network [53]. Granzyme M also specifically cleaves the granzyme B inhibitor PI-9 [56], 
therefore the application of this enzyme increases the potential to kill even immune-resistant tumor 
cells, particularly when applied in combination with granzyme B (see 1.4).  
As with granzyme B, granzyme M requires a free N-terminus for enzymatic activity. Recombinant 
expression of the active protein has so far only been reported to be successful in the eukaryotic 
expression system P. pastoris featuring the S. cerevisiae mating factor α prepro-leader sequence as 
described above for granzyme B (1.3.1). 
 
1.4 TUMOR ESCAPE MECHANISMS TO EVADE IMMUNOSURVEILLANCE 
There are many examples of the immune system operating as a significant barrier to tumor 
formation and progression, especially with non-virus-induced cancer types [57]. This has been proven 
by experiments where mice that are deficient in various components of the immune system (e.g. 
missing functions of CTLs and NK cells) have increased tumor development [58]. This is further 
illustrated in patients with colon and ovarian tumors where prognosis was better if the tumors were 
heavily infiltrated with CTLs and NK cells [59].  
However, there is also evidence that tumor cells are able to escape the body’s immune surveillance, 
thus avoiding this barrier to tumorigenesis and tumor progression. Infiltrating immune cells can bind 
to cancer cells and thereby take the place of the tumor’s disconnected epithelial surrounding cells, 
allowing them to survive in ectopic microenvironments by suppression of cell death pathway 
stimulation [2]. Furthermore, actively immunosuppressive tumors can recruit infiltrating immune 
cells, which comprise regulatory T cells and myeloid-derived suppressor cells. Both types are 
suppressive towards the activity of CTLs.  
Another example of an escape mechanism of tumor cells is the secretion of immunosuppressive 
factors such as TGF-β leading to paralysis of CTLs and NK cells [60]. In several studies on breast 
cancer it was also shown that tumor-associated macrophages provide survival signals to cancer cells 
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such that tissue-protective and therapy-induced mechanisms no longer trigger cell death [61]. Tumor 
cells’ strategies to overcome innate and adaptive immune responses also include impaired tumor 
antigen presentation by the downregulation of MHC class I molecules, and the expression of factors 
that either directly kill or inhibit effector cells or recruit regulatory T-cells and thereby induce 
immunotolerance [62]. In addition, tumors can regulate apoptosis by the overexpression of different 
classes of anti-apoptotic proteins. For example, FLICE-inhibitory proteins (FLIPs) interfere with signal 
transduction by death receptor pathways, anti-apoptotic proteins of the Bcl-2 family regulate 
apoptosis at the mitochondrial level and IAP (inhibitors of apoptosis proteins) family members inhibit 
caspase activity [4]. Another escape mechanism from immune response, which is discussed in detail 
in chapter 1.4.1, is displayed by the expression of serpin B9 (PI-9) in many tumor cells. PI-9 is the 
main inhibitor of granzyme B (1.3.1). 
Over the last decade the importance of cancer stem cells has also been discussed (1.1), noting that 
tumors are maintained by their own stem cells. Central for this concept is the observation that not all 
tumors cells are equal. Conventional therapeutic approaches like chemotherapy or radiation may kill 
the majority of the tumor cells, but rare cancer stem cells may be able to survive and later multiply. 
Additionally, quiescent tumor cells that have drifted to distant sites, will avoid removal by curative 
surgical treatment of a primary tumor and this may be responsible for metastasis that can appear 
many years after the surgical treatment [63].  
The above described new findings, especially the complexity of the tumors, and the presence of 
infiltrating immune cells and the maintenance of the tumors by cancer stem cells are connected with 
unfavorable clinical outcome [2], greatly influence the development of new treatment approaches 
against human cancer. Development of new treatment approaches requires consideration of the 
many different aspects and influences within the tumor microenvironment. These aspects and 
influences show that combinatorial therapies will be more and more important in eliminating as 
many of these multiple characteristic malignant cells as possible, including the ‘heart’ of the tumor - 
cancer stem cells. Therapeutics comprising multiple apoptosis induction mechanisms are highly 
advantageous to overcome the resistance of tumors and to eliminate residual malignant cells.  
1.4.1 The granzyme B inhibitor PI-9 
As mentioned above, the expression of the granzyme B inhibitor PI-9 plays an important role in one 
tumor cell escape mechanism from immune response (1.4). PI-9 is a member of the clade B serpin 
superfamily, a group of structurally-related proteins that regulate proteases in the vertebrate 
adaptive and innate immune systems [64,65]. Since granzymes are an integral component of the 
human immune system they are tightly controlled at the posttranslational level by serpins. PI-9 is the 
best-known granzyme-regulating serpin. This 42 kDa protein accumulates in the cytosol of 
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lymphocytes to avoid self-inflicted injury caused by granule leakage and the subsequently 
misdirected activity of granzyme B. Cells at immune-privileged sites therefore express PI-9. These 
sites include the lens capsula, ovaries, placenta, testes and embryonic stem cells [66,67]. The 
inhibition of granzyme B by PI-9 involves a stoichiometric interaction, leading to the irreversible 
inactivation of both the enzyme and the inhibitor [4]. Many studies have focused on the expression 
profile of PI-9 within different cell types and its induction by different stimuli (see also 4.2). In 
addition to effector T cells, PI-9 is expressed by inflammatory cells [68] and in human peripheral 
blood mesenchymal stem cells [69]. It is also present in cells infected by cytomegalovirus (CMV), 
Epstein-Barr virus (EBV) and the BK polyomavirus [70-72] as well as in endothelial, mesothelial cells 
[73] and dendritic cells [66]. PI-9 can be induced in different cell lines by nuclear factor κB (NFκB), 
activator protein-1 (AP-1), as well as pro-inflammatory cytokines such as TNFα, and 
lipopolysaccharides [68,72,74]. It is also induced by phorbol myristate acetate and IL-2 in CD8+ T cells 
[75,76], by viral dsRNA sensors in human renal tubular epithelial cells [70] and by estrogens and 
estrogen receptor-α in breast cancer cells [77]. The expression of PI-9 in renal tubular cells is 
upregulated following renal allograft rejection, suggesting that its induction could be used to confer 
resistance against granzyme B-mediated cytotoxic effects leading to improved graft survival [78].  
The widespread expression of PI-9 has to be taken into account when developing therapeutic 
strategies based on granzyme B, particularly because malignant cells can also involve multiple 
mechanisms to escape the pro-apoptotic signals induced by CTLs and NK cells [79]. Hence, many 
studies have reported a direct correlation between the presence of PI-9 and a reduced pro-apoptotic 
granzyme B activity [64,80]. Examples for tumor cells that have been found to express PI-9 to 
circumvent immune response and therefore might be resistant to granzyme B based 
immunotherapeutics are summarized in Table 10 and Table 11. In addition, high expression of PI-9 
has been discussed in context of poor clinical prognosis (compare 4.2). 
The crystal structure of PI-9 has not been elucidated yet, but serpins share a characteristic 
metastable structure and efficient inhibitory activity [65]. The three-dimensional structure comprises 
nine α-helices, three β-helices and a variable reactive center loop (RCL), which is the primary site of 
interaction with target proteases and is therefore critical for serpin specificity. Members of this 
protein family have high sequence homology in a region of about 350 amino acids and are presumed 
to have structural similarity [81]. The amino acid residues in the RCL of PI-9 are necessary for its 
activity and the residue at the P1 position is a glutamic acid [82,83], explaining its specificity for 
granzyme B which favors acidic P1 amino acids (1.3.1). The RCL of serpins acts as a pseudo-substrate, 
which is recognized by the protease so the two molecules dock and form a reversible ‘Michaelis 
complex’ (initial enzyme-substrate complex) (Figure 1). Rapidly, the protease cleaves at the favored 
P1 position resulting in major structural rearrangements within the serpin that involve alternative 
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Today HL is sub-divided according to differences in morphology and phenotype of the cells and the 
composition of the cellular infiltrate into classical HL (cHL, 95 % of all cases) and nodular lymphocyte-
predominant HL (NLPHL, 5 % of all cases) [91]. CHL is further classified into nodular sclerosis, mixed 
cellularity, lymphocyte depletion and lymphocyte-rich HL lymphoma. HRS cells of cHL probably 
originate from germinal center B cells that have acquired disadvantageous immunoglobulin variable 
chain gene mutations which usually results in cell death. Lymphocytic and histiocytic cells of NLPHL 
apparently derive from antigen-selected germinal center B cells. Only a few cases of cHL originate 
from T cells. The extent to which the cHL cells undergo reprogramming of gene expression is unique 
among human lymphomas. They succeed in expression of multiple genes that are actually typical for 
other types of cells within the immune system and lose the expression of most B cell-typical genes 
[92]. NFkB, a key anti-apoptosis factor in HL, is one of the signaling pathways and transcription 
factors that are de-regulated within HRS cells [93]. This transcription factor is activated by various 
external stimuli of which many trigger inflammation as well. Its inactive form is present in the 
cytoplasm of almost every cell type, bound to an inhibitory protein called IkB, of which IkBα is the 
best studied. Upon stimulation of NFkB, IkB kinases are activated which lead to phosphorylation and 
ubiquitin-mediated degradation of IkB, so active NFkB is released. NFkB activity comprises its 
translocation into the nucleus where it induces the expression of dozens of different genes involved 
in cellular processes as diverse as the immune system, in inflammation, cell proliferation, and 
inhibition of apoptosis as well as in angiogenesis, invasion and metastasis [94,95]. Recent studies 
showed that the constitutive activation of NFkB in chronic inflammation is a central molecular link 
between inflammation and cancer development [96]. NFkB was found to be expressed in many HL 
cell lines as well [93]. Discussions are ongoing if stimulation of CD30, a receptor highly over-
expressed on HL cells, activates NFkB, leading to increased resistance of the cells towards apoptosis 
[97-100].  
Other hypotheses on how HRS cells circumvent immune attack by CTLs or NK cells include the 
formation of an inflammatory microenvironment resulting from the attraction of many nonmalignant 
inflammatory cells into the lymphoma tissue. Thus, unlike most other human malignancies, the HRS 
cells are vastly outnumbered by the surrounding nonmalignant inflammatory cells. 99 % of the tumor 
mass consists of reactive inflammatory cells (lymphocytes, histiocytes, eosinophils, fibroblasts, 
neutrophils, plasma cells) [96]. Thus, the histological appearance is reminiscent of an inflammatory 
process as seen for viral infections, which supports the widely accepted finding of a causative role of 
EBV infection in HL in epidemiological studies. In 40 % of cHL cases in the western world, HRS cells 
contain EBV [101,102].  
HL is one of the most curable cancer types. In recent years combinatorial treatment approaches 
using chemotherapy and radiation therapy have led to promising cure rates. The estimated 5- and 
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10- year relative survival for patients with HL is 85 % and 80 %, respectively [103,104]. However, 
patients suffer from high toxicity of current therapeutic regimens and in addition there are still 
patients that relapse even after autologous hematopoietic stem-cell transplantation which is 
reserved for patients with recurrent or progressive HL after failure of conventional therapy. Those 
patients have bad prognosis and limited therapeutic options. Hence, efforts have been made to find 
alternative therapies for those resistant cancer subtypes.  
The CD30 receptor is an activation-induced antigen that is predominantly expressed on lymphoid 
cells. CD30 has been shown to be over-expressed on malignant cells of HL, anaplastic large cell 
lymphoma (ALCL) and adult T cell leukemia. Therefore it is a promising target for the treatment of 
those HL patients which do not respond to standard therapy [105,106]. CD30 is a glycosylated type I 
transmembrane protein and belongs to the TNF receptor superfamily [107]. It can be proteolytically 
cleaved in close proximity to the cell membrane by the membrane-anchored metalloproteinase TNF-
α converting enzyme (TACE), leading to the release of the soluble ectodomain of CD30. This is found 
at low levels in the serum of healthy donors but is detected at elevated levels in patients suffering 
from CD30-positive neoplasms, viral infections, and autoimmune disorders. Hence, in most cases the 
level of soluble CD30 provides a prognostic marker [108].  
The most recent novel immunotherapeutic agent that targets CD30 is the above mentioned 
Brentuximab Vedotin (1.2.1) for the treatment of HL patients that have not responded to prior 
chemotherapy or autologous stem cell transplantation. Other immunotherapeutic agents targeting 
this receptor have been described in context of in vitro, pre-clinical and clinical studies. Apart from a 
CFP consisting of the human RNase angiogenin and the natural ligand of CD30 (CD30L) [109] there 
are several other anti-CD30 human IL-2 fusion proteins that have Ber-H2(scFv), among others, as a 
binding domain [110]. In addition the construct Ki4(scFv)-ETA’, which as with Ber-H2(scFv), does not 
bind soluble CD30 receptor and even prevents shedding [111], has shown promising results in vitro 
and in vivo [112]. However, it has the disadvantage of containing a toxic compound of non-human 
origin that has the potential to provoke undesirable immune responses. Therefore, fusion to human 
effector molecules would be advantageous. 
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1.6 CHRONIC AND ACUTE MYELOMONOCYTIC LEUKEMIA AND THE CD64 
RECEPTOR 
Chronic myelomonocytic leukemia (CMML) is one of the three rare myeloid neoplasms termed 
myelodysplastic/ myeloproliferative diseases according to the World Health Organization (WHO). 
This clonal hematopoietic stem cell disorder is characterized by persistent monocytosis in peripheral 
blood, at least one dysplasia component within the bone marrow and a percentage lower than 20 % 
of promonocytes and blasts in peripheral blood and bone marrow [113]. It can be further classified 
depending on the amount of blasts into CMML 1 (< 5 % blasts in peripheral blood, < 10 % blasts in 
bone marrow) and CMML 2 (< 20 % blasts in peripheral blood, 10 - 19 % blasts in bone marrow) 
[114]. CMML mainly occurs in elderly people with median survival of 15 – 20 months and leukemic 
transformation rates in 15 – 30 % (both depending on type 1 or 2) [115]. Other diagnostic criteria 
include immunophenotyping, whereby CMML and monocytic AML show overlapping antigen 
expression patterns. Only the expression of CD56 combined with underexpression of a myeloid 
marker like CD15 or CD13 seems to be unique to CMML monocytes [116]. Furthermore an over-
expression of CD33 [117,118] and also of CD14 on marrow monocytes was found in CMML compared 
to reactive monocytosis and normal marrow samples [116]. In addition, clonal cytogenetic 
abnormalities are found in 20 – 40 % of patients with CMML, but none is specific [119-121]. The close 
similarity among the other myelodysplastic/ myeloproliferative diseases such as atypical chronic 
myeloid leukemia (CML) and juvenile myelomonocytic leukemia (JMML) means a constant challenge 
for diagnosis as well as the appropriate therapy. New molecular markers have been described in 
recent years such as mutations in TET2 (Tet Methylcytosine Dioxygenase 2) or CBL (Casitas B-lineage 
Lymphoma) [122]. However, these aberrations are non specific for CMML and no targeted therapies 
are available for these genetic changes today. Because of this and its rare occurrence, the 
establishment of new therapeutic approaches specific to CMML is difficult. 
Conventional treatment of CMML is very heterogeneous. It usually starts with the ‘watch and wait 
strategy’. The only curative approach for CMML is allogeneic hematopoietic stem cell 
transplantation, but this treatment option is often not applicable in patients affected by CMML due 
to the age distribution of the disease. Actually, the gold standard treatment is to decrease the 
amount of white blood cells in peripheral blood in the beginning with low dose cytarabine, 
hydroxycarbamide or etoposide. Another option is supportive care with transfusion. Depending on 
the variant of the disease, compounds which had been used to treat myelodysplastic syndrome were 
explored for usage in CMML, especially the demethylating agents azacytidin und decitabin, 
topoisomerase inhibitors such as valproic acid and farnesyltransferase inhibitors like lonafarnib. 
However, information on the significance of these drugs is very limited due to the rare occurrence of 
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CMML [123]. In patients with CMML 2, a treatment with DNA methyltransferase-inhibitors has also 
been shown to be effective by reducing the rate of transformation into AML and to reduce the 
transfusion need. However approaches based on molecular or biological characteristics of the 
disease are urgently needed [123]. Those new treatment strategies are unmet medical need for 
these patients. 
In some patients with a history of CMML, the disease converts into acute myelomonocytic leukemia 
(AMML) which is also called AML-M4, the fourth sub-category of AML according to FAB (French-
American-British) classification. This disease is diagnosed in 15-20 % of all AML cases. It occurs in all 
age groups, but is more common in older adults, and is initially treated with chemotherapy. AML-M4 
cases have a population of < 20 % myeloblasts and monoblasts and < 80 % of total nucleated cells are 
monoblasts. As indicated above, the expression patterns of AMML do not distinguish significantly 
from those of CMML. In general, myeloblasts express CD13, CD33, CD34 and CD117 whereas 
monocytoid cells including monoblasts and promonocytes express CD11b, CD11c, CD13, CD14, CD33 
and CD64 [114,118]. Treatment of AMML includes usually intensive multidrug chemotherapy and in 
some cases allogeneic hematopoietic stem cell transplantation. 
Treatment approaches of other leukemic diseases such as AML comprise targeting of the 72 kDa 
glycoprotein CD64, the high affinity receptor for human IgG (Fc γ receptor I, FcγRI), which is 
expressed on cells of the myeloid lineage, i. e. monocytes, macrophages and dendritic cells, but is 
also over-expressed on the surface of leukemic cells [124,125]. The corresponding cells can be 
activated by several cytokines, such as IFNγ, which plays a crucial role in inflammatory responses. It 
also leads to a 5- to 10-fold increase of CD64 expression as well as enhanced receptor activity [126], 
whereby the amount of CD64 receptors is no prime requisite for sensitivity of the cells, but rather 
their activation state. This means that an increased CD64 expression is not necessarily accompanied 
by a greater sensitivity to cell-death inducing agents, but rather their corresponding activation via 
e.g. IFNγ [127,128]. The advantages of CD64 for targeted delivery of cytotoxic effector molecules 
include its highly efficient internalization rate and its limited expression, so normal, non-activated 
CD64-expressing cells are not affected by the fusion proteins [127,129,130]. The specific killing of 
target cells via CD64 can be accomplished by the fusion of cell-death inducing moieties to H22(scFv), 
a humanized single chain antibody fragment [131,132]. The potential of fusions of H22(scFv) to both 
Ricin A and ETA' as therapeutic agents against AML or inflammatory cells has been shown previously 
[129,133] as well as the efficacy of Gb-H22(scFv) against AML cell lines and primary cells (Table 9).  
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1.7 MOLECULAR MODELING 
Molecular modeling can be applied to model or mimic the behavior of molecules and for studying the 
interaction between more than one molecule and large molecular systems. The underlying features 
of the computational calculations use atoms as the smallest individual unit. Alanine scanning is a fast 
computational approach for the prediction of energetically important amino acid residues in protein-
protein interfaces [134,135]. To determine the role of a specific side chain group of a specific residue, 
systematic mutations to alanine are performed. Alanine has a small and inert functional group; 
therefore it is possible to measure the effect of the deletion of potential crucial side chains. The 
output is a list of ‘hot spots’ or amino acid side chains that are predicted to significantly destabilize 
the interface when mutated to alanine [136]. Despite the large size of binding interfaces, single 
residues can contribute to a large fraction of the binding free energy in an interface [134]. The 
disadvantages of alanine scanning are that it does not allow the investigation of the impact of 
mutations other than alanine; it does not include hydration at the protein-protein interface in spite 
of the fact that water molecules may play a very important role for complex stability; and, it does not 
fully take into account the complete flexibility properties of the complex. Hence, alanine scanning 
provides only very approximate results. To overcome these limitations, these first predictions are 
succeeded by molecular dynamics (MD) simulations in a vacuum (gas-phase simulation), in the 
presence of solvent molecules (explicit solvent simulation) or in empirical mathematically expressed 
solvents (implicit solvent simulation). Subsequently, those calculations allow predicting which of the 
suggested mutation sites (from alanine scanning) destabilize the determined protein-protein 
complex the most.  
Today, molecular modeling methods are routinely used in pharmaceutical research to investigate 
protein folding, enzyme catalysis, protein stability, conformational changes associated with bio-
molecular function, and molecular recognition of proteins, DNA, and membrane complexes to e.g. 
design novel drug candidates.   
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1.8 AIMS AND OBJECTIVES 
Conventional cancer treatment usually involves chemotherapy and radiotherapy, which can cause 
severe side effects. More targeted approaches are therefore preferred, such as immunotherapy 
based on immunotoxins (ITs) comprising an antibody-based ligand that specifically binds to diseased 
cells, and a pro-apoptotic protein. However, if the toxin component is derived from bacteria or plants 
it can trigger a neutralizing immune response; therefore, human effector molecules are more 
suitable. This results in the fourth generation of ITs, human CFPs. The most prominent example of 
these fourth generation ITs, that has been successfully tested in cytotoxicity assays against different 
cancer cells in vitro and ex vivo, comprises granzyme B as pro-apoptotic candidate. There are three 
main reasons for the application of granzyme B as part of CFPs. First, it is a human effector molecule 
so the risk of immunogenic responses is limited. Second, the use of granzyme B is not only beneficial 
due to its high apoptotic efficiency as the major mediator of cellular immunity, but also because of its 
capacity to induce apoptosis at multiple levels so the cancer cells’ lack of sensitivity due to 
deregulated apoptotic pathways or overexpression of certain inhibitors may be overcome. Third, it is 
relatively flexible concerning heterologous expression. On the downside, during the last decade, the 
presence of the endogenous inhibitor PI-9 has been discovered in different types of cancer cells. This 
diminishes the universal potential of granzyme B in targeted tumor therapy. Since the expression of 
PI-9 has especially been described in the context of treatment-resistant cells and poor clinical 
outcome, it becomes evident that alternative therapeutic approaches become necessary to kill these 
cells. The aim of this work was the evaluation of human CFPs which induce cell-death independent of 
the endogenous expression of PI-9. This should be achieved by highly cytotoxic granzyme B mutants 
resistant to PI-9 inhibition. 
The following steps will be pursued to achieve this goal (overview shown in Figure 2): 
• Elucidation of the most important amino acids responsible for the interaction between the 
serine protease and the RCL of its specific inhibitor by molecular homology modeling. 
• Identification of suitable amino acids to replace the identified residues with the aim to 
prevent an irreversible inactivation of the enzyme by covalent complex formation without 
affecting proteolytic activity. 
• Verification of the desired effects in silico (cooperation with German Research School for 
Simulation Sciences in Juelich, Prof. Dr. rer. nat. Paolo Carloni). 
• Generation of different fusion constructs comprising granzyme B and the CD30-targeting 
Ki4(scFv) and CD64-targeting H22(scFv), mammalian secretory expression and purification of 
the granzyme B mutants.  
• Identification of the most promising mutants by in vitro PI-9 inhibition assay. 
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2 Material and methods 
2.1 CHEMICAL AND BIO-CHEMICAL MATERIAL 
2.1.1 Equipment 
The equipment and devices used in this work are listed below. 
Autoclaves: Varioklav (H+P) 75S (Thermo Electron Corporation) 
Balances: Precision and analysis balances, Talent: TE6101, TE64, TE31025, 
TE12000 (Sartorius) 
Cell counter: Casy1 (Schaerfe System)  
Centrifuges: Table centrifuge 5415D and 5415R (Eppendorf), Multifuge 3 S-R / 1S 
(Heraeus Instruments), Avanti J-25I Centrifuge (Beckman Coulter), 
Rotina 420 R (‘Hettich Zentrifuge’)  
Cryo sections: Cryostat CM 3050 (Leica)  
DNA sequencing: ABI Prism 3730 Capillary-Sequencer (Applied Biosystems)  
End-over-end shaker (CMV): Innova TM 4000 incubator shaker or Innova TM 4430 incubator 
shaker (New Brunswick Scientific) 
Flow cytometry:  FACScalibur (Becton Dickinson), FACS-Vantage with DiVa option 
(Becton Dickinson)  
FPLC: Aekta FPLC (Amersham Pharmacia Biotech)  
Gelelectrophoresis and 
Electroblotting:  
Mini Protean III gel chamber (BioRad Laboratories, Inc.), Protein Gel-
Apparatus and supplies Mini PROTEAN II™ (BioRad), Gel Air Dryer 
(BioRad), Mini Trans-Blot Cell (BioRad)  
Ice machine: Icematic D201 (Castel Mac) 
Incubators: Thermomixer compact (Eppendorf AG), Incubator Function Line Type 
UT12 (Heraeus Instruments); cell culture: CD210 (Binder) 
Liquid handling: Pipetman P (Gilson), Multichannel Pipettes (Eppendorf)  
Microplate reader: ELISAreader ELx808 (Bio-TEK Instruments) and Epoch (Bio-TEK 
Instruments)  
Microscopes:  TCS SP5 confocal laser microscope (Leica), DMIL inverted microscope 
with mercury fluorescence light source (Leica), DM2000 (Leica)  
PCR-Cyclers: Primus 96 Plus (MWG-Biotech), Programmable Thermal Controller 
PTC-200™ (MJ Research Inc.)  
pH-Meter: Basic Meter PB-11 (Sartorius) 
Photometer: Biophotometer (Eppendorf),  
Software: AIDA image analyzer (Raytest), GraphPad Prism 4.0, WinMDI 2.8  
Sonication: Bandelin Sonopuls HD 2070 (Bandelin Electronic) Micro tip MS72/73  
Transiluminator: Molecular Imager Gel Doc XR System (BioRad)  
Waterbaths: TE31025, TE12000 (Sartorius) 
 
Material and methods 
________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
20 
2.1.2 Chemicals and consumables 
If not otherwise indicated, the chemicals used were purchased from the following companies in the 
highest available purity: BD Biosciences (Heidelberg), Bio-Rad (Munich), Qualilab (Olivet, France), 
Merck (Darmstadt), Roche Diagnostics (Mannheim), Roth (Karlsruhe), Invitrogen (San Diego, USA), 
Sigma (Munich), MWG-Biotech (Ebersberg), KMF Laborchemie Handels GmbH (Siegburg), Peprotech 
GmbH (Hamburg). 
Expendable materials were usually purchased from: BD Biosciences (Heidelberg), Biozym 
(Oldendorf), Eppendorf (Hamburg), Greiner (Solingen), Invitrogen (San Diego, USA) , Labomedic 
(Bonn), Millipore (Eschborn), Pierce Biotechnology (Rockford, USA), Qiagen (Hilden), Schott (Mainz), 
Whatman (Bender & Hobheim, Bruchsal), Zeiss (Oberkochen). 
2.1.3 Kits, enzymes and standards 
If not otherwise indicated, the restriction enzymes, Quick ligase, T4-DNA-Ligase and Phusion High 
Fidelity DNA-polymerase used were purchased from: Invitrogen (San Diego, USA), MWG-Biotech 
(Ebersberg) and New Englands Biolab (NEB) (Frankfurt am Main). 
The following kits from Macherey-Nagel (Dueren) were used for isolation and purification of DNA or 
RNA according to the manufacturer’s instructions: 
Plasmid isolation kit (Mini): NucleoSpin® Plasmid 
Plasmid isolation kit (Maxi): NucleoBond® AX 
DNA-purification kit: NucleoSpin® Extract II 
RNA purification kit: NucleoSpin® RNA II 
Protein standards: 
Pre-stained broad range marker: 175 / 80 / 58 / 46 / 30 / 25 / 17 / 7 kDa; #P7708, NEB (Frankfurt am 
Main) 
Protein broad range marker: 212 / 158 / 116 / /97.2 / 66.4 / 55.6 / 42.7 / 34.6 / 27.0 / 20.0 / 14.3 / 
6.5 kDa, #P7702, NEB (Frankfurt am Main) 
Nucleic acid standards: 
2-log ladder: 10.0 / 8.0 / 6.0 / 5.0 / 4.0 / 3.0 / 2.0 / 1.5 / 1.2 / 1.0 / 0.9 / 0.8 / 0.7 / 0.6 / 0.5 / 0.4 / 0.3 
/ 0.2 / 0.1 kb, #N3200, NEB (Frankfurt am Main) 
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2.1.4 Synthetic oligonucleotides and plasmids 
Synthetic oligonucleotides were purchased from MWG-Biotech (Ebersberg) in standard quality. The 
DNA oligonucleotides used in this work are listed in Table 1. 
Table 1: List of oligo nucleotides used for cloning and DNA sequencing. 
Oligo name Oligo sequence 
Sequencing  
T7 promotor 5‘-TAATACGACTCACTATAGGG-3‘ 
Hinterhis rev 3‘-CCAACAGCTGGCCCTCGCAGACAG-5‘ 
3’Gb seq 3‘-CTTCACCTGGGCCTTGTTGC-5‘ 
5‘ pMS 5‘-GGGCGGTAGGCGTGTACGGTGGG-3‘ 
5‘ PI9 seq 5‘-AGTGGAATGAACCGTTTGAC-3‘ 
3‘ PI9 seq 3‘-CGAGCTTAAACGTGGCCTCC-5‘ 
Cloning  
5‘ pMS 5‘-GGGCGGTAGGCGTGTACGGTGGG-3‘ 
3‘ Gb (BlpI) 3‘-CGCGCTCAGCGTAGCGTTTCATGGTTTTC-5‘ 
5‘ PI9 (XbaI) 5‘-GCGTCTAGAGAAACTCTTTCTAATGCAAGTGGTAC-3‘ 
5‘ PI9 (NheI) 5‘-GCCGCTAGCCACCATGGAAACTCTTTCTAATGC-3‘ 
3‘ PI9 (NotI) 3‘-CGGCGCGGCCGCTGGCGATGAGAACCTGCCACAG-5‘ 
3‘ PI9 (EcoRI) 3‘-CGCGAATTCTCATGGCGATGAGAACCTGCCACAG-5‘ 
SOE primer  
5‘ Gb SOE K27A 5‘-CAGAAGTCTCTGGCGAGGTGCGGTGGCTTCC-3‘ 
5‘ Gb SOE R28A 5‘-CAGAAGTCTCTGAAGGCGTGCGGTGGCTTCC -3‘ 
5‘ Gb SOE R28E 5‘-CAGAAGTCTCTGAAGGAGTGCGGTGGCTTCC-3‘ 
5‘ Gb SOE R28K 5‘-CAGAAGTCTCTGAAGAAGTGCGGTGGCTTCC-3‘ 
5‘-EGb S195A 5‘-CTTTAAGGGGGACGCTGGAGGCCCTCTTGTGTG-3‘ 
3‘ Gb SOE K27A 3‘-GGAAGCCACCGCACCTCGCCAGAGACTTCTG-5‘ 
3‘ Gb SOE R28A 3‘-GGAAGCCACCGCACGCCTTCAGAGACTTCTG-5‘ 
3‘ Gb SOE R28E 3‘-GGAAGCCACCGCACTCCTTCAGAGACTTCTG-5‘ 
3‘ Gb SOE R28K 3‘-GGAAGCCACCGCACTTCTTCAGAGACTTCTG-5‘ 
3‘-EGb S195A 3‘-CACACAAGAGGGCCTCCAGCGTCCCCCTTAAAG-5‘ 
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The underlying plasmids for all molecular cloning procedures were pMS for mammalian expression 
[137] or pMT for bacterial expression [133]. All cloning work was adapted to the characteristics of the 
chosen vectors, such as corresponding restriction sites, and performed according to standard 
methods (2.2).  
For expression of all recombinant granzyme B and granzyme M constructs the already published 
plasmids pMS-L-EGb-H22-IV [138] and the earlier generated pMS-L-EGb-Ki4-IV and pMS-L-EGb-IV 
were applied as template plasmids. The granzyme M sequence was prepared earlier during a 
bachelor thesis by PCR using specific primers based on a full-length cDNA clone (IRATp970D0643D) 
from the German Resource Centre for Genome Research (RZPD). 
For expression of recombinant human PI-9, cDNA was derived from RNA preparations of target cell 
lines by reverse transcription and specific primers (2.1.4). The derived sequence was either cloned 
into the pMS vector, deleting the Igκ leader sequence for cytosolic mammalian expression 
(pMS-PI9-IV) or into the pMT plasmid to express PI-9 in E. coli (pMT-L-PI9). 
2.1.5 Antibodies and antibody fragments 
The following antibodies and antibody conjugates were used in this work for western blot (2.4.2) or 
flow cytometric (2.5) detection of recombinant or soluble proteins with the indicated dilutions: 
- GAM-AP (1:5000) or GAM-PO (1:5000) or GAM-FITC (1:100): Goat-anti-mouse polyclonal 
antibody directed against the Fc-part of murine IgGs, conjugated to Alkaline Phosphatase 
(AP), horseradish peroxidase (PO) or Fluorescein-Isothiocyanat (FITC) (Sigma, Munich) 
- anti-His (1:5000): monoclonal mouse-anti-penta-His antibody directed against C- or 
N-terminal Histidin Tags (His-tags) of recombinant proteins (Sigma, Munich) 
- anti-His Alexa488 (1:300): monoclonal mouse-anti-penta-His Alexa Fluor®488 antibody 
directed against the C- or N-His-tags of recombinant proteins, conjugated to fluorescent dye 
Alexa Fluor 488 (Qiagen, Hilden) 
- anti-human Gb-PE (1:50): monoclonal mouse-anti-granzyme B-PE antibody directed against 
human granzyme B, conjugated to R-Phycoerythrin (PE) (BD Bioscience, Heidelberg) 
- anti-human Gm (1:500): monoclonal mouse-anti-granzyme M antibody directed against 
human granzyme M, clone 4D11 (Abnova, Heidelberg) 
- anti-human Gb (1:1000): monoclonal mouse-anti-granzyme B antibody directed against 
human granzyme B, clone 2C5 (Santa Cruz, San Diego) 
- anti-human PI-9 (1:300): monoclonal mouse-anti-PI-9 antibody directed against human PI-9, 
clone 7D8 (Santa Cruz, San Diego) 
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The following antibodies were used for the flow cytometric (2.5) detection of surface antigens on 
cancer cell lines or primary leukemic cells according to the manufacturer’s instructions. They are 
monoclonal mouse-anti-human antibodies conjugated either to FITC, PE, Allophycocyanin (APC), 
Alexa 647 or 488 and detect the antigens as indicated by their name. 
- anti-CD64-FITC (AbD Serotec, Duesseldorf) 
- anti-CD64-488 (Biolegend, San Diego, USA) 
- anti-CD64-Alexa 647 (AbD Serotec, Duesseldorf) 
- anti-CD14-APC (eBioscience, Frankfurt) 
- anti-CD14-FITC (Dako, Hamburg) 
- anti-CD56-APC (eBioscience, Frankfurt) 
- anti-CD56-PE (eBioscience, Frankfurt) 
- anti-CD33-APC (eBioscience, Frankfurt) 
- anti-CD25-PE (eBioscience, Frankfurt) 
 
In addition, the single chain antibody fragments (scFv) listed in Table 2 were used in this study. 
Table 2: Origin and specificity of antibody fragments. 
Antibody/ligand specificity origin/specification 
H22(scFv)  human CD64  humanized monoclonal 
antibody H22  
Ki4(scFv)  human CD30  mouse monoclonal 
antibody Ki4  
425(scFv)  human EGF receptor, extracellular 
domain III (no mouse cross reactivity)  
mouse monoclonal 
antibody 425 
 
2.1.6 Bacterial strains 
The following E. coli strains were used for selection and amplification of plasmid DNA, and for 
expression of recombinant protein respectively: 
DH5α: F- φ80 lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17(rk-, mk+) phoA supE44thi-1 gyrA96 
relA1 tonA (resistant to phage T1) (Invitrogen, Darmstadt) 
BL21 StarTM (DE3): F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) (Invitrogen, Darmstadt) 
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2.1.7 Mammalian cell lines 
The list in Table 3 displays all mammalian cell lines used, including their background and indicating 
the receptor that played a role in this work. 
Table 3: Mammalian cell lines. 
Name Background Receptor 
used 
Reference / Source 
HEK293T highly transfectable derivative of the human 
primary embryonal kidney cell line 293 
/ ATCC, CRL-11268 
HL60 established from the peripheral blood of a 
35-year-old woman with AML FAB M2 in 
1976 
have to be stimulated with IFNγ (50 U/mL) 
24 h prior to cytotoxicity/ apoptosis assays 
[139] 
CD64 DSMZ, ACC 3 
L540 established from the bone marrow of a 20-
year-old woman with HL 
CD30 DSMZ, ACC 72 
L540cy subline of L540: was recultured from a 
tumor grown in a nude mouse after 
injection of L540 and treatment of the 
mouse with cyclophosphamide 
CD30  [140] 
L428 established from the pleural effusion of a 
37-year-old woman with HL 1978 
for mouse experiments transfected with far 
red fluorescent protein Kat2 (pTag-
Katushka2-N; Evrogen) 
CD30  DSMZ, ACC 197 
L1236 established from the peripheral blood of a 
34-year-old man with HL in 1994 
CD30  DSMZ, ACC 530 
K562 established from the pleural effusion of a 
53-year-old woman with CML in blast crisis 
in 1970 
CD30 DSMZ, ACC 10 
Jurkat established from the peripheral blood of a 
14-year-old boy with acute lymphoblastic 
leukemia (ALL) at first relapse in 1976 
/ DSMZ, ACC 282 
A431 established from the solid tumor of an 85-
year-old woman (epidermoid carcinoma) 
EGFR DSMZ, ACC 91 
Ramos established from the ascitic fluid of a 3-year-
old boy with American-type Burkitt 
lymphoma in 1972 
/ DSMZ, ACC 603 
Karpas 299 established from the peripheral blood of a 
25-year-old man with T cell non-HL in 1986 
/ DSMZ, ACC 31 
Kasumi-1 established from the peripheral blood of a 7-
year-old Japanese boy with AML FAB M2 (in 
2nd relapse after bone marrow 
transplantation) in 1989 
/ DSMZ, ACC 220 
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2.1.8 Primary cells 
Primary cells from patients were obtained through PD Dr. med. Edgar Jost (University Hospital of 
Aachen) after informed consent and with the approval of the Clinical Research Ethics Board of the 
RWTH Aachen University. The patients’ diagnosis was either AMML or CMML 1 (here abbreviated as 
CMML). Diagnosis of CMML was made according to the commonly used WHO-criteria. No prior 
treatment occurred for any patients except for CMML II (2000 mg/d hydroxyurea) and CMML III 
(1500 mg/d hydroxyurea). Mononuclear cells were isolated from peripheral blood by density 
gradient centrifugation using Biocoll separating solution (Biochrom AG) and subsequently cultured in 
RPMI complex medium (2.3). Prior to cytotoxicity and apoptosis assays they were stimulated with 
200 U/mL IFNγ for 1-2 h. 
CMML I:  male (83 years),  16 % monocytes,  31.5 G/L WBC,      20 G/L PLT,    95 g/L Hb 
CMML II: male (66 years),    7 % monocytes,  48.7 G/L WBC,  1212 G/L PLT,  101 g/L Hb 
CMML III:  male (64 years),  29 % monocytes,     61 G/L WBC,     306 G/L PLT,    86 g/L Hb 
CMML IV:  male (74 years),  20 % monocytes,  117 G/L WBC,     471 G/L PLT,  11 1g/L Hb 
AMML I:  male (78 years),  30 % monocytes,  268 G/L WBC,       58 G/L PLT,    88 g/L Hb 
AMML II:  female (68 years),  70 % monocytes,     37 G/L WBC,       66 G/L PLT,    99 g/L Hb 
AMML III:  male (45 years),  37 % monocytes,     44 G/L WBC,       44 G/L PLT,   88 g/L Hb 
2.1.9 Media and buffers 
In Table 4, buffer, solutions and media used in this study are listed.  
Table 4: Buffers and media. 
Buffer Composition Concentration  
10x PBS (pH 7.4)  NaCl  
KCl  
Na2HPO4 x 12 H2O  
KH2PO4  
1.37  
27  
81  
15  
M  
mM  
mM  
mM  
1x PBST  1x PBS (pH 7.4) 
Tween 20  
 
0.05  
 
% (w/v)  
5x TGS  Tris-HCl (pH 8.3)  
Glycine  
SDS  
125  
960  
0.5  
mM  
mM  
% (w/v)  
50x TAE Tris-HCl (pH 8.3)  
Glacial acetic acid  
EDTA  
2  
5.7  
50  
M  
% (v/v)  
mM  
5x OrangeG loading 
buffer 
OrangeG  
Glycerol  
in 1x TAE 
0.01  
30  
 
% (w/v)  
% (v/v)  
 
Coomassie staining 
solution  
Coomassie bb. G-250  
Methanol  
Glacial acetic acid  
0.25  
50  
9  
% (w/v)  
% (v/v)  
% (v/v)  
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Table 4: Cont. 
Buffer Composition Concentration  
Coomassie destaining 
solution  
Methanol  
Glacial acetic acid  
10  
10  
% (v/v)  
% (v/v)  
5x (reducing) protein 
loading buffer  
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
(ß-Mercaptoethanol)  
62.5  
30  
4  
0.05  
10  
mM  
% (v/v)  
% (w/v)  
% (w/v)  
% (v/v)  
SDS PAGE gel  
(separating gel)  
Acrylamide/Bisacrylamide (30/1) 
Tris-HCl (pH 8.8)  
SDS (10 % (w/v))  
TEMED  
APS (20 % (w/v))  
x  
375  
0.1  
0.1  
0.1  
mL  
mM  
% (w/v)  
% (v/v)  
% (v/v)  
SDS PAGE gel  
(stacking gel)  
Acrylamide/Bisacrylamide (30/1) 
Tris-HCl (pH 6.8)  
SDS  
TEMED  
APS  
5  
150  
0.1  
0.1  
0.1  
% (w/v)  
mM  
% (w/v)  
% (v/v)  
% (v/v)  
AP buffer  Tris-HCl (pH 9.6) 
NaCl 
MgCl2 
100 
100 
5 
mM 
mM 
mM 
Transfer buffer for 
western blotting  
Tris-HCl (pH 8.3) 
Glycine 
SDS 
Methanol 
25 
192 
0.05 
20 
mM 
mM 
% (w/v) 
% (v/v) 
Stripping buffer  
 
Tris-HCl (pH 6.8) 
SDS 
β-mercaptoethanol 
62.5 
2 
100 
mM 
% (w/v) 
mM 
For FPLC protein purification: 
4x binding buffer  Tris-HCl (pH 7.4) 
NaCl  
Imidazol  
200  
1.2  
40  
mM  
M 
mM 
Wash buffer  Tris-HCl (pH 7.4) 
NaCl  
Imidazol  
50  
300  
40  
mM  
mM  
mM  
Elution buffer  Tris-HCl (pH 7.4)  
NaCl  
Imidazol  
50  
300  
500  
mM  
mM  
mM  
Media  
LB (pH 7.5)  NaCl  
Peptone  
Yeast extract  
(Agar 
1 
0.5 
1.5 
1.6 
% (w/v)  
% (w/v)  
% (w/v)  
% (w/v)) 
SOC  Peptone  
Yeast extract  
NaCl  
KCl  
MgCl2  
MgSO4  
Glucose  
2 %  
0,5 %  
10  
25  
10  
10  
20  
(w/v)  
(w/v)  
mM  
mM  
mM  
mM  
mM 
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Their application will be described in later chapters. All media were autoclaved for 
20 min/121 °C/1 bar. If necessary, buffers were sterile filtrated with a 0.2 µm PES membrane. The 
following antibiotics were applied in media for bacterial cultivation, if necessary, with the indicated 
concentrations: Ampicillin (100 µg/µL), Kanamycin (50 µg/µL) and Chloramphenicol (25 µg/µL). 
 
2.2 MOLECULAR-BIOLOGICAL METHODS 
The described methods followed standard techniques according to Sambrook and Russell [141]. 
2.2.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) for the amplification of DNA segments was performed using 
Phusion High-Fidelity DNA Polymerase (NEB), a proofreading polymerase with 3´→5´ exonuclease 
activity resulting in higher accuracy during amplification. The standard volume of a PCR procedure 
was 50 μL and composed of 1x HF buffer including MgCl2, 10 pmol 5’ primer, 10 pmol 3’ primer, 
0.2 mM dNTPs. After the addition of 50 ng of the template and double distilled water (ddH2O), 
0.5 % (v/v) polymerase was added.  
The following standard protocol with 30 cycles was used: 
30 sec 98 °C 
Loop30 cycles start  10 sec 98 °C 
20 sec 55 °C 
30 sec 72 °C 
Loop30 cycles end 
5 min 72 °C 
To verify the successful transformation of a specific insert into bacterial cells, a colony PCR reaction 
was run using home-made Taq DNA polymerase. Therefore colonies were picked and heated at 95 °C 
for 15 min in 20 µl ddH2O in order to destroy the bacterial cells. After spinning off the cell debris 
10 µl of the mixture was added to the PCR mixture containing 1x PCR buffer, 1 mM MgCl2, 10 pmol 
5’ primer, 10 pmol 3’ primer, 0.2 mM dNTPs, 1 U Taq DNA polymerase in 25 µL total volume.  
The following protocol with 30 cycles was applied: 
5 min 96 °C 
Loop30 cycles start   1 min 96 °C 
30 sec 55 °C 
45 sec 72 °C 
Loop30 cycles end 
5 min 72 °C 
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The purification of the PCR products was done according to the manufacturer’s instructions 
(Macherey-Nagel Kits, 2.1.3). 
2.2.2 Site-directed mutagenesis  
Site-directed mutagenesis was conducted by overlap extension PCR using specific primers during an 
SOE (splicing by overlapping extension) PCR. The primer pairs for PCR 1 containing the corresponding 
mutations are listed in Table 1. To obtain the two fragments, the primer 5’ pMS was used to generate 
the 5’ to 3’ fragment and the primer 3’ Gb (BlpI) was used to generate the 3’ to 5’ fragment. A 
construct containing the desired single chain sequence as ligand, including the wild-type sequence of 
granzyme B, was used as a template. (2.1.4). The PCR mixtures and programs were as follows.  
PCR 1: 
1x HF buffer 
10 ng template DNA 
10 pmol 5’ primer 
10 pmol 3’ primer 
0.2 mM dNTPs 
0.02 U/µL Phusion DNA polymerase 
Ad 50 µL ddH2O 
Program 1: 
30 sec 98 °C 
Loop30 cycles start 10 sec 98 °C 
              20 sec 60 °C 
              30 sec 72 °C 
Loop end 
5 min 72 °C 
Annealing: 
2 µL fragment 1 
2 µL fragment 2 
1x HF buffer 
0.2 mM dNTPs 
0.02 U/µL Phusion DNA polymerase 
Ad 50 µL ddH2O 
Program 2: 
30 sec 98 °C 
Loop7 cycles start 10 sec 98 °C 
               1 min 50 °C 
              30 sec 72 °C 
Loop end 
5 min 72 °C 
Amplification: 
10 µL annealing product 
1x HF buffer 
10 pmol 5’ primer (5’ pMS) 
10 pmol 3’ primer (3’ Gb (BlpI)) 
0.2 mM dNTPs 
0.02 U/µL Phusion DNA polymerase 
Ad 50 µL ddH2O 
Program 3: 
30 sec 98 °C 
Loop25 cycles start 10 sec 98 °C 
              20 sec 60 °C 
              30 sec 72 °C 
Loop end 
5 min 72 °C 
 
 
Material and methods 
________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
29 
2.2.3 Agarose gel electrophoresis 
To analyze the size and concentration of the PCR products (2.2.1), isolated plasmids (2.2.8) and 
restriction fragments (2.2.5), analytical agarose gel electrophoresis was carried out in 1.2 % (w/v) 
agarose at field strength of 120 V after addition of 5x OrangeG loading buffer (Table 4). 
Electrophoresis was run in 1x TAE buffer with 0.3 μg/mL ethidium bromide. 0.33-0.6 μg 2-Log DNA 
Ladder (NEB) was used as the standard for determining the size and concentration of the fragments 
(2.1.3). DNA bands were visualized on a UV transilluminator at a wavelength of 302 nm. The bands 
obtained were documented with a video documentation system using the software ‘Quantity One 
Document Software’ version 4.6 (BioRad, Munich). 
2.2.4 Zero blunt TOPO PCR cloning 
Since the digestion of PCR products (2.2.1) was often inefficient, the PCR products were cloned into a 
TOPO vector according to the manufacturer’s instructions of Zero Blunt® TOPO® PCR Cloning Kit 
(Invitrogen, Darmstadt). After growing of the corresponding bacteria, the purified plasmids could be 
digested as described below (2.2.5). 
2.2.5 Endonuclease restriction of DNA 
The double digestion with endonucleases and buffers from NEB (Frankfurt am Main) was performed 
according to the manufacturer’s instructions in a total volume of 50 µL with 1 to 2 µg DNA. The 
isolation of restricted DNA occurred via preparative agarose gel electrophoresis (2.2.3). After 
separation of DNA fragments, desired DNA bands were excised using a clean scalpel on a UV 
transilluminator. The isolation of the DNA from the gel was performed according to the 
manufacturer's protocol (2.1.3). The concentration of the purified DNA was determined using 
analytical agarose gel electrophoresis (2.2.3) or by measuring the absorbance at 260 nm. The 
extracted and purified DNA was then used for ligation (2.2.6). For control digestions, 5 times less 
than the recommended volume was used and the specific bands were visualized as described above 
(2.2.3). 
2.2.6 Ligation of DNA fragments 
Two purified restriction digested fragments (2.2.5) were ligated with T4 DNA ligase and Quick ligase 
respectively, using the buffer system specified by the manufacturer with a total volume of 20 μL. The 
ligation mix contained the insert in triplicate molar excess of vector quantity, and the mixture was 
incubated overnight at 16 °C and for 5 min at room temperature (RT) respectively. Afterwards, the 
whole ligation mixture was transformed into heat shock competent bacteria (2.2.7), as explained 
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below. 
2.2.7 Transformation of plasmid DNA into competent E. coli  
Heat shock competent cells (2.1.6) were prepared with Rhubidium-chloride according to Hanahan 
[142]. The aliquoted cells were thawed on ice before the DNA was added (using either 20 µL ligation 
mix (2.2.6) or 30 ng purified plasmid DNA (2.2.8) for re-transformation). After incubation for 30 min 
on ice, the cells were incubated at 42 °C for 30 sec (heat shock). The transformed bacteria were 
stored on ice for 2 min and then mixed with 800 μL of sterile SOC medium. For regeneration, the 
bacteria were incubated for 1 h at 37 °C before they were plated on LB agar plates (2.1.9) containing 
the corresponding antibiotic (ampicillin for pMS-plasmids, kanamycin for pMT-plasmids). The plates 
were incubated overnight at 37 °C and colonies were analyzed using colony PCR (2.2.1) the next day. 
Replica plates were prepared for at least three clones. 
For the final clones glycerol stocks were prepared in 25 % (v/v) glycerol solution and stored at -80 °C. 
2.2.8 Preparation of plasmid DNA from E. coli 
For small scale DNA preparation, 3 mL of LB medium supplemented with the appropriate antibiotic 
(2.1.9) was inoculated and then the recombinant plasmid DNA (2.2.8) was isolated using a 
NucleoSpin plasmid kit according to the manufacturer’s instructions (2.1.3). The concentration was 
determined at 260 nm.  
2.2.9 Sequencing of DNA 
To verify the desired sequence of recombinant clones (2.2.7, 2.2.8), sequencing was carried out at 
the Fraunhofer IME sequencing facility by the chain termination method using the ‘Applied 
Biosystems 3700 DNA Analyzer’ and the BigDye™ cycle sequencing kit. 160 ng/kb plasmid DNA was 
added to ddH2O in a total volume of 28 μL with 20 pmol of sequencing primer (2.1.4). The resulting 
sequences were evaluated with the ‘CLC Main Workbench 6.0’ and ‘Clone Manager 9.0’ software. 
 
2.3 CELL CULTURE 
2.3.1 Cultivation of cell lines and primary cells 
All mammalian cell lines (Table 3) as well as the primary monocytic cells (2.1.8) were cultured in T25 
or T75 cell culture flasks (Greiner) in RPMI1640 (Gibco) supplemented with 10 % (v/v) heat-
inactivated fetal calf serum (FCS) (Gibco), 50 μg/mL penicillin and 50 μg/mL streptomycin. The cells 
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were maintained at 37 °C in a humidified atmosphere of 5 % CO2. After transfection of HEK293T cells, 
100 µg/mL Zeocin was added for selection purposes. 
When large amounts of secretory expressed protein were intended, triple flasks (VWR, Darmstadt) or 
cell factories (Thermo Fisher Scientific, Waltham, USA) were inoculated, so supernatant volumes 
above 1 L could be collected easily for purification. 
For viability and apoptosis assays 200 or 50 U/mL Interferon (IFN) γ was added for stimulation of 
CD64 expression in the primary cells or HL60 cell line, respectively. 
2.3.2 Transfection of cell lines 
The physical or chemical transfection of different mammalian cell lines was performed according to 
the manufacturer’s instructions (Table 5) and using their protocols for optimization. As 
recommended, the cells were kept in serum-free RPMI medium or RPMI containing 10 % (v/v) FCS 
without antibiotics. The efficiency of transfection was monitored via flow cytometric analysis.  
 
Table 5: Reagents for physical or chemical transfection of mammalian cell lines. 
Name Company 
Physical:  
Amaxa Nucleofection Kit V Lonza (Cologne) 
Neon Transfection systems Life technologies (Darmstadt) 
Chemical:  
Nanofectin Kit PAA (Pasching, Austria) 
Attractene Transfection 
reagent 
Qiagen (Hilden) 
GeneJuice Transfection 
Reagent 
Novagen (Darmstadt) 
TransIT-Jurkat MirusBio (Madison, USA) 
Ingenio Electroporation Kit MIR 
50109 
MirusBio (Madison, USA) 
Roti-Fect Reagent  Roth (Karlsruhe) 
 
2.3.3 Protein delivery into cells via streptolysin O 
Reversible permeabilization of cells can be achieved via streptolysin O (Sigma, Munich). For protein 
delivery 5*106 cells/mL were washed once with HEPES buffer (20 mM HEPES, pH 7.4, 150 mM NaCl) 
and re-suspended in 100 µL HEPES buffer containing 0.5 % (w/v) BSA, 5 mM DTT and 10 mM glucose. 
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The cells were incubated with 8 µg/mL streptolysin O for 15 min at 37 °C in a 96-well plate. 
Afterwards the cell-death inducing protein was added and cells were further incubated for 4 h. The 
permeabilization step was conducted in the absence of Ca2+, whereby resealing of the cells was 
induced by addition of 1.25 mM Ca2+ 1 h after addition of the cell-death inducing protein. Apoptotic 
effects were monitored via Annexin V/ PI assay as described in 2.7.2.1. 
 
2.4 PROTEIN-BIOCHEMICAL METHODS 
2.4.1 SDS-PAGE 
To determine the amount and identity of proteins (2.4.3, 2.4.4) according to their molecular weight, 
analytical protein separation was performed via discontinuous SDS- poly-acryl-amide (SDS-PAA) gel 
electrophoresis (SDS-PAGE) based on the method of Laemmli [143]. The denaturing SDS-PAA gel was 
prepared with the above mentioned buffers (Table 4). Before the gel was loaded, the samples were 
mixed with Laemmli sample buffer and heated for 5 min at 95 °C to destroy the structure of the 
proteins. The gel was run with 160 mV in ‘Mini-Protean III’-protein gel electrophoresis chamber 
(BioRad) until the samples reached the bottom of the gel. The gel was dyed in a coomassie brilliant 
blue solution for 10-30 min and destained with the described buffer (Table 4). With the help of the 
loaded standard (2.1.3) the proteins could be identified. 
2.4.2 Western blot analysis 
Western blot analysis was performed using the ‘Mini Trans-Blot® Electrophoretic Transfer Cell’ (BIO-
RAD) according to the manufacturer's instructions with transfer buffer (Table 4). After the transfer 
(250 mA for 90 min or 40 V overnight at 4 °C) of proteins, separated by SDS-PAGE, on a nitrocellulose 
membrane (Protran, Whatman), blocking was performed using 2.5 % (w/v) milk powder resolved in 
PBST either for 1 h at RT or overnight at 4 °C. After washing three times with PBST, the membrane 
was incubated with the primary antibody in PBST for 1 h at RT. The same procedure was followed for 
incubation with the secondary antibody. After final washing in PBST and water, the membrane was 
developed in the dark depending on the conjugation of the second antibody (2.1.5) if not otherwise 
indicated using NBT/BCIP [3.33 % (w/v) NBT, 1.67 % (w/v) BCIP in dimethylformamide] added to the 
100x volume of AP buffer (Table 4) for AP-labeled antibodies or with an enhanced 
chemiluminescence (ECL) system (Thermo Scientific) and LAS-3000 reader (Fujifilm) for PO-
conjugated ones.  
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2.4.3 Bacterial expression and purification 
For the expression of recombinant PI-9, the E. coli expression strain BL21 (DE3) was used (2.1.6). To 
evaluate successful protein expression, optimal conditions and sufficient purification steps, small 
scale experiments were performed in a volume of 300 mL according to the published stress-
expression protocols [144] or the protocols from Qiagen (‘The QiaExpressionistTM’). In order to obtain 
enough protein for further determinations, fermentation with 4 L volume (BioFlo 110 fermenter, 
400-1000 rpm) was run in synthetic minimal medium (16.6 g/L KH2PO4, 4.6 g/L NH4(H2PO4), 70 mg/L 
CaCl2*2H2O, 140 g/L FeSO4*7H2O, 1.5 g/L MgSO4*7H2O, 2.1 g/L citric acid, 0.2 g/L L-methionine, 
0.2 g/L L-arginine-hydrochloride, 1 mL/L PTM1-trace metals, 25 mg/L Kanamycin, 0.5 mL/L Antifoam) 
supplemented with 20 g/L glucose. Inoculation was prepared with 400 mL bacteria culture grown at 
37°C overnight in LB medium. The bacteria were harvested 24 h after induction with 1 mM Isopropyl 
Thiogalactoside (IPTG). 
After harvesting and centrifugation (4000 g, 15 minutes, 4°C) the bacterial pellet was re-suspended in 
lysis buffer (50 mM NaH2PO4, pH 8.0, 500 mM NaCl, 0.5 mM DTT) and sonicated six times for 60 s, 
70 %, 9 cycles (2.1.1). Due to its enzymatic activity towards proteases, the addition of protease 
inhibitor was disclaimed. Cell debris was removed by centrifugation at 30.000 g, 4 °C for 30 min. The 
supernatant was supplemented with 10 mM imidazol and purified via Immobilized Metal-ion Affinity 
Chromatography (IMAC) and Fast Performance Liquid Chromatography (FPLC) as described below 
(2.4.4.2). After a second IMAC step, the protein was re-buffered into 20 mM Tris, pH 7.4, 1 mM DTT 
and further purified via anion exchange chromatography (Q-Sepharose XL, 1 mL, GE Healthcare) with 
a salt gradient of 0.05–1 M NaCl. To achieve satisfying purity, gel filtration chromatography followed 
using a Superdex 75 (GE Healthcare) column in 20 mM Tris, pH 7.5, 50 mM NaCl and 1 mM DTT. 
2.4.4 Mammalian expression and purification 
All granzyme B- and granzyme M-based constructs were produced secretory in mammalian HEK293T 
cells. In addition, PI-9 was expressed cytosolically within these cells. 
2.4.4.1 Expression of recombinant protein in HEK293T cells 
HEK293T cells were used as the expression cell line (2.1.6). The cells were transfected with 1 µg DNA 
according to the manufacturer’s instructions using RotiFect (Roth) (2.3.2). The pMS plasmid used 
(2.1.4) encodes for the bicistronic EGFP reporter, so expression of the target protein could be verified 
by the green fluorescence via fluorescence microscopy. To obtain high producing cultures 
fluorescence activated cell sorting was performed to select high reporter EGFP producing cells. 
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The secretory expression was enabled by the signal peptide sequence of immunoglobulin kappa light 
chain (Igκ) encoded by the pMS plasmid (2.1.4). Protein containing supernatants were kept sterile 
and were stored at 4 °C until sufficient volumes were collected for purification (2.4.4.2). In case of 
cytosolically expressed protein, the cells were harvested, washed with PBS and stored at -20 °C until 
further processing (2.4.4.3). 
2.4.4.2 Purification of recombinant protein from supernatant 
The secreted protein could be purified from the cell culture supernatant via IMAC and FPLC. The 
cleared supernatant was supplemented with 10 mM imidazole before loading onto an XK16/20 
column (Amersham/ GE Healthcare) containing 8 mL Sepharose 6 Fast Flow resin (GE Healthcare). 
The buffers used are listed in Table 4. Afterwards the elution buffer was exchanged with adequate 
buffer to enable enterokinase digestion (20 mM Tris-HCl, 200 mM NaCl) via a HiPrep 26/10 desalting 
column (GE Healthcare). To obtain higher purity of proteins especially for in vivo experiments, the 
protein solution was additionally loaded onto a gel filtration chromatography column (Superdex 75, 
GE Healthcare) using the enterokinase buffer. 
In order to concentrate the protein solutions, Vivaspin 6 ultrafiltration spin columns (10 kDa MWCO; 
Sartorius) were centrifuged at 4000 g and 4 °C. Aliquoted proteins were stored at -80 °C. To activate 
granzyme-based constructs enterokinase was added to the protein (0.02 U/µg) with 2 mM CaCl2 for 
16 h incubation at 23 °C prior to use. Activated protein was stored after the addition of 1 mM DTT at 
-80 °C. The purified proteins or cell lysates were analyzed via SDS-PAGE under reducing conditions 
and coomassie staining (2.4.1) or western blots (2.4.2). 
2.4.4.3 Purification of recombinant protein from cell lysate 
HEK293T cells transfected with pMS-PI9-IV (2.1.4) were harvested and lysed within a native buffer 
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 % (v/v) Triton X100). Incubation of the cells in buffer took 
place for 30 min on ice. Cell debris was then removed by centrifugation at 13.000 g for 15 min at 4 °C 
and the supernatant containing the desired protein was purified as described in 2.4.4.2. 
2.4.5 Protein quantification 
Three different methods were applied for the determination of protein concentration. For purified 
protein the concentration was determined after SDS-PAGE and coomassie staining using ‘AIDA Image 
Analyzer’ Software (Raytest Isotopenmessgerate). The concentration could be correlated to the 
additionally loaded bovine serum albumin (BSA) standard (100 ng, 250 ng, 500 ng, 1000 ng). The 
values were confirmed by Bradford assay in a 96-well plate using 1x Roti-Nanoquant (Roth). All 
samples were pipetted in triplicates. A stock solution with 1 μg/μL purified BSA (0, 0.5, 1, 2, 4, 6, 8, 
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10 μg/well) was used as a calibration standard. In order to determine the total protein concentration 
of cell extracts Bradford or BCA assay (Thermo Scientific Pierce) was performed according to each 
manufacturer’s instructions. Absorption was measured at 595 nm for BSA and at 562 nm for BCA in a 
microplate reader. Data were analyzed with MS Office Excel software, and the total protein 
concentration of the samples was determined according to the BSA standard curve. 
2.4.6 Labeling of SNAP constructs  
The establishment of the SNAP (engineered version of the human DNA-repair enzyme O(6)-
alkylguanine DNA alkyltransferase) -tag technology and the preparation of the corresponding 
constructs and their covalent conjugation to substrates containing O(6)-benzylguanine (BG) via a 
stable thioether bond in a rapid and highly specific self-labeling reaction has been described before 
[145]. Here, in HEK293T cells, secretory expressed and subsequently purified SNAP-tag fusion 
proteins (Ki4(scFv)-SNAP and H22(scFv)-SNAP) were conjugated with the BG-modified dyes BG Alexa 
Fluor 647 (BG 647), BG Alexa Fluor 747 (BG 747) or BG Vista Green (Covalys Biosciences AG, 
Witterswil) by incubation in the dark with 1.5-3-fold molar excess of the dye overnight at 4 °C. 
Residual dye was removed using PD 10 columns (GE Healthcare). Stained proteins were visualized 
after separation by SDS-PAGE with either a UV transilluminator (BioRad Gel Doc XR) or with a CRi 
Maestro imaging system using blue, red and near-infrared filter sets. 
2.4.7 Detection of endogenous PI-9 from cell lines or primary cells 
For the detection of cytosolic expressed PI-9 within tumor cell lines or primary cells, 106 cells were 
lysed within 50 µL lysis buffer (PBS supplemented with 1 % (v/v) Triton X-100) for 30 min on ice. The 
cell extract was cleared via centrifugation and the protein concentration was determined with 
Bradford reagent (2.4.5). 40 µg total protein amount were loaded on a SDS-gel for western blot 
analysis. PI-9 was detected by incubation for 1 h with anti-human PI-9 (2.1.5) in PBST. After washing 
with PBST, GAM-PO was added and signals could be detected as described in 2.4.2. 
In parallel, detection was performed via flow cytometry (2.5.1) which allows more quantitative 
analysis. Therefore 106 cells were washed with PBS and resuspended in 500 µl Cytofix/ Cytoperm (BD 
Bioscience, Heidelberg). After incubation for 20 min on ice and washing of the cells, a blocking step 
was included with 5 % (w/v) BSA in 200 µl PBS for 20 min on ice. The cells were washed with PBS 
containing 0.2 % (v/v) Tween 20 and incubated with anti-human PI-9 (2.1.5) for 30 min on ice. The 
second antibody GAM-FITC (2.1.5) was added to the washed cells and incubated as described above. 
The final wash step and resuspension of the cells was performed in PBS comprising 0.2 % (v/v) 
Tween 20. The measured shift during flow cytometric analysis due to a specific binding of the 
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antibody to the fixed and permeabilized cells was quantified as MFI (Median Fluorescence Intensity) 
in WinMDI 2.8. MFIs due to low unspecific binding of the secondary antibody were subtracted.  
2.4.8 Serum stability assays 
70 ng/µL purified protein was incubated with 50 % murine serum (AbD Serotec, Duesseldorf) or 
human serum (obtained by centrifugation of 500 to 1000 µL patient-derived blood samples (2.1.8) 
for 10 min, 300x g at RT) at 37 °C for different time periods between 0 and 48 h. The amount of 
functional remaining protein binding was measured via flow cytometric analysis (2.5.1), here with 
400-fold dilution of 7.5 µL of the mixture.  
2.4.9 ELISA for detection of CD30 receptor in blood  
Mouse serum of L540cy bearing mice was obtained by centrifugation of 10-30 µL mouse-derived 
blood samples for 10 min and 300x g at RT and stored at -20 °C until use. The concentration of 
soluble CD30 receptor within blood serum was evaluated by an ELISA set-up as previously published 
[146]. High binding ELISA plates were coated with 50 µl Ki2 monoclonal antibody (240 µg/mL) in PBS 
overnight at 4 °C. After washing with PBST and blocking in PBS containing 5 % (w/v) milk powder for 
1 h at RT, 50 µl CD30-containing mouse serum (1:5 dilution in PBS) was added and incubated for 2 h 
at RT. Plates were washed three times and 50 µl Biotin coupled Ki3 monoclonal antibody (270 ng/µL, 
1:100 dilution in PBS) was added for a 1 h incubation at RT. For detection, plates were first incubated 
with 50 µl Streptavidin-PO (1:200 in PBS, Abcam, Cambridge, UK) for 1 h; then washed in PBST and 
then incubated for 1 h with 50 µl ABTS solution (Roche Diagnostics, Mannheim). Plates were read out 
at 405 nm in a microplate reader. 
 
2.5 FLOW CYTOMETRIC ANALYSIS 
2.5.1 Binding analysis 
The binding of fusion proteins to the target cells (Table 3) or the endogenous protein thereof (2.4.7) 
was evaluated via flow cytometric analysis (CellQuest Version 3.3 (Becton Dickinson, Heidelberg)) 
and WinMDI 2.8. For standard binding analysis 4*105 cells were washed with PBS and incubated with 
50 nM purified protein in 100-300 µL PBS for 30 min on ice. After 2 wash cycles the cells were 
incubated with anti-His Alexa 488 (2.1.5) for 30 min on ice, in the dark. Negative controls with cell 
lines not expressing the target receptor were run in parallel. Monocytic cells of primary PBMCs were 
gated in forward and sideward scatter (FSC/ SSC) dotplot prior to evaluation.   
 
Material and methods 
________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
37 
2.5.2 Determination of Kd values 
For the determination of the affinity constant (Kd) different concentrations of the fusion proteins 
(0-16.7 nM, 1:2 dilution) were incubated with the cells and evaluated by flow cytometric analysis 
(2.5.1) and non-linear-regression determinations in GraphPad Prism 4.0. 
2.5.3 Determination of specific cell death of primary cells 
The specific reduction of the target cell population was determined by staining primary cells with 
anti-CD64 Alexa647 (AbD Serotec, Duesseldorf) to localize the population within the FSC/SSC dotplot 
during flow cytometry. These cells were gated with WinMDI 2.8 so their reduction after treatment 
could be evaluated accordingly and compared to untreated control. 
To further specify reduction of the target cell population specific antibodies displayed in 2.1.5 were 
incubated with the treated cells and reduction of the stained target cell population could be 
compared to the untreated control by flow cytometric analysis. 
 
2.6 CONFOCAL MICROSCOPY 
All images were taken with a LEICA confocal microscope (TCS SP5) equipped with the following 
lasers: 458 nm, 488 nm, 561 nm and 633 nm. A 40x optical magnification was used. Cells were 
stained with SNAP-based constructs (2.4.6) as indicated and prepared as described above for flow 
cytometry (2.5), resuspended in 50 µL PBS and pipetted onto a microscope slide. 
 
2.7 FUNCTIONAL CHARACTERIZATION OF RECOMBINANT PROTEINS 
2.7.1 Protease assays 
2.7.1.1 Colorimetric substrate assays 
The activity of 100 nM granzyme B-based constructs after enterokinase digestion was detected by 
cleavage of 200 µM of the synthetic substrate Ac-IETD-pNA (Calbiochem/Merck, Darmstadt) which 
mimics the cleavage site of pro-caspase 3. The reaction was monitored in 96-well plates in a 
microplate reader at 405 nm and 37 °C at 1 or 2 min intervals for 1 h. Afterwards, time was plotted 
against the absorbance so differences in activity could be evaluated. After complex formation 
(2.7.1.4) and measurement of the remaining activity the velocity of the reaction was calculated from 
the linear slope of the reaction within the first 10-12 min and converted to pmol/min with the help of 
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the corresponding conversion factor (µM/A405nm) according to the manufacturer’s protocol of the 
Caspase-8 Assay kit (Calbiochem).  
Granzyme M activity, after enterokinase digestion, was evaluated using the colorimetric substrate 
Suc-Ala-Ala-Pro-Leu-pNA (Bachem, Bubendorf, Switzerland) according to a published protocol [56]. 
The change in absorbance at 405 nm was measured as above with the difference that here only the 
absolute change was recorded, not the kinetics. 
2.7.1.2 Determination of Michaelis-Menten Kinetics 
To analyze the activity of the wild-type protein and its most promising mutant, Km values were 
evaluated according to the manufacturer’s protocol of the Caspase-8 Assay kit (Calbiochem). The 
enzymatic reaction was prepared and measured as described above (2.7.1.1). For evaluation, change 
in absorbance at 405 nm during the first 12 min of the reaction was determined. Km values were 
derived by non-linear curve fitting to the Michaelis–Menten equation using GraphPad Prism 4.0. 
2.7.1.3 Cleavage of PI-9 by granzyme M 
The activity of the granzyme M-based constructs was verified by their ability to cleave recombinant 
PI-9 (1.3.2). The fusion protein was incubated at a 1:3 molar ratio with PI-9 at 25 °C in 100 mM HEPES 
(pH 7.4), 200 mM NaCl, 0.01 % (v/v) Tween 20 and 1 mM DTT. After 24 h the reaction mixture was 
analyzed by SDS-PAGE and western blotting using anti-human PI-9 and GAM-PO as described in 2.4.2. 
2.7.1.4 Formation of the granzyme B and PI-9 Complex 
The complex of recombinant PI-9 and Gb-H22(scFv) and its mutants was formed using a 5:1 molar 
ratio (PI-9:Gb-H22(scFv)) under reducing conditions in 20 mM Tris-HCl (pH 7.4), 50 mM NaCl and 
1 mM DTT. 600 ng of wild-type or mutant granzyme B construct was incubated with or without PI-9 
for 1 h at 37 °C and the retained enzymatic activity was evaluated as described above (2.7.1.1). For 
western blot analysis (2.4.2) adequate amounts containing at least 100 ng of granzyme B-based 
protein was prepared for SDS-PAGE in the same manner. For detection of specific bands, anti-human 
PI-9, anti-human Gb or anti-His were used followed by the second antibody GAM-PO (2.1.5).  
Endogenous complex formation was determined after incubation using Gb-Ki4(scFv) as described for 
apoptosis assay (2.7.2.1). Analysis was done as described above using anti-human Gb and GAM-PO. 
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2.7.2 Apoptosis assays 
Apoptosis was documented via Annexin V/ propidium iodide (PI) staining (2.7.2.1) or via 
determination of caspase 3/7 activation (2.7.2.2) within the target cells. 
2.7.2.1 Annexin V/ PI Assay  
Annexin V binds to phosphatidylserine which is exposed on the surface of apoptotic cells. Thus, dead 
cells can be visualized using labeled Annexin V protein. In addition, PI enters through the permeable 
membrane of dead cells, so necrotic and apoptotic cells can be distinguished. 2*105 cells/mL were 
incubated at 37 °C, 5 % CO2, with different concentrations of fusion protein (between 11 and 
100 nM), depending on target cells and construct, for 48 h in 12-well plates containing 1 mL 
supplemented RPMI medium (2.3.1). Afterwards, the cells were washed in PBS and the pellet was re-
suspended either in 100 µL 1x Annexin V binding buffer (10 mM HEPES (pH 7.5), 140 mM NaCl, 
0.5 mM CaCl2) supplemented with 2.5 µL Annexin V-FITC (eBioscience, Frankfurt) or in 450 µL cell-
free culture supernatant from HEK293T cells expressing Annexin V-labeled green fluorescent protein 
(EGFP, [147]) supplemented with 10x Annexin V binding buffer and 5 µg/mL PI. The incubation with 
labeled Annexin V protein took place in the dark, either at RT for 15 min or on ice for 20 min 
respectively. Results were analyzed via flow cytometry (2.5). 
2.7.2.2 Caspase 3/7 assay 
To determine the caspase 3/7 activity within apoptotic, granzyme B-treated cells (2.7.2.1), a pre-
luminescent caspase 3/7-DEVD-aminoluciferine substrate was applied (Caspase-Glo™ 3/7 Assay, 
Promega). Caspase 3/7 is a direct substrate of granzyme B. If it is cleaved after granzyme B delivery 
into the target cells and thereby activated, it can cleave the pre-luminescent caspase 3/7-DEVD-
aminoluciferine substrate so free unbound aminoluciferine is released. This is subsequently used by 
luciferase whereby a luminescence signal is produced. For the evaluation, cells were transferred into 
96-well plates and the read out was done in a microplate reader. The amount of luminescence was 
directly proportional to the activity of caspase 3/7. 
2.7.3 Viability assay 
The cytotoxic effect of the granzyme B-based fusion proteins was monitored using the ability of 
metabolic active cells to reduce the tetrazolium salt XTT ((sodium 2,3,-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium) inner salt, Life Technologies (Invitrogen)) to 
orange colored compounds of formazan. The dye intensity was measured by a microplate reader and 
is directly proportional to the number of living cells.  
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For Gb-Ki4(scFv) and its mutants 2*105 cells were plated in 1 mL in 12-well plates with 1:3 dilutions 
and incubated for 48 or 72 h at 37 °C and 5 % CO2. For Gb-H22(scFv) and its variants and 
Gm-H22(scFv), cells were incubated in 96-well plates with 5.000 IFNγ stimulated HL60 cells (or 
control cell lines) or 20.000 primary cells per 100 µL with 1:3 or 1:5 dilutions of protein for 72 h at 
37 °C. In a different approach, XTT was used for read out of viable cells after incubation with single 
doses of fusion protein (concentrations as indicated, depending on target cells and construct) in 12-
well plates and evaluated after transfer of 100 µL of each approach into 96-well plates as described 
above. 50 µL XTT was added to a 100 µL cell suspension and extinction was measured after a 4 h 
incubation at 450 nm at a reference wavelength of 630 nm.  
Viability curves and IC50 values were evaluated with GraphPad Prism4.0. Therefore dilution effects by 
the protein volume used were normed using respective buffer controls. Zeocin was used as the 
negative control. 
Competition assays were carried out with H22(scFv) by adding 10 nM Gb-H22(scFv) or Gm-H22(scFv) 
to IFNγ stimulated HL60 cells and incubating them for 48 h in the presence or absence of 10 or 
100 nM H22(scFv). The buffer control was assigned a viability of 100 % and the converted XTT signal 
was read out as above. 
 
2.8 IMMUNOHISTOCHEMISTRY 
Resected cryo-conserved tumors were cut into 8 µm sections on a freezing microtome (Cryostat CM 
3050 (Leica) and mounted on coated slides. After drying for 48-72 h, sections were fixed for 10 min 
with dry acetone and air-dried. In order to detect endothelial cells, slides were incubated with 
naphthol AS-BI phosphate (sodium salt, 50 mg/100 mL; Sigma, Munich) as substrate and new fuchsin 
(10 mg/100 mL; Merck, Darmstadt) as chromogen dissolved in 0.1 M Tris-HCl (pH 8.5) resulting in 
pink/red staining. By omitting the addition of levamisole to the reaction mixture, endothelial cells 
became visible. Slides were counterstained with hematoxylin. 
In order to visualize remaining CD30 receptor expression in resected tumors, 12.5 nM 
Ki4(scFv)-SNAP-BG-Vista-Green diluted in PBS was added to the slides and incubated for 30 min in 
the dark at RT. After washing, images were collected via a Leica confocal microscope (2.6). 
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2.9 IN VIVO EXPERIMENTS 
The experiments were officially approved by the local Animal Care and Use Review Committee (AZ: 
87-51.04.2010.A278). All animals received human care in accordance with the requirements of the 
‘German Tierschutzgesetz’, §8 Abs. 1 and in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the National Institute of Health. 
2.9.1 Mouse strains, housing and maintenance of animals  
For animal experiments 6 to 8 week-old female BALBc nu/nu mice (Charles River GmbH) were used. 
Mice were housed in the ‘Institut fuer Versuchstierkunde’ of the university hospital, Aachen, during 
tumor take rate studies, and in the animal facility of the Fraunhofer IME during the treatment 
experiments.  
2.9.2 Handling of mice and anesthesia 
Anesthesia of the mice was performed either by intramuscular administration of 75 mg/kg Ketamin – 
10 mg/kg Xylazin for periods up to 30 min or by isoflurane for shorter times up to 2 min. 
Proteins were administered intravenously (i. v.) with volumes up to 100 μL. Samples were brought up 
to RT before injection. Before and after image acquisition, anesthetized mice were kept warm on a 
hot-water bag. As in previous imaging experiments, the mice injected with far red fluorescent protein 
Kat2 (pTag-Katushka2-N; Evrogen) transfected cells were fed a purified, chlorophyll-free diet 
(AIN93G, SSNIFF GmbH) 7 days before the imaging experiments were started whereas mice injected 
with L540cy were fed a normal diet (SSNIFF GmbH). 
Blood samples (10-30 µL) were obtained through the tail vein of the mice.  
2.9.3 Establishment of xenograft subcutaneous tumor models 
Before treatment of the mice with fusion proteins could be started, the tumor take rates of the 
potential target cell lines had to be determined. For injection of tumor cells, L428 cells transfected 
with Kat2 or L540cy cells (not transfected) were used after washing with PBS and resuspension in 
50 % BD Matrigel™ Basement Membrane Matrix High Concentration, Growth Factor Reduced (BD 
Bioscience, Heidelberg). 5*106 cells in a volume of 30 µL were injected subcutaneously into the right 
hind limb of 5 mice for L428 and 5 mice for L540cy. Tumor growth was monitored by molecular 
imaging with the CRi-Maestro Imaging System (2.9.4) in the case of Kat2 transfected L428; for L540cy 
triplet caliper measurements were executed. Based on the evaluated tumor take rates and tumor 
sizes, adequate treatment schedules could be set up. 
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2.9.4 In vivo optical imaging by Cri-Maestro system 
In vivo optical imaging was performed with the CRi-Maestro Imaging System (Cri Inc., Woburn, MA, 
USA) and analyzed with the Maestro Spectral Imaging Software. The Maestro imager has a Xenon 
light source and allows measurements through the complete visible and near infrared light spectrum 
by applying different filter sets. Whole mouse images were taken with constant stage height and 
illumination settings. The Kat2 signal of the transfected L428 cells was visualized with the yellow filter 
set (630–850 nm). To identify and discriminate the individual spectra within the images, spectral 
libraries were defined. Therefore the different dye spectra were unmixed from the cube images. The 
component images, which display the targeted signal, were used to define the tumor to background 
ratios (TBRs) by drawing a region of interest (ROI) around the tumor and a larger area on the back 
representing average background signal. The thereby calculated values for the tumor size in mm² for 
the region of interest were used to calculate the tumor regression. 
2.9.5 Biological activity of Gb-Ki4(scFv) and GbR201K-Ki4(scFv) 
To determine the in vivo biological activity of Gb-Ki4(scFv) and GbR201K-Ki4(scFv), the cell lines L428 
(Kat2 transfected) and L540cy were injected into the mice respectively as described in 2.9.3. The 
mice were randomized equally into groups and received 50 µg GbR201K-H22(scFv) (as non-binding 
control), Gb-Ki4(scFv) or GbR201K-Ki4(scFv) i. v. per treatment day. Tumor size was measured as 
described in 2.9.3 and 2.9.4. Relative tumor size was calculated by setting the tumor size on first day 
of treatment to 100 % and adapting the following values accordingly.  
In vivo targeting of CD30-positive L540cy cells was accomplished by injection of 0.75 nmol 
Ki4(scFv)-SNAP-BG-747 into L540cy bearing mice. 6 h later, the mice were imaged with the CRi-
Maestro system using the deep red filter set (730-950 nm) (2.9.4).  
 
2.10 STATISTICAL ANALYSIS 
Data were analyzed using a two-tailed t-test in GraphPad Prism 4.0, with p < 0.05 considered as 
statistically significant. 
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3 Results 
3.1 PI-9 EXPRESSION IN CANCER CELL LINES 
The high potential of granzyme B-based CFPs has already been reported by several groups in vitro 
and in vivo; however, one of the major challenges for its therapeutic application is the expression of 
the specific granzyme B inhibitor PI-9 in many tumor cells (see 1.4.1). Based on these findings and the 
observed limitations of cytotoxic effects induced by different granzyme B-based CFPs within this 
group, the PI-9 expression profiles of the most commonly used cancer cell lines were evaluated. 
Therefore total soluble protein of native cell extracts (2.4.7) of different cancer cell lines (2.1.6) was 
separated by SDS-PAGE and transferred to a nitrocellulose membrane. The expression of 
endogenous PI-9 could be confirmed by specific anti-human PI-9 staining of a 42 kDa protein band 
correlating to the calculated molecular weight. An overview of the results for all tested cell lines is 
displayed in Table 6. Representative results are shown for CD30-positive cell lines in Figure 3A.  
 
Table 6: Overview of the PI-9 expression profile of different cancer cell lines. 
(++: strong, +: moderate, (+): low, -: no expression) 
Cell line Cell type Target receptor PI-9 expression 
(protein level) 
L428 HL CD30 ++ 
L1236 HL CD30 ++ 
L540/ L540cy HL CD30 - 
K562 Chronic myeloid leukemia in blast crisis CD30 + 
Karpas 299 T cell lymphoma CD30 - 
L3.6pl Pancreatic carcinoma EGFR ++ 
PT45 Pancreatic adenocarcinoma EGFR - 
A431 Epidermoid carcinoma EGFR - 
HL60 AML CD64 - 
U937 Histiocytic lymphoma CD64 - 
Jurkat T cell leukemia / - 
Kasumi 1 AML / (+) 
 
PI-9-positive as well as PI-9–negative cell lines expressing the tumor marker CD30 were identified. 
Corresponding qualitative results from western blotting were confirmed by flow cytometry providing 
more quantitative data. For this purpose triplicate flow cytometric analysis of fixed and 
permeabilized cells (2.4.7) was performed (Figure 3B).  
Jurkat cells were PI-9-negative according to Godal et al. [148] so they could be used as a negative 
control. The CML cell line K562, also previously published to express PI-9 at moderate level [148], 
showed the lowest expression level compared to the Hodgkin lymphoma (HL) cell lines L428 and 
L1236 which express similar amounts of PI-9. L428 retained their PI-9 expression after transfection 
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structure describing the initial Michaelis complex, in which the protease was inactivated by mutating 
S195 to alanine; allowing the interacting amino acids responsible for complex formation to be 
identified. The published rat trypsin - M. sexta serpin B1 complex [87] was found to be suitable for 
fulfilling the prerequisites. In addition, the crystal structure of human granzyme B bound to a five-
residue peptide, solved at 2 Å resolution [42], is known. Human granzyme B and rat trypsin have a 
sequence identity of 36 % according to results from homology modeling (MODELLERv7 software). In 
addition, it is known that these proteins have similar length and are closely functionally and 
structurally related. Thus, the backbone of human granzyme B structure could be fitted with that of 
rat trypsin. Because the crystal structure of human PI-9 has not yet been solved, its structure had to 
be built using molecular homology modeling based on the X-ray structure of the rat trypsin - M. sexta 
serpin B1 complex. The sequence identity between M. sexta serpin B1 and human PI-9 was 27 %. 
In cooperation with the German Research School for Simulation Sciences in Juelich (Prof. Dr. rer. nat. 
Paolo Carloni), the modeled complex was inserted into a water box and key interactions at the 
interface of the two proteins were screened by Baker’s alanine scanning procedure using ROBETTA 
server (AMBER ff99SB, TIP3P and Aaqvist force fields were used for the protein, water, and counter 
ions respectively, evaluation of long-range electrostatic interactions via particle mesh Ewald 
method). The residues R28 and R201, according to the numbering of residues in mature granzyme B, 
were found to have the largest destabilization in terms of loss of contacts. According to the 
respective charge of the amino acids (neutral, opposite and same charge as the original amino acid, 
respectively) arginine was substituted with alanine, glutamic acid and lysine by site-directed 
mutagenesis (2.2.2). To investigate a potential supportive effect of both sites at once, the double 
mutant R28A/R201A was considered as well, so in total, seven putative PI-9 resistant variants were 
generated in silico: R28A, R28K, R28E, R201A, R201K, R201E and R28A-R201A. Their influence on 
complex formation was analyzed during 50 ns molecular dynamic simulations in aqueous solution 
(NAMD 2.7 package). In all of these mutated complexes the structure of the active sites was 
maintained according to molecular modeling results. The three mutants R28K, R201A and R201K 
were predicted to be the most destabilized, whereas the others were almost as stable as those of the 
wild-type complex. Further details about the molecular simulation studies are published in Losasso et 
al. [149]. 
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3.4 PREPARATION AND FUNCTIONAL CHARACTERIZATION OF RECOMBINANT PI-9 
Recombinant PI-9 had to be produced in order to evaluate the enzymatic activity of the new 
granzyme B mutants in the presence of the inhibitor in vitro during a substrate assay to pre-select the 
most promising mutants. As during the initially planned mammalian expression in HEK293T cells, only 
low amounts of PI-9 could be produced (2.1.4, data not shown); therefore another alternative for the 
production of PI-9 was pursued, namely expression in E. coli. The PI-9-encoding sequence was cloned 
into the E. coli expression vector pMT (2.1.4) by HindIII/NotI restriction sites (Figure 6A). The 
periplasmic expression under osmotic stress (2.4.3) has been proven to be successful in small scale 
by SDS-PAGE and western blotting (data not shown); so a 4 L batch fermentation was carried out. As 
shown in Figure 6B, the four subsequent purification steps included two IMAC purifications, one 
purification step via anion exchange chromatography and a final run using a gel filtration column 
(2.4.3). The purified protein was sterile filtered and stored at -80 °C in the presence of 1 mM DTT. 
Functionality of the produced PI-9 was confirmed by its ability to form covalent, SDS-stable 
complexes with recombinant wild-type granzyme B-based proteins. Therefore PI-9 and wild-type 
Gb-H22(scFv) were incubated in a 5:1 molar ratio for 1 h at 37 °C under reducing conditions in 
presence of 1 mM DTT (2.7.1.4). Successful complex formation and thereby functionality of the 
produced PI-9 was verified via western blot analysis (Figure 6C).  
Complexes were formed between PI-9 and free Gb which was present as a degradation product 
within the Gb-H22(scFv) sample running at approximately 77 kDa and between full length 
Gb-H22(scFv) and PI-9 resulting in a complex above 100 kDa (correlates with 175 kDa band of marker 
which is inaccurate at high molecular sizes). The complex could not be verified using anti-His, maybe 
due to sterical hindrance of the antigen binding site; therefore the complex was verified using anti-
human Gb and anti-human PI-9. During analysis with anti-His it turned out that the band running 
below the more intense band was not functional, since it remained within the sample after 
incubation with granzyme B in contrast to the higher running band (Figure 6C, III, lane 2).  
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PI-9-positive cells. Second, the identification of PI-9-positive as well as -negative cell lines 
overexpressing identical target receptors. The different approaches which were evaluated in parallel 
are described in detail in the following. 
1) The direct delivery of the protein into potential target cells is independent of receptor 
expression and specific binders, and thereby parameters based on affinity, internalization and 
endosomal release. This approach was followed by generating a granzyme B construct lacking 
the binding moiety (Figure 4A). Protein delivery into the cytosol of PI-9-positive L428 and L1236 
cells as well as PI-9-negative Jurkat cells, among others, (3.1) was analyzed with the pore-
forming reagent streptolysin O (2.3.3), an oxygen-labile streptococcal hemolytic exotoxin. The 
delivery of granzyme B variants was only successful for Jurkat cells as shown by western blot 
analysis of total soluble protein of cell lysates and resulting cytotoxic effects. The efficacy was 
determined via apoptosis assays done 4 h after Gb delivery into the cells (2.7.2.1). In contrast, 
translocation efficiencies for L428 and L1236 cells were not sufficient to compare the effect of 
different granzyme B variants to inherently PI-9-positive or -negative cells. Since Jurkat cells 
could not be transfected with PI-9 even though all common transfection reagents and methods 
were tested (Table 5), this approach was not further pursued. 
2) Since the functionality of Gb-H22(scFv) was established before with AML cell line U937 and 
primary CD64-positive leukemic cells, this construct could be used to test the new granzyme B 
mutants targeting the CD64-positive AML cell line HL60 (U937 lost its sensitivity to Gb-H22(scFv) 
for unknown reasons and was therefore no longer applicable for this purpose). HL60 cells were 
tested to be PI-9-negative (Table 6), so PI-9 transfection of this cell line would allow comparable 
assays to confirm resistance of granzyme B mutants against PI-9. For this purpose different 
transfection methods were evaluated using varying conditions as listed in Table 5. However, as 
for Jurkat cells (3.5, 1)) all transfection efficiencies were too low to establish a stable transfected 
cell line.  
3) The other available granzyme B-based construct was Gb-Ki4(scFv) whose cytotoxic potential 
could be evaluated in this study using the CD30-positive cell lines L540 and L540cy (2.1.6). Both 
target cell lines were tested to be PI-9-negative (Figure 3). As was seen with HL60 cells, 
transfection with PI-9 was not successful for L540cy cells (3.5, 2). Alternatively, the in vitro anti-
tumor efficacy in cells expressing both endogenous PI-9 and the CD30 receptor was tested. 
Here, depending on the ability of the target cell lines to express PI-9 or not, no induction of 
apoptosis was determined by an Annexin V/ PI assay after incubation with wild-type 
Gb-Ki4(scFv) for 48 h. Results are shown in Figure 7A. Apoptotic cells were only observed in the 
PI-9-negative cell line L540cy. No cell death was induced in PI-9-positive L428 cells. To verify that 
complex formation with the inhibitor was the cause for the cytotoxic limitation, the cells were 
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3.6 IN VITRO FUNCTIONAL CHARACTERIZATION OF WILD-TYPE AND MUTANT 
GB-H22(SCFV) AND GB-KI4(SCFV) 
The main challenge during generation of granzyme B mutants was to avoid a negative effect of the 
mutations on the active site of the enzyme and its tertiary structure. To exclude hampering of 
functionality, the wild-type and mutated granzyme B-based fusion proteins were tested in 
comparative assays regarding their enzymatic activity, their binding affinity, and their specific cell 
cytotoxicity.  
3.6.1 Proteolytic activity of granzyme B in absence and presence of PI-9 
The influence of the single point mutations on the granzyme B proteolytic activity was determined 
via a colorimetric substrate assay based on the synthetic granzyme B substrate Ac-IETD-pNA, which 
mimics the cleavage and activation site of human procaspase-3 (2.7.1.1). Results for Gb-Ki4(scFv) and 
GbR201K-Ki4(scFv) are shown in Figure 8.  
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Figure 8: Enzymatic activity of Gb-Ki4(scFv) and GbR201K-Ki4(scFv).  
The proteolytic activity of activated protein was measured via a colorimetric assay based on the synthetic 
granzyme B substrate Ac-IETD-pNA (2.7.1.1). Reaction was documented for 1 h with a 2 min interval at 37 °C 
and 405 nm in an Elisa plate reader. Graphs were plotted using GraphPad Prism 4.0. 
 
No differences were observed regarding the measured enzymatic kinetics so it could be concluded 
that the active site was not affected by these mutations.  
Enzymatic activity of Gb-H22(scFv) and GbR201K-H22(scFv) was additionally quantified via Michaelis-
Menten kinetics. KM values were comparable for both constructs with 104 ± 32 µM for the wild-type 
and 105 ± 13 µM for the mutant. 
A comparative overview of the activity of all generated mutants, including GbK27A, a mutant 
published before and supposed to bind less efficiently to PI-9 (1.4.1), is depicted as grey bars in 
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Figure 9. Except for the double mutant R28A/R201A and the single mutant R201E, no significant 
differences were measured in comparison to the wild-type protein.  
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Figure 9: Enzymatic activity of Gb-H22(scFv) wild-type and its mutants in the presence and absence of PI-9. 
Gb-H22(scFv) was incubated either with our without recombinant PI-9 according to 2.7.1.4. The proteolytic 
activity was measured via a colorimetric assay based on the synthetic granzyme B substrate Ac-IETD-pNA 
(2.7.1.1, 2.7.1.4). The graph shows means ± SD of 3 to 6 independent experiments [149]. 
 
To confirm the earlier obtained in silico findings (3.23.2) in vitro, the proteolytic activity of wild-type 
and mutant granzyme B was analyzed after challenge with recombinant PI-9 in a comparative 
enzymatic assay. In the presence of PI-9, GbR28K retained 76 % of its original activity, and GbR201A 
retained 46 %. The enzymatic activity of GbR201K was almost the same in the presence or absence of 
PI-9 (6 % reduction after PI-9 challenge), so this variant was the least inhibited variant according to 
this assay. The catalytic activity of the other mutated granzyme B variants decreased relative to wild-
type granzyme B, or was even lower in the case of the double mutant. Their remaining activity after 
complexing ranged from 0.5 % for the double mutant (R28A-R201A) to 25 % for R28E. An exception 
was R28A with a remaining activity of 54 % as opposed to the computed predictions [149]. Even 
though the result of the latter was promising, this variant was not further tested since it did not show 
good results during preliminary cytotoxicity studies on PI-9—positive and –negative cells (data not 
shown). The PI-9 insensitivity of the earlier described granzyme B variant K27A (see above) could not 
be reproduced either during the in silico or during the in vitro experiments. 
The most promising constructs with retained proteolytic activity after incubation with recombinant 
PI-9, GbR28K, GbR201A and GbR201K, were further tested, always in comparison to GbK27A and Gb 
wild-type.  
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3.6.2 Target cell binding 
To exclude an influence of the point
activity of the granzyme B variants, flow 
Gb-Ki4(scFv) or Gb-H22(scFv) variants
human Gb-PE or anti-His Alexa 488
Representative results for Gb-Ki4(scFv) and GbR201K
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Figure 10: Binding analysis of granzyme B
50 nM Gb-based constructs were incubated with 
binding was detected with anti-His Alexa488 (
GbR201K-Ki4(scFv) on CD30-positive L428 and CD30
GbR201K-H22(scFv) on CD64-positive HL60 and
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No difference in binding activity was found for any of the new constructs compared to the wild-type, 
on CD30-positive HL cell lines L428, L1236 and L540cy, or on the CML cell line K562. No unspecific 
binding to the CD30-negative AML cell line HL60 was detected. 
The corresponding Kd values for Gb-Ki4(scFv) and GbR201K-Ki4(scFv) on all of the cell lines used are 
summarized in Table 7 and are all in the same nM range, independent of both the mutation and the 
level of the CD30 receptor expression. The latter was evaluated since significant differences were 
observed during previous flow cytometric analysis. CD30 expression level was set to 100 % for L540cy 
since for this cell line the highest shift in fluorescence was measured. K562 was determined to have 
the lowest CD30 expression. 
 
Table 7: Affinity constants and relative receptor expression level of CD30-positive cell lines. 
(n. d.: not determined) 
Cell line KD of Gb-Ki4(scFv) 
[nM] 
KD of GbR201K-Ki4(scFv) 
[nM] 
CD30 expression 
[% MFI] 
L540cy 3.6 5.7 100 
L428 1.5 1.9 32 
L1236 n. d. n. d. 35 
K562 5.2 4.8 7 
 
Specific binding of Gb-H22(scFv) and its mutants was determined using CD64-positive HL60 cells and 
CD64-negative Burkitt lymphoma cell line Ramos as a control. Data are shown representatively for 
Gb-H22(scFv) and GbR201K-H22(scFv) in Figure 10B. The affinity constant (Kd) for each of these 
constructs was measured to be 2.1 nM; which shows specific and high affinity to the receptor.  
The described data indicated that the point-mutations within granzyme B did not affect the high 
affinity binding of the determined CFPs to their respective target cells. 
3.6.3 Internalization activity 
Since marked dissimilarities in CD30 receptor expression were observed (Table 7) and to assure that 
cytotoxic differences were not due to subsequent diminished internalization, target cell 
internalization was analyzed by confocal microscopy (2.6). For that purpose cells were incubated 
with Ki4(scFv)-SNAP-BG-647, a red fluorescent protein based on the SNAP-tag technology (2.4.6), at 
37 °C or 4 °C. Incubation times were adapted to CD30 expression levels so K562 was incubated for 4 h 
with the fluorescent fusion protein whereas the other cell lines were investigated after 2 h. This 
longer incubation time for K562 was chosen based on the low CD30 expression to allow for additional 
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accumulation of fluorescent protein to bind and internalize allowing it to be visualized via confocal 
microscopy. Internalization and binding was also shown for CD64-positive HL60 cells after 2 h 
incubation with H22(scFv)-SNAP-BG-647 (Figure 11). Results are depicted in Figure 11. 
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Figure 11: Internalization analysis of Ki4(scFv)-SNAP-BG-647 and H22(scFv)-SNAP-BG-647 into corresponding 
target cell lines. 
50 nM fluorescent fusion protein or buffer only (-) were incubated with 4*105 target cell lines at 37 °C or 4 °C 
and internalization was detected with confocal microscopy after 2 h for L540cy, L428, L1236 and HL60 and after 
4 h for K562 (2.6). The (scFv)-SNAP-BG-647 signal (upper left), a transmitted light picture (upper right) and the 
overlay of the two (lower left) are shown. 
 
External binding only was observed at 4 °C; expression level signals differed in intensity depending on 
the receptor used. Incubation at 37 °C led to receptor-mediated endocytosis in all cell lines tested 
(Figure 11). The more intense fluorescent signal observed for H22(scFv)-SNAP-BG-647 was probably 
due to a better coupling efficiency of the SNAP-based protein.  
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Taken together, on a qualitative basis successful protein delivery into the CD30-positive cells could 
be verified despite of their differences in receptor expression level. In addition, successful 
internalization could be demonstrated for CD64-positive HL60 cells. 
3.6.4 Cytotoxic activity against PI-9-negative cell lines 
The next step was to verify that the three most promising mutants, and the mutant described in the 
literature (3.6.1), were still able to induce cell death of PI-9-negative target cells in the same manner 
as the wild-type. For this purpose comparative cell proliferation assays (2.7.3), using the 
corresponding wild-type granzyme B constructs as standards, were conducted. As described above, 
the sensitivity of CD64-positive HL60 cells depends on their activation with adequate concentrations 
of IFNγ (1.6, 2.1.6). The optimal concentration resulting in sensitive and at the same time viable HL60 
cells after 24 h was evaluated to be 50 U/mL. CD30-positive cells did not have to be treated with 
cytokines prior to cytotoxicity assays. 
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Figure 12: Cytotoxic effects of Gb-Ki4(scFv) and Gb-H22(scFv) wild-type and their mutants respectively on 
PI-9-negative target cell lines.  
L540cy and stimulated (50 U/mL IFNγ) HL60 cells were incubated for 72 h at 37 °C with decreasing protein 
concentrations (serial dilution 1:3) of Gb-Ki4(scFv) and its mutants or Gb-H22(scFv) and its mutants, 
respectively. Cell viability was evaluated with a colorimetric XTT-based assay (2.7.3). Viability of untreated cells 
was set to 100 %. The graphs show means ± SD of triplicates per dilution. IC50 values were evaluated with 
GraphPad Prism 4.0 and are listed for all constructs. 
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Due to the absence of PI-9 in L540cy and HL60 cells, no differences of functionality should occur 
during the performed assays. This could be confirmed by the dose-depending curves whose values 
were determined after incubation of the target cells with the fusion proteins Gb-Ki4(scFv) and 
Gb-H22(scFv) and their mutants. The IC50 values (between 1.7 and 5.1 nM or 1.2 and 5.3 nM, 
respectively, summarized in Figure 12) were all in the same range not differing significantly from the 
wild-type. No cytotoxic effects were determined on target receptor negative cell lines HL60 for 
Gb-Ki4(scFv) constructs and Ramos for Gb-H22(scFv) constructs (data not shown). 
The specificity of cell death induced by GbR201K-H22(scFv) was additionally confirmed by a 
competitive assay (2.7.3). Therefore cells were incubated with 10 nM of the fusion protein in the 
absence and presence of 10 or 100 nM H22(scFv). 48 h incubation of HL60 cells with 
GbR201K-H22(scFv) alone resulted in a remaining cell viability of 44 % compared to 100 % of 
untreated cells determined via XTT assay. Cytotoxic effects were significantly reduced by 14 % or 
25 % in presence of 10 nM H22(scFv) or 100 nM H22(scFv), respectively. Incubation with H22(scFv) 
alone did not reduce cell viability significantly (data not shown). 
3.6.5 Apoptotic activity on PI-9-negative cell lines 
To verify apoptosis induction as underlying mechanism of the observed cell death, an Annexin V/ PI 
assay was performed as described in 2.7.2.1. Results are depicted in Figure 13.  
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Figure 13: Apoptotic effects of Gb-Ki4(scFv) or Gb-H22(scFv) wild-type and their mutants respectively on PI-9-
negative target cell lines. 
21 nM CFPs were incubated with target cell lines for 48 h at 37°C. Apoptotic effects were measured via 
Annexin V/ PI assay (2.7.2.1), normalized to buffer control and converted to viability. The bar graphs show 
means ± SD of three independent experiments. (A) Result after incubation of Gb-Ki4(scFv) and its mutants with 
CD30+ L540cy cell line. (B) Result after incubation of Gb-H22(scFv) and its mutants with stimulated (50 U/mL 
IFNγ) CD64+ HL60 cell line. CD64 K562 cell line was used as negative control. 
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Here, up to 60 % of the targeted L540cy cells were apoptotic after incubation with Gb-Ki4(scFv) or its 
mutants (Figure 13A). Receptor-negative HL60 cells were not affected by the fusion proteins (data 
not shown) confirming specificity of apoptosis induction.  
In case of Gb-H22(scFv) and its most promising mutant GbR201K-H22(scFv), apoptosis induction after 
incubation with these CFPs was observed in more than 50 % of the stimulated HL60 cells, whereas no 
unspecific effect could be detected on the CD64-negative CML cell line K562 (Figure 13B).  
Apoptosis induction was additionally confirmed via a colorimetric caspase 3/7 assay (2.7.2.2) which is 
a good indicator for apoptosis after treatment with granzyme B since caspase 3 is a direct substrate 
of the enzyme. After incubation of HL60 cells with 33 nM Gb-H22(scFv) or GbR201K-H22(scFv) for 
48 h the specific signal for caspase activity was in both cases increased 2.5-fold compared to the 
buffer control. The same increase was determined for the positive control treated with Zeocin (data 
not shown).  
Since the above data showed no differences in cytotoxic potential for the tested granzyme B variants 
on PI-9-negative cell lines, they were all further tested on PI-9-positive cells to select the most 
promising one. 
 
3.7 SELECTION OF THE MOST PROMISING GRANZYME B MUTANT ON PI-9-
POSITIVE CELL LINES 
As described in 3.5, the in vitro test system used for this purpose was based on CD30-positive cell 
lines which can be targeted with the construct Gb-Ki4(scFv). Decreased apoptotic effects were 
observed in PI-9-expressing cells after incubation with Gb-Ki4(scFv) in contrast to PI-9-negative cells 
(Figure 7A). Based on the assumption that the observed resistance to cell death is related to the 
expression of the endogenous granzyme B inhibitor (Figure 7B) and subsequently depending on the 
remaining sensitivity of the novel constructs towards the inhibitor, differences in their cytotoxic 
potential were expected here.  
3.7.1 Cytotoxic activity on PI-9-positive cell lines 
To select the optimal granzyme B variant, the in vitro anti-tumor efficacy of the granzyme B mutants 
GbR28K-Ki4(scFv), GbR201A-Ki4(scFv) and GbR201K-Ki4(scFv) was tested on the PI-9-positive HL cell 
lines L428 and L1236 as well as the PI-9-positive CML cell line K562 and compared with the effects 
triggered by the wild-type Gb-Ki4(scFv) or GbK27A-Ki4(scFv), respectively (2.7.3).  
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Figure 14: Cytotoxic effect of Gb-Ki4(scFv) and its 
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Cell viability was evaluated with a colorimetric XTT
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Figure 15: Apoptotic effect of Gb-Ki4(scFv) and 
11 nM CFPs were incubated with PI
Apoptosis was evaluated by caspase
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Figure 16: Serum stability of Gb-Ki4(scFv) and GbR201K
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As the tumors seemed to be encapsulated, the resected tumors were also examined for the presence 
of blood vessels. Tumor-derived tissue sections were stained with alkaline phosphatase without 
levamisole to visualize any endothelial cells (2.8). Low vascularization was determined as 
representatively shown in Figure 17A, therefore it had to be determined if intravenously applied 
constructs could be delivered to the tumors. For that purpose, the reported CD30 ectodomain 
shedding (1.5) was turned to account, since its level in mouse blood serum could provide information 
on a connection of tumors with the bloodstream. The CD30 concentration in blood serum was 
quantified with an earlier established ELISA set-up (2.4.9). It was found that it clearly correlated to 
tumor size, such that the higher the CD30 level in blood serum the bigger the tumors (Figure 17B). In 
addition, specific in vivo targeting of tumors was performed using Ki4(scFv)-SNAP-BG-747 and 
molecular imaging (2.9.4). After injection into L540cy tumor-bearing mice localization of the signal in 
the tumor was observed (Figure 17C) confirming continuous in vivo CD30 receptor expression and 
successful delivery of the Ki4(scFv)-derived construct.  
No obvious tumor growth was detected with L428 cells after tumor cell injection as described above, 
so caliper measurements were impossible. Therefore, based on earlier obtained findings in this group 
indicating the successful correlation between caliper determinations and the signals obtained by 
optical imaging [150], Kat2 transfected L428 cells (2.1.6) were used that enable the visualization of 
even slow and transient tumor growth via molecular imaging (Figure 17D). 5*106 cells were injected 
into the right hind limb of 5 mice. Tumor growth was monitored by optical imaging using a Cri-
Maestro system with the yellow filter set (630-850 nm) and an exposure time of 500 ms every other 
day. Tumor sizes remained constant for at least one week. Afterwards spontaneous tumor remission 
was observed. A tumor take rate of 90 % was determined.  
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Figure 17: Evaluation of the established L540cy and L428 tumor models.  
(A) L540cy-tumor was resected from sacrificed animals and 8 µm cryo-sections were prepared in a freezing 
microtome. Endothelial cells were stained pink with alkaline phosphatase without levamisole to determine 
vascularization of the tumor (2.8). (B) Blood serum was isolated from tumor-bearing mice and CD30 
concentration was quantified via an ELISA assay (2.4.9). The results were correlated to the corresponding 
tumor sizes. M1, M2 and M3: three different mice determined. (C) 0.75 nM Ki4(scFv)-SNAP-BG-747 was 
injected into an L540cy-tumor bearing mouse. Measurement was performed with deep red filter set (730–950 
nm), exposure time 500 ms. I) background signal, II) image with fluorescence signal (yellow, Ki4(scFv)-SNAP-BG-
747). Receptor depending targeting of the tumor (left side) was detected after 6 h via in vivo molecular imaging 
with the CRi-Maestro system (2.9.4). Unspecific accumulation of the 747 signal in the kidney was observed 
(right side) as well as retained signal at the injection site (right eye). (D) 5*106 Katushka transfected L428 cells 
resuspended in 50 % Matrigel™ were injected subcutaneously into the right hind limb (2.9.3). Tumor area was 
detected and calculated via in vivo molecular imaging with CRi-Maestro system (2.9.4). Measurement was 
performed with yellow filter set (630–850 nm), exposure time 500 ms. I) fluorescence image with red circled 
tumor area of one representative mouse, II) same picture as I, edited to visualize the mouse.  
 
  
 
Results 
________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
65 
Based on all described pre-testing, the L540cy tumor model can be regarded as well established so a 
treatment schedule starting approximately after two weeks when tumor size was 2 to 5 mm was set-
up. Also, an appropriate L428-based tumor model could successfully be established with the help of 
in vivo optical imaging technique so a treatment schedule starting one day after cell injection could 
be implemented. 
3.8.3 In vivo effects of GbR201K-Ki4(scFv) on PI-9-negative L540cy cells 
No difference in cytotoxic activity between Gb-Ki4(scFv) and its mutant GbR201K-Ki4(scFv) was 
detected on PI-9-negative cells in vitro, so only the mutant was used to confirm its effectiveness on 
PI-9-negative cells in vivo. As a control the non-binding fusion protein GbR201K-H22(scFv) was used. 
The treatment schedule followed is shown in Figure 18A. Mice were injected with cells as described 
above (3.8.2), and then randomized in two groups (N = 3 for control group, N = 6 for treatment 
group) as soon as the tumor size was 2 – 5 mm according to caliper measurements (after 16 days). 
The mice were treated with 50 µg protein for 5 consecutive days. Treatment was then continued 
every other day until day 13. CFPs were administered i. v. by retro-orbital injection. The size of the 
tumors on day 1 of the treatment was set to 100 %. Results are shown in Figure 18B. 
In addition, L540cy tumor derived tissue sections were stained after excision by 
Ki4(scFv)-SNAP-BG-Vista-Green to confirm continued expression of CD30 after treatment with the 
Ki4(scFv)-based construct (Figure 18C). 
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(A) 
(B) 
Figure 18: Evaluation of the in vivo 
(A) Treatment schedule indicating intravenous (i.v.) injection of 
into the right hind limb (2.9.3), protein injection and days of measurement. (B) 
GbR201K-Ki4(scFv) (N = 6) or with non
with caliper and related to initial tumor 
test, (***): p < 0.001 (2.10). (C) L540c
and cut into 8 µm sections in a freezing microtome. CD30 receptor 
Ki4(scFv)-SNAP-BG-Vista-Green (2.8
 
The data obtained clearly indicate
successfully triggered an arrest of tumor growth, whereas tumors in mice receiving non
GbR201K-H22(scFv) more than doubled in size
3.8.4 Comparative in vivo 
positive L428 cells 
The established model based on Kat2 transfected L428 cells (
used to compare the therapeutic efficacy
wild-type Gb-Ki4(scFv) in vivo against PI
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 
(C) 
anti-tumor activity against L540cy-induced tumors. 
5*106 L540cy cells resuspended in Matrigel
Mice were treated either with 
-binding control GbR201K-H22(scFv) (N = 3). Tumor size
size (100 %). Statistical significance was determined via two
y-tumor was resected from sacrificed GbR201K-Ki4(scFv) 
expression was visualized by 
) and confocal microscopy (2.6). 
s that treatment with GbR201K-Ki4(scFv) was CD30
 (mm²) (p < 0.001).  
effects of Gb-Ki4(scFv) and GbR201K-Ki4(scFv)
3.8.2) and molecular imaging (
 of the most promising mutant GbR201K
-9-positive tumors. 21 mice were divided 
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3 groups and injected with cells as described above (
GbR201K-Ki4(scFv), administered 
Figure 19A. GbR201K-H22(scFv) was used as
Only the mutant GbR201K-Ki4(scFv) 
reduction was statistically significant compared to both wild
whereas the difference between wild
statistically significant (Figure 19
 
(A) 
(B) 
Figure 19: Evaluation of the in vivo 
(A) Treatment schedule indicating intravenous (i.v.) injection of 
in Matrigel™ into right hind limb (2.9.3
either with GbR201K-Ki4(scFv) (N =
(N = 7). Tumor size was measured via
related to initial tumor size (100 %). 
(**): p < 0.005, ns: not significant (2.10
and cut into 8 µm sections on a freezing microtome. 
Ki4(scFv)-SNAP-BG-Vista-Green (2.8
Kat2 signal from transfected cells, III) 
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
3.8.2). Treatment with 50
i.v., was started one day after injection of cells
 the non-binding control.  
killed the PI-9-positive cells in vivo. Here, the tumor size 
-type (p < 0.05) and control (p
-type induced tumor size decrease and control group was not 
B).  
(C) 
I                                             
anti-tumor activity against L428-induced tumors.  
5*106 Kat2-transfected L428 cells
), protein injection and days of measurement. (B) 
 7), Gb-Ki4(scFv) (N = 7) or with non-binding control GbR201K
 in vivo molecular imaging with the CRi-Maestro System (
Statistical significance was determined via two-tailed t
). (C) L428-tumor was resected from sacrificed control
CD30 receptor expression was visualized by staining with 
) and confocal microscopy (2.6): I) Ki4(scFv)-SNAP-BG
overlay of an enlarged image. 
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The continuous presence of CD30 receptor after treatment with Ki4(scFv)-specific CFPs in L428-
derived tumors was verified by immunohistochemical analysis of tissue sections (2.8). Successful 
receptor staining with Ki4(scFv)-SNAP-BG-Vista-Green as well as the sustained fluorescence of the 
cytosolically expressed Kat2 protein is shown in Figure 19C.  
During the animal experiments, all mice involved were active and did not show any symptoms of 
disease caused by treatment. 
These results confirmed the earlier in vitro data. GbR201K-Ki4(scFv) was able to kill PI-9-positive as 
well as PI-9-negative cells in contrast to the wild-type which only killed the latter. To further verify 
these findings, ex vivo studies were performed. 
 
3.9 EX VIVO STUDIES WITH CMML AND AMML PATIENT-DERIVED MONOCYTES  
Effective apoptosis induction of Gb-H22(scFv) in AML patient-derived primary cells which are known 
to overexpress CD64 has been shown before [138]. Therefore they are a valuable target for this CFP 
(1.6). In this study the rare diseases CMML as well as AMML were put into focus to determine if 
these cells are also suitable for an immunotherapeutic granzyme B-based approach. In addition, 
during these ex vivo studies, the potential of the newly generated granzyme B variants could be 
further evaluated.  
Peripheral blood samples of leukemic patients, mostly prior to any clinical treatment, were obtained 
from the university hospital Aachen (PD Dr. med. Edgar Jost) after pre-testing for over-expression of 
CD64. PBMCs were isolated via Ficoll gradient, cultivated in supplemented RPMI medium (2.1.8) and 
used for the following investigations.  
3.9.1 PI-9 expression in patient-derived PBMCs 
As described for the investigation of cancer cell lines previously (3.1), primary cells were tested for 
their ability to express PI-9 via western blot analysis (2.4.7). To evaluate if the cells up-regulate 
endogenous PI-9 during cultivation, or as a result of external stimuli, primary cells were harvested 
and lysed immediately after isolation from peripheral blood and again after different time points 
either in the presence or absence of IFNγ. The addition of IFNγ prior to cytotoxicity assays was shown 
to be essential in this study to retain the activation status of the isolated cells and thereby sensitivity 
to the used CFPs (1.6).  
The results, representatively displayed in Figure 20A for CMML IV, indicated that PI-9 expression was 
independent of the addition of IFNγ, but dependent on cultivation time. Except for CMML II, all 
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CMML samples exhibited expression of PI
CMML I and CMML III, PI-9 was detected at time point 0 as well, albeit significantly lower than after 
14 or 24 h respectively (data not show
positive. Results for all determined cells are summarized in 
PI-9-negative did not even express PI
 
(A)
 
Figure 20: Expression of endogenous PI
CMML or AMML patients (2.1.8). 
(A) Exemplary data for patient CMML
for different time intervals, before harvesting. 
separated by SDS-PAGE (2.4.1) and transferred to a nitrocellulose membrane. Endogenous
a western blot (2.4.2) using anti-human PI
(NEB); Pos.: recombinant PI-9 as positive control. 
patient cells after at least 14 h cultivation duration.
 
In summary, three out of the four investigated CMML samples and one out of the three determined 
AMML samples exhibited PI-9 expression after 5 days in culture.
3.9.2 Receptor phenotyping of PBMCs
So far it is not clear if the receptor CD64 is 
overexpression on the isolated cells and to determine its co
markers for AMML and CMML (CD56, CD33 and CD14, compare 
accordingly by flow cytometry and confocal microscopy
shown in Figure 21A.  
All patient samples showed a high CD64 expression ranging from 56 to 98
staining revealed that in most patients co
occurred. Co-expression of CD64 and CD14 also became evident during the investigations. 
and C confirm the double staining of cells during confocal micro
CMML I clearly showed double staining via anti
for CMML III double staining with anti
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
-9 after at least 14 h of incubation in R10 medium. In 
n). Only one AMML probe (AMML I) turned out to be PI
Figure 20B, whereby the cells indicated as 
-9 after 5 days in supplemented RPMI medium
 
(B) 
Patient 
CMML I 
CMML II 
CMML III 
CMML IV 
AMML I 
AMML II 
AMML III 
 
-9 (2.4.7) in primary leukemic cells derived from peripheral blood of 
 IV. Cells were incubated in R10 in presence or absence of 200
Total soluble protein from cell lysates
-9 and GAM-PO (2.1.5). M: Pre-stained broad range marker in kDa 
(B) Overview of PI-9 expression for all determined primary 
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-expression with the known tumor 
1.6), the cells were phenotyped 
. An overview of the flow cytometric r
 % on all cells. Double 
-expression of CD64 and CD33 as well as CD64 and CD
scopy (2.6). Here, cells from patient 
-CD56-APC and anti-CD64-FITC (
-CD56-APC + anti-CD64-FITC, anti-CD33-APC + anti
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and anti-CD14-APC + anti-CD64-FITC showed heterogeneity of the cell population, as indicated by 
flow cytometry before (Figure 21C). 
 
(A) 
Tumor marker Receptor expression [%] 
 CMML I CMML II CMML III CMML IV AMML I AMML II AMML III 
CD64 79 59 56 98 (7.4) 82 59 (18) 82 (31) 
CD56 68 3 57 65 n.d. 7 30 
CD64+CD56 60 2 36 64 n.d. n.d. 28 
CD14 50 39 59 97 n.d. 31 30 
CD64+CD14 45 n.d. 44 97 n.d. n.d. 30 
CD33 n.d. n.d. 75 98 n.d. 63 31 
CD64+CD33 n.d. n.d. 50 97 n.d. 59 30 
CD56+CD14 46 3 32 97 n.d. 2 n.d. 
CD33+CD14 n.d. n.d. 46 51 n.d. 23 20 
 
 
(B)      CD56-APC/ 
           CD64-FITC 
 
 
(C)     CD56-APC/                        CD33-APC/                     CD14-APC/   
          CD64-FITC                          CD64-FITC                       CD64-FITC 
   
Figure 21: Phenotyping of primary leukemic cells.  
PBMCs were isolated from peripheral blood of leukemic patients (CMML or AMML, 2.1.8) and incubated with 
specific antibodies (2.1.5) according to manufacturer’s instructions (2.5.3). Binding was detected by flow 
cytometry (2.5.3) or confocal microscopy (2.6) (A) Overview of expression profile of patient-derived primary 
leukemic cells determined via flow cytometry; %: portion of receptor positive cells within the whole isolated 
cell population; n.d.: not determined; numbers in brackets: strong CD64 expression detected. (B-C) Confocal 
microscopy of cells from patient CMML I (B) and CMML III (C) stained with antibodies (2.1.5) as indicated.  
 
As a result of the described observations, targeting AMML and CMML patient-derived cells and 
potentially killing them with the CD64-specific H22(scFv)-based CFPs was pursued. 
3.9.3 Target cell binding and internalization 
After detection of CD64 expression, specific binding of the H22(scFv)-derived fusion proteins was 
likewise determined. Exemplary results are shown in Figure 22A for cells from patient CMML IV after 
incubation with Gb-H22(scFv), GbR201K-H22(scFv) or H22(scFv)-ETA’, respectively. All constructs 
bound specifically to the cells.  
10 µm 30 µM 10 µM 30 µM 
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Specific CD64-based internalization was demonstrate
H22(scFv)-SNAP-BG-647 or H22(scFv)
CMML III and CMML IV in Figure 
indicating that no unspecific binding occurred to CD64
 
(A) 
I                                                                         
(B) 
                I 
Figure 22: Binding and internalization a
(A) 50 nM H22(scFv)-fused constructs were incubated with 
peripheral blood of patient CMML IV for 30
(2.1.5) and flow cytometry (2.5.1). 
incubated with 4*105 CD64-positive primary cells from patient 
10 min at 37 °C and internalization was detected with c
 
Since specific binding and internalization 
performed to evaluate the cell death inducing 
  
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
d after incubation of primary cells with 
-SNAP-BG-Vista-Green as representatively depicted for patient 
22B. Some cells were not stained by the CD64
-negative cells.  
                 II 
 
 
               II 
nalysis with primary leukemic cells (2.1.8). 
4*105 CD64-positive primary cells 
 min on ice. Specific binding was detected with anti
(B) 50 nM H22(scFv)-SNAP-BG-647 or H22(scFv)-SNAP
CMML III (I) or CMML IV (II) respectively
onfocal microscopy (2.6). 
to the primary cells was hereby verified
efficacy of the corresponding CFPs.
10 µM 
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3.9.4 Cytotoxic activity on primary cells
Primary cells were incubated with the
GbR201K-H22(scFv) to evaluate differences in their efficacy depending on 
targeted cells. The PI-9 insensitive
viability was measured via XTT 
Prior to cytotoxic studies, cells were stimulated with IFNγ to retain activation of the cells, which was 
confirmed via flow cytometry using CD64
did not induce apoptosis within the targeted cells (data not shown).
 
CMML 
(A) 
(B) 
Figure 23: Cytotoxic and apoptotic
primary leukemic cells. 
21 nM fusion protein was incubated with stimulated (200
peripheral blood (2.1.8) of CMML (left
evaluated by XTT metabolization (A) (
(2.7.2.1) (B), normalized to buffer control and converted to viability
independent experiments. For CMML
H22(scFv)-ETA’. Statistical significance was determined via two
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 
 CFPs Gb-H22(scFv) and the PI-9 
PI-
 IT H22(scFv)-ETA’ was used as positive control
(Figure 23A) and Annexin V/ PI staining (Figure 
-specific antibodies. Without the addition of IFNγ, the CFPs 
 
AMML 
 
 
 
 effects of Gb-H22(scFv), GbR201K-H22(scFv) and H22(scFv)
 U/mL IFNγ) primary mononuclear cells derived from 
 side) or AMML patients (right side) for 48 h at 37°C. Viability was 
2.7.3) and apoptotic effects were measured via Annexin
. The bar graphs show means ± SD of three 
 I, AMML I and AMML II no experiments were performed with 
-tailed t-test, (*): p<0.05, (***)
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9 expression of the 
. Apoptosis and 
23B), respectively. 
 
-ETA’ on 
 V/ PI assay 
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A statistically significant increased reduction in cell viability was observed after XTT evaluation for 
GbR201K-H22(scFv) compared to the wild-type protein for all PI-9-positive cells CMML I, CMML III 
and CMML IV as well as AMML I. Hence, more than 50 % of cells died in the presence of 
GbR201K-H22(scFv) in sample CMML I whereas only 30 % died after incubation with the wild-type 
protein. For CMML II almost 30 % of the cells were eliminated. The results for PI-9-positive CMML III 
after incubation with GbR201K-H22(scFv) were in the same range, whereby the effect of the wild-
type fusion was 10 % lower. In CMML IV the difference between the mutant and Gb-H22(scFv) is 
even more evident. Here more than 40 % of the monocytes died in the presence of 
GbR201K-H22(scFv) but only 18 % were killed by the unmodified version. The largest difference and 
thereby the most significant evidence for the superior performance of the mutant compared to the 
wild-type was observed in PI-9-positive cells from patient AMML I. Here 75 % of the cells could be 
killed by GbR201K-H22(scFv), but only 15 % by Gb-H22(scFv). In contrast the cytotoxic efficacy of 
both constructs was the same on PI-9-negative CMML II, AMML II and AMML III cells (Figure 23A). 
The cytotoxic efficacy H22(scFv)-ETA’ was as high as for the mutant granzyme B construct in case of 
patient CMML III. In contrast, for all other determined cells, the performance of H22(scFv)-ETA’ was 
significantly lower than for Gb-H22(scFv) or GbR201K-H22(scFv). 
To confirm that cell death occurred through apoptosis, Annexin V/ PI assays were additionally 
performed. The viability detected here were in general higher than the ones measured via XTT; 
however the same tendencies were seen (Figure 23B). 
Incubation of the primary cells with the inactive variant GbS184A-H22(scFv) or the non-binding 
GbR201K-Ki4(scFv) did not reduce cell viability (data not shown). 
In addition, the concentration-dependent cytotoxic effect of the granzyme B-based constructs was 
compared using XTT. As indicated by the data above, the most evident results for the better 
performance of the mutant were obtained for AMML I and are shown in Figure 24.  
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Figure 24: Cytotoxic effects of Gb-H22(scFv) and GbR201K-H22(scFv) on primary leukemic cells of AMML I. 
Stimulated (200 U/mL IFNγ) target cells isolated from peripheral blood (2.1.8) were incubated for 72 h at 37 °C 
with decreasing protein concentrations (serial dilution 1:3) of Gb-H22(scFv) (grey curve) and 
GbR201K H22(scFv) (black curve). Cell viability was evaluated with a colorimetric XTT-based assay (2.7.3). The 
graphs show means ± SD of triplicates per dilution. 
 
The determined sigmoidal viability curve confirmed specific and dose-depending cell death for 
AMML I with superior efficacy of the mutant. The IC50 value for GbR201K-H22(scFv) was 8.4 nM. 
3.9.5 Specificity of target cell death 
Since the viability and apoptosis assays were performed with the entire cell population isolated from 
blood after Ficoll gradient, it had to be confirmed that cell death was exclusive for malignant cells. 
Different approaches were followed.  
The challenge here is that positive selection for CD64 expression (either prior to treatment for pre-
selection of only the target cells or after treatment to identify specific reduction of CD64-positive 
cells) was not possible, because limited binding of the CD64-specific antibody was observed on cells 
after incubation with non-toxic H22(scFv)-binding constructs (data not shown).  
Therefore indirect approaches based on flow cytometric analysis had to be evaluated to confirm 
successful elimination of the target cells. The first approach was to identify the location of the target 
cell population (R1) within the FCS/ SSC dotplot via a CD64-specific antibody. After treatment with 
Gb-H22(scFv) or GbR201K-H22(scFv), this particular population decreased by half which is shown in 
Figure 25A for the investigated CMML patients. Representative data for CMML I are shown in Figure 
25B where a higher decrease for the mutant than for the wild-type protein was detected.  
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(A) 
(B) 
                Buffer                                             Gb
Figure 25: Specific reduction of target 
H22(scFv)-ETA’ detected in FSC/SSC dotplot after flow cytometry
21 nM fusion protein was incubated with stimulated (200
peripheral blood (2.1.8) of all determined 
with CD64-specific antibody the location of
FSC/SSC dotplot (R1) and their reduction evaluated with WinMDI
SD of three independent experiments for CMML samples. 
t-test, (**): p < 0.005, (***): p < 0.001 (
gated CD64-positive R1 region; portion
 
The data obtained correspond
Annexin V/ PI measurements (
activity.  
Other methods to verify specificity of cell death within the mixed cell population 
staining of treated cells with Annexin
significant co-expression with CD64. The latter was chosen accord
however, only gave reliable results for cells from patient CMML
explanation see 4.5.2). Here CD56
the amount of apoptotic cells within the CD56
treatment with Gb-H22(scFv) and even
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 
-H22(scFv)                                GbR201K
cancer cell population by Gb-H22(scFv), GbR201K
.  
 U/mL IFNγ) primary mononuclear cells derived from 
CMML patients for 48 h at 37 °C. By labeling of mononuclear cells 
 the target cell population was identified via flow cytometry 
 2.8 (2.5.3). (A) The bar graphs show means ± 
Statistical significance was determined via two
2.10). (B) Exemplary data shown for treated cells of patient 
 of target cells shown in percentage. 
s to the results of the previously obtained 
3.9.4). This confirms the specificity of the determined cytotoxic 
 V/ PI and a cell-specific APC-labeled antibody
ing to the results from 
 I as shown in 
-positive cells were gated so it could clearly be 
-positive target cell population increased after 
 more significantly after treatment with GbR201K
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(A) 
               Buffer                                    
(B) 
  Buffer                                                 
Figure 26: Reduction of target cancer cell population 
specific antibodies (2.1.5). 
21 nM fusion protein was incubated with stimulated (200
peripheral blood (2.1.8) of CMML patients for 48
were labeled in parallel with CD56
Dotplots show Annexin V/ PI stained cells after specific CD56
cells; bottom right: early apoptosis; top right: late apoptosis/dead cells. Numbers in the quadrants represent 
the percentage of cells of each category.
CD14-specific antibody (anti-CD14-APC,
 
The third approach to verify specificity 
treated cells with certain antibodies
monitoring of the decrease of 
phenotyping experiments (Figure 
remaining CD14-positive cells after treatment 
cells. After incubation with the 
Results are displayed as histograms in 
to the buffer control was detected
With the help of all described approaches, specificity of cell death within the heterogeneous primary 
cell population induced by the CD64
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 Gb-H22(scFv)                          GbR201K-H22(scFv)
Gb-H22(scFv)                                        GbR201K-
by Gb-H22(scFv) and GbR201K-H22(scFv) 
 U/mL IFNγ) primary mononuclear cells derived from 
 h at 37°C. (A) Treated and untreated cells 
-specific antibody (anti-CD56-APC, 2.1.5) and Annexin
- gating. Bottom left: viable cells; top left: necrotic 
 (B) Treated and untreated cells of patient CMML II were
 2.1.5). M1 represents cells with strong CD14 expression.
of CD64-selected cell death was accomplished by staining the 
 which were co-expressed with CD64 (Figure 
specific receptor expressing cells. For example, for
21) indicated a co-expression of CD14 and CD64 so 
could be correlated to the targeted 
CFPs, the cells were harvested and labeled with anti
Figure 26B. A clear decrease for the treated samples compared 
 so it could be concluded that cell death was specific.
-targeting constructs could be confirmed. 
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3.9.6 Serum stability of Gb-H22(scFv) fusion proteins in patient-derived serum 
Serum stability is an important pre-requisite for later systemic, intravenous application of the 
immunotherapeutic. Hence, Gb-H22(scFv) and GbR201K-H22(scFv) were incubated in either 50 % 
human patient serum derived from patient CMML III or PBS at 37 °C for 1, 6 or 24 h (2.4.8). Stability 
was determined by measuring residual binding activity via flow cytometry as described for the 
Ki4(scFv)-based constructs (3.8.1). Results are summarized in Table 8. 
 
Table 8: Serum stability of Gb-H22(scFv) and GbR201K-H22(scFv) in human patient serum (CMML III) or PBS. 
 Stability in serum [%] Stability in PBS [%] 
Time [h] Gb-H22(scFv) GbR201K-H22(scFv) Gb-H22(scFv) GbR201K-H22(scFv) 
0 100 100 100 100 
1 98 96 96 96 
6 80 74 92 93 
24 66 62 92 92 
 
Serum stability was comparable for both variants and could be confirmed for at least 6 h. After 24 h 
serum stability was clearly reduced whereas retained binding activity after incubation in PBS was 
significantly higher (reduction of 8 %). Hence, the serum- and time-dependent stability for both 
constructs was determined. 
 
3.10 EVALUATION OF GRANZYME M AS NOVEL EFFECTOR MOLECULE IN CYTOLYTIC 
FUSION PROTEINS 
Granzyme M has been described to possess anti-tumor activity (1.3.2), so in this study CFPs 
containing this serine protease as an alternative to granzyme B were generated. To confirm the 
potential of granzyme M, it was fused to different tumor-specific single chains and functionality 
assays were performed. To evaluate the results properly, experiments were prepared in comparison 
to the corresponding granzyme B-based CFP. 
3.10.1 Generation and preparation of granzyme M fusion proteins 
The fusion constructs comprised of granzyme M and the CD64-specific H22(scFv) or CD30-specific 
Ki4(scFv) (2.1.5) are shown in Figure 27A. They were generated as described in 2.1.4 by replacing the 
granzyme B sequence with that of granzyme M within the corresponding constructs.  
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(A) 
(B) 
                                                           
Figure 27: Overview of granzyme
Gm-H22(scFv) (B). 
(A) Schematic structure of the binary eukaryotic expression vector pMS 
EGm-Ki4(scFv). Ig-κ: signal peptide sequence
cleavage site, H: 6x histidine tag, IVS/IRES: synthetic intron and internal ribosome entry site, EGFP: enhanced 
green fluorescent protein. Enterokinase cleavage site indicated with 
in HEK293T cells and purified from supernatant via 
0.02 U/µg Enterokinase (2.4.4). Protein w
(2.4.1) or transferred to a nitrocellulose membrane 
(2.4.2). Specific protein bands were detected at 61.5
kDa (NEB). 
 
As in the case of the granzyme
N-terminus to facilitate expression in eukaryotic cells. 
supernatant should allow correct post
glycosylation sites. The protein was purified by affinity chromatography selecting for the His
with a yield of 1 mg/L, as determined by SDS
The identity of the protein was confirmed by western blot analysis using an anti
(2.4.2). Under denaturing conditions, SDS
150 kDa, a band with the expected molecular weight of 61.5
Hence, the intended granzyme
expressed in HEK293T cells. 
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 M-based constructs (A) and SDS-PAGE and western blot analysis 
encoding for
 (L) of immunoglobulin kappa light chain, ECS: enterokinase 
arrow. (B) Fusion proteins were expressed 
IMAC (2.4.4). Activation of the protein was done with 
as separated by SDS-PAGE and either stained with coomassie (I) 
for western blotting with anti-human 
 kDa and ~150 kDa. M: Pre-stained broad range marker in 
 B-based CFPs, an enterokinase site precedes the granzyme
The secretion of the fusion proteins into the 
-translational modification because granzyme
-PAGE (2.4.5) and activated with enterokinase (
-
-PAGE revealed, apart from a band at approximately 
 kDa (Figure 27B).  
 M constructs could successfully be generated and 
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3.10.2 Functional characterization of granzyme M 
Successful activation after enterokinase cleavage 
ability of granzyme M to cleave PI
synthetic granzyme M substrate, Suc
Western blot analysis with anti-human PI
Gm-H22(scFv) in a 3:1 molar ratio. Recombinant PI
unknown reasons (3.4) but cleavage by granzyme
lower band (Figure 28A). The same results were obtained for Gm
The enzymatic functionality of the fusion protein was also verified by the applied colorimetric assay. 
No activity was detected for the uncleaved variant EGm
dependent increase in extinction was observed for
 
(A) 
 
 
 
Figure 28: Enzymatic activity of Gm
(A) Recombinant PI-9 (3.4) and Gm-
was separated by SDS-PAGE and transferred to a nitrocellulose membrane (
was detected in a western blot using anti
in kDa (NEB). (B) The proteolytic activity of activated protein was measured via a colorimetric assay based on 
the synthetic granzyme M substrate Suc
405 nm for different concentrations as indicated and compared to uncleaved variant EGm
graphs show means ± SD of three independent experiments.
 
These results confirm that enzymatically 
expression in HEK293T cells and subsequent enterokinase digestion
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fusion proteins 
was tested by two methods, one based on the 
-9 (2.7.1.3), and the other one using a colorimetric assay with a 
-Ala-Ala-Pro-Leu-pNA (2.7.1.1).  
-9 confirmed the cleavage of PI-9 after 24
-9 was partially degraded during purification for 
 M was nevertheless clearly visible, intensifying the 
-Ki4(scFv) (data not shown). 
-H22(scFv), whereas a concentration
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3.10.3 Target cell binding  
The antigen-specific binding of all 
corresponding target cell lines. 
CD64-positive AML cell line HL60 (
(Figure 29B). CD64-negative L428
 
(A)                                                                                        (B
(C) 
Figure 29: Binding analysis of Gm-H22(scFv
50 nM Gm-H22(scFv) was incubated with 4*10
blood of patient CMML IV (B) for 30 min on ice
cytometry (2.5.1). CD64- L428 cell line was 
 
An obvious fluorescence shift was detected on CD64
attested for the granzyme M-based CFP. No binding was observed on the control cell line L428 
confirming that the binding activity was s
___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
granzyme M-based CFPs was tested by flow cytometry using the 
Exemplary results are shown for Gm-H22(scFv) targeting human 
Figure 29A) and CD64-positive primary cells from a CMML patient 
 cells were used as the control cell line (Figure 29
) 
 
 
).  
5 HL60 cells (A) or primary leukemic cells derived from peripheral 
. Binding was detected with anti-His Alexa488 (
used as negative control.  
-positive cells, so specific binding could be 
elective for the targeted receptor. 
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target-specific binding was confirmed for Gm-Ki4(scFv) using CD30-positive cell lines (data not 
shown). 
3.10.4 Cytotoxic activity of granzyme M fusion proteins 
In accordance with the viability and apoptosis assays performed and described for Gb-H22(scFv) 
(3.6.4 and 3.6.5), the CD64-positive AML cell line HL60 was used for the evaluation of Gm-H22(scFv). 
The concentration-dependent cytotoxicity of Gm-H22(scFv) was evaluated using an XTT-based 
colorimetric cell proliferation assay (2.7.3) with IFNγ stimulated HL60 cells. Unstimulated HL60 cells 
and CD64-negative L428 cells were used as negative control. 
As shown in Figure 30A, the viability of the stimulated HL60 cells declined significantly, whereas CD64 
receptor negative L428 cells and unstimulated HL60 cells remained unaffected. The IC50 values were 
between 1.2 and 6.4 nM which is in the same range as shown before in Figure 12B for Gb-H22(scFv). 
A non-specific granzyme M fusion protein showed no evidence of cytotoxicity (data not shown). 
The antigen-dependency of Gm-H22(scFv)-induced cytotoxicity was confirmed by carrying out a 
competitive assay which showed a statistically significant dose-dependent reduction in cytotoxicity in 
the presence of free H22(scFv) (Figure 30B). There was no significant difference between the viability 
of cells incubated with free H22(scFv) alone or with the buffer alone. 
The mechanism of Gm-H22(scFv) toxicity in HL60 cells was further characterized by carrying out an 
Annexin V/ PI apoptosis assay (Figure 30C). When stimulated HL60 cells were incubated with 66 nM 
Gm-H22(scFv) for 48 h, the number of apoptotic cells stained with Annexin V/ PI was 65 % greater 
than in control experiments lacking the protein. This was in accordance with the results obtained 
after treatment with Gb-H22(scFv) and demonstrated efficient programmed cell death. No difference 
between experimental cultures and controls was detected for the CD64-negative CML cell line K562. 
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Figure 30: Cytotoxic and apoptotic effects of Gm
(A) Target cells were incubated for 72 
Gm-H22(scFv) on stimulated (50 U/m
based assay (2.7.3). Viability of untreated cells was set to 100
dilution. CD64- cell line L428 and non
HL60 cells were incubated for 72 h 
free H22(scFv). Viability was evaluated via
three independent experiments. Statistical significance was determined via two
(2.10); ns: not significant. (C) 66 nM G
48 h at 37°C. CD64 K562 cell line was used as 
PI assay (2.7.2.1). Bottom left: viable cells; top left: necrotic cells; bottom right: early apoptosis; top right: late 
apoptosis/dead cells. Numbers in the quadrants represent the percentage of cells of each category.
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To evaluate the potential of granzyme
granzyme B Gm-Ki4(scFv) was tested in comparison to Gb
L428, L1236 and L540cy. The former 
resistant against apoptosis induction by wild
PI assay are shown in Figure 31.  
 
Figure 31: Apoptotic effect of Gm-Ki4(scFv) compared to 
11 nM fusion protein was incubated with HL cell lines L428 (PI
at 37 °C. Apoptotic effects were measured via Annexin
necrotic cells; bottom right: early apoptosis; top right: late apoptosis/dead cells. Numbers in the quadrants 
represent the percentage of cells of each category
 
Gm-Ki4(scFv) is able to kill PI-9
L540cy. As expected, Gb-Ki4(scFv) only kills 
effectively than Gm-Ki4(scFv). During a dose
for Gm-Ki4(scFv) on L540cy was 272
(Figure 12A). No unspecific toxic effects were determined on CD3
shown). 
To confirm the potential of granzyme
Gm-425(scFv) and Gb-425(scFv)
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 M with PI-9-positive cells, in comparison to wild
-Ki4(scFv) on the CD30
of these two are PI-9-positive and have been shown to be 
-type Gb-Ki4(scFv) (Figure 7). Results for an Annexin
Gb-Ki4(scFv). 
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overexpressed in a variety of tumor cells [151], were analyzed in comparative assays. Both granzyme 
constructs showed a similar specific cytotoxic as well as apoptotic effects against the EGFR-positive 
epidermoid cancer cell line A431, but did not affect the EGFR-negative cell line L540cy (data not 
shown). 
Concluding, granzyme M was fused to three different cell-binding moieties and showed specific anti-
tumor activity towards the corresponding target cells while leaving receptor negative cells 
unaffected. It is also able to kill cells in presence of the granzyme B inhibitor PI-9 in contrast to the 
wild-type granzyme B construct.  
3.10.5 Ex vivo studies with Gm-H22(scFv) 
Apart from in vivo studies, ex vivo experiments with primary cells are important assays to determine 
the efficacy of novel immunotherapeutics. The characteristics of these patient-derived cells predict 
the later effects in humans much better than artificial cell lines (see also 4.5). Hence, the potential of 
the novel human effector molecule granzyme M fused to H22(scFv) was tested comparative to 
Gb-H22(scFv) using the same primary cells as used in the experiments described in 3.9. In addition, 
by parallel experiments with GbR201K-H22(scFv) the prospective of granzyme M on PI-9-expressing 
cells in comparison to this newly established PI-9 insensitive variant could also be assessed.  
Cytotoxic effects were monitored using the XTT assay (Figure 32A) or by Annexin V/ PI staining 
(Figure 32B) as described in 3.9.4. For Gm-H22(scFv) both assays indicated that cell viability was 
reduced by about 40 % in all samples. The same was observed for GbR201K-H22(scFv). Significant 
differences of these both constructs compared to the wild-type Gb-H22(scFv) were evident for cells 
from patient CMML IV, tested PI-9-positive before (Figure 20A). Here only 15 % of the cells could be 
killed by the wild-type granzyme B-based construct.  
The specificity of the cytotoxic effect and thereby the selective reduction of the CD64-positive target 
cell population was demonstrated here in the same manner as described earlier in 3.9.5 (data not 
shown). 
To further evaluate the cytotoxic effect of Gm-H22(scFv) on primary cells, dose-dependent cell 
viability assays were prepared for cells from patient AMML II (Figure 32C) and AMML III (Figure 32D). 
The sigmoidal curves evidently demonstrated the dose-dependency of cell death triggered by 
Gm-H22(scFv) ex vivo, even though general cell viability remained rather high. 
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Figure 32: Cytotoxic and apoptotic effects of Gm
(A,B) 21 nM fusion protein was incubated with stimulated (200
from peripheral blood (2.1.8) of AMML or CMML patients (as indicated) for 48
been tested according to 3.9.1. Viability was evaluated by XTT metabolization (A) (
were measured via Annexin V/ PI assay (
Data for Gm-H22(scFv) were compared to Gb
show means ± SD of three independent experiments.
test, (*): p < 0.05 (2.10); n.d.: not determined.
peripheral blood (2.1.8) of patient AMML II (PI
with decreasing protein concentrations (serial 
colorimetric XTT-based assay (2.7.3).
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2.7.3
2.7.2.1), normalized to buffer control and converted to viability (B). 
-H22(scFv) and GbR201K-H22(scFv) from Figure 
 Statistical significance was determined via two
 (C,D) Stimulated (200 U/mL IFNγ) target cells 
-9-) (A) and AMML III (PI-9-) (B) were incubated for 72
dilution 1:3) of Gm-H22(scFv). Cell viability was evaluated with a 
 The graphs show means ± SD of triplicates per dilution.
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4 Discussion 
The use of immunotoxins (ITs) highly increases the efficacy of cancer therapy leaving healthy cells 
mostly unaffected. However, the clinical deployment of early generation ITs was limited due to their 
immunogenicity, resulting in the generation of neutralizing antibodies that exclude repeated 
applications. Therefore complete humanization of ITs is an important prerequisite for the successful 
development of more effective ITs [24,31], called cytolytic fusion proteins (CFPs). This concept is based 
on the use of endogenous human enzymes that induce cell death, fused to humanized or even fully 
human antibody fragments. Candidate human enzymes include proteases, RNases and kinases 
[4,31,109,152,153]. In this thesis, the focus was granzymes, which are human immunoproteases 
involved in the granule-mediated apoptosis of virus-infected or transformed tumor cells. The 
efficiency of granzyme B was elucidated in relation to the expression of its specific inhibitor PI-9. 
Since limited effects were observed for the wild-type protein on PI-9-positive cells, the intention was 
to generate novel variants via molecular modeling and site-directed mutagenesis, which are 
enzymatically active even in presence of PI-9. When fused to the CD30-targeting Ki4(scFv) or CD64-
targeting H22(scFv), the most promising variant was eventually selected and its efficacy was proven 
in vitro and in vivo on CD30-positive Hodgkin lymphoma and CML cell lines, as well as ex vivo on 
CD64-positive primary leukemic cells. In addition, another member of the granzyme family, 
granzyme M, was introduced in this study bearing the potential to become a novel effector molecule 
in context of CFPs. Combined with different cancer cell-specific ligands, its cytotoxic efficacy could 
successfully be shown in vitro as well as ex vivo, with the advantage to be active despite the presence 
of the inhibitor PI-9. In the following, the hallmarks of granzyme B and its PI-9 insensitive mutants as 
well as of granzyme M will be discussed in detail focusing on their therapeutic potential and 
applicability for later clinical use as immunotherapeutics. 
 
4.1 THE THERAPEUTIC POTENTIAL OF GRANZYME B-BASED CYTOLYTIC FUSION 
PROTEINS 
Granzyme B has been evaluated as a CFP targeting CD64-positive cells during a previous PhD thesis in 
this work-group and was published before by Stahnke et al. [138]. In this study Gb-H22(scFv) was 
successfully used to selectively kill AML-derived HL60 cells and primary leukemic cells (Figure 12 and 
Figure 23). In addition the in vitro protocols for another granzyme B-based CFP, Gb-Ki4(scFv), have 
been optimized to allow IC50 value determination. The IC50 values were comparable with the ones 
determined for Gb-H22(scFv).  
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Other groups have also shown the great anti-tumor potential of granzyme B-based CFPs as 
summarized in Table 9. Apart from its low immunogenicity, granzyme B has several inherent 
advantages as an immunotherapeutic component like high cytotoxic efficacy reflecting its status as 
an effector molecule of the cellular immune system, broad range of apoptosis inducing mechanisms 
with the potential to circumvent anti-apoptotic proteins (1.3.1). Furthermore, compared to other cell 
death inducing proteins like microtubule-associated proteins which exclusively kill proliferating cells 
[153], it is independent of cell proliferation, which is advantageous for non- or low-proliferating 
malignant diseases like CMML. Also, the production of granzyme B (and CFPs derived therefrom) in 
various heterologous expression systems (E. coli, Pichia pastoris, insect cells and mammalian cells 
such as HEK293T, HeLa, Jurkat and COS [4]) is relatively straightforward, which reflects a significant 
prerequisite before biopharmaceuticals can enter clinical studies. 
The involvement of granzyme B in natural cellular defense, however, is a mixed blessing in targeted 
cancer therapy since the efficacy of ITs/ CFPs depends on the sensitivity of tumor cells to pro-
apoptotic signals. One of the major challenges in both targeted cancer therapy and standard 
chemotherapy approaches, that induce programmed cell death, is the tendency for tumor cells to 
develop either escape mechanisms or resistance to pro-apoptotic signals allowing host 
immunosurveillance. This limits the clinical application of granzyme B insofar as that it is specifically 
inhibited by PI-9, which usually protects cells from misdirected granzyme B (1.4.1), but is also 
upregulated in certain tumors (4.2). Other limiting factors are, that granzyme B has a high isoelectric 
point (pI ~ 10), resulting in a positive surface charge contributing to non-specific binding to negatively 
charged cell surface proteoglycans via electrostatic interactions. In addition, it is, as all CFPs in 
general, released slowly after uptake by the receptor-mediated endocytosis which reduces its 
cytotoxic impact [4]. In this study, the PI-9-related challenge is focused and in detail discussed in the 
following sections, whereas solutions to the latter factors will be introduced in chapter 5. 
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Table 9: Overview of different granzyme B-based cytolytic fusion proteins (CFPs) published so far. 
(blue background: data generated in this study and internal publication of this group) 
CFP (as 
published) 
(expression 
system) 
Indication Target 
receptor / 
antigen 
Target cells IC50 values PI-9 expression 
reported from 
others 
Activation / 
generation 
of free N-
terminus 
Ref. 
Gb-H22(scFv) 
(HEK293T) 
AML, CD64+ 
malignancies 
CD64 U937 
AML cells (ex 
vivo) 
HL60 
CMML; AMML 
(ex vivo) 
1.7–17 nM 
-- 
 
~ 1.2 nM 
-- 
No*, yes [155] 
yes [155] 
 
No*, yes [156] 
Partially (see 
Figure 20)) 
In vitro 
activation 
via EK 
[138] 
This 
work 
Gb-Ki4(scFv) 
(HEK293T) 
CD30+ 
malignancies, 
e.g. Hodgkin 
lymphoma 
CD30 L540cy, 
L428, L1236, 
K562 
~ 2.5 nM No* 
Yes* 
In vitro 
activation 
via EK 
[157] 
This 
work 
GrB-scFvMEL 
(E.coli) 
Melanoma gp240 A375-M 
 
~ 20 nM 
 
n.d. In vitro 
activation 
via EK  
[158] 
GrB-scFvMEL 
(E.coli) 
Melanoma gp240 A375-M (in 
vivo) 
MEL-526 
TXM-18L 
~ 30 nM 
 
~ 50 nM 
~ 150 nM 
n.d. 
 
n.d. 
n.d. 
In vitro 
activation 
via EK  
[159] 
GrB-TGFα 
GrB-scFv 
(FRP5) 
(P.pastoris) 
Breast 
carcinoma 
EGFR,  
ErbB2 
(Her2) 
MDA-MB468 0.25 nM 
0.29 nM 
(+chloro-
quin for 
both) 
n.d. In vivo 
activation 
by Kex2 
[160] 
B3-GzmB, 
GzmB-CD8 
(E.coli) 
Breast 
carcinoma 
Lewis Y 
antigen 
SK-BR3  
 
MCF-7  
 
(MCF-7casp3) 
98 nM,  
1595 nM 
140 nM  
(35 nM),  
198 nM  
(394 nM) 
Yes [80] 
 
Yes, after 
induction by 
estrogens [77] 
Polyionic 
adapters 
between 
granzyme B 
and dsFv-B3 
[161] 
GrB-VEGF
121 
 
(E.coli) 
Tumor 
vascular 
endothelial 
cells 
VEGF PAE/FLK-1 
PAE/FLT-1 
~ 10 nM 
-- 
n.d. 
n.d. 
In vitro 
activation 
via EK  
[162] 
ImmunoGrB-
PEAII 
(HeLa, Jurkat) 
Breast and 
ovarian 
carcinoma 
Her2 SK-BR3 (in 
vivo) 
SKOV-3 
 
Not 
applicable 
since 
supernatant 
was used 
 
Yes [80] 
 
n.d. 
PEAII trans-
location 
motif to 
allow 
endogenous 
furin 
activation: 
e23sFv-
PEAII-GrB 
[163] 
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Table 9: Cont. 
CFP (as 
published) 
(expression 
system) 
Indication Target 
receptor / 
antigen 
Target cells IC50 values PI-9 expression 
reported from 
others 
Structural 
hallmarks 
Ref. 
ImmunoGrB- 
Fpe/Fdt/R9 
# 
(HeLa, Jurkat) 
Breast, gastric 
and 
hepatocellular 
carcinoma 
Her2 SK-BR3 
SGC-7901 (in 
vivo) 
AGS  
Hep G2 
Not 
applicable 
since 
supernatant 
was used 
Yes [80] 
n.d. 
 
n.d. 
n.d. 
Introduction 
of novel 
furin 
cleavable 
sites 
between 
e23Fv and 
granzyme B 
(compare 
above) 
[164] 
GrB-YCG 
(insect Sf9 
cells) 
Ovarian, 
breast, 
endometrial 
and prostate 
carcinoma 
hLHR MA-10 
(murine) 
MCF-7 
PC-3 
0.16 µM 
 
-- 
-- 
No PI-9 
expected in 
murine cell line 
In vitro 
activation 
via EK prior 
to use 
[165] 
GrB/4D5/26 
(HEK293T) 
Breast, 
 
 
 
gastric, 
lung, 
cervical 
carcinoma 
Her2/neu BT474 M1 
Calu3 
eB-1 
MDA MB435 
NCI-N87 
MDA MB453 
Me180 
29.3 nM 
40.5 nM 
93.1 nM 
< 500 nM 
90.4 nM 
56.8 nM 
< 500 nM 
Yes** 
Yes (strong)** 
No** 
No** 
Yes** 
Yes** 
Yes** 
Insertion of 
a pH-
sensitive 
fusogenic 
peptide for 
improved 
delivery of 
granzyme B 
into the 
cytosol 
[166] 
Abbreviations: GrB, Gb, GzmB: granzyme B; hLHR: human luteinizing hormone receptor; Her2: human epidermal growth 
factor receptor 2; Kex2: killer expression defective 2; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial 
growth factor; dsFv: disulfide stabilized Fv fragment; n.d.: not determined in other publications; EK: Enterokinase; PEAII: 
second domain of Pseudomonas Exotoxin A (residues 253-364); (in vivo): cell line was successful killed in mice; * compare 
3.1; # Fpe: furin site sequence from PEA (amino acids 273-282), Fdt: furin site sequence from diphtheria toxin (amino acids 
187-196), R9: poly-arginine tract; **as determined in the same study. 
 
 
4.2 IMPACT OF ENDOGENOUS PI-9 EXPRESSION IN CANCER CELLS ON THE PRO-
APOPTOTIC ACTIVITY OF GRANZYME B 
A direct correlation between PI-9 expression and resistance to apoptosis induction by wild-type 
granzyme B was verified in this study (Figure 7). Several groups have already determined the 
expression of the granzyme B inhibitor PI-9 in primary cancer cells. An overview of the results is 
shown in Table 10 and Table 11. The impact of resistance on granzyme B-based immunotherapeutics 
is controversial, since some reports claim that resistance to perforin-dependent pathways is not a 
relevant escape mechanism in lymphoma [148] and that the induction of apoptosis by granzyme B 
can be even achieved in cells expressing or upregulating PI-9 (compare Table 9). For example, Cao et 
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al. have not observed any relationship between PI-9 levels and cell sensitivity in their granzyme B 
fusion protein targeting Her2/neu-positive cell lines [166]. Another example is a CFP comprising 
granzyme B and dsFv-B3, targeting the Lewis Y carbohydrate antigen overexpressed e. g. on 
squamous cell lung carcinoma or lung adenocarcinoma, which has been shown to kill the human 
breast cancer lines SK-BR3 and MCF-7 in an antigen-dependent manner [161]. The reported IC50 
values are rather low compared to the ETA-based reference, which might reflect the expression of 
PI-9 in SK-BR3 cells and the ability of MCF-7 cells to upregulate PI-9 in the presence of estrogen [77]. 
However, it is difficult to confirm in retrospect whether these cells actually expressed PI-9, because 
cell lines can differ depending on their source, cultivation conditions, and cell cycle phases [167]. 
Indeed, several studies have revealed a direct correlation between PI-9 expression and the loss of 
granzyme B pro-apoptotic activity in vitro and in xenograft mouse models [64,80,168-170].  
As a consequence of these published data, and since a limited effect induced by some granzyme B-
based CFPs has been observed in our group, a closer look at the PI-9 protein expression profiles in 
potential target cell lines was carried out in this work (3.1). Hereby, the influence of cultivation time 
on the PI-9 level could be excluded via investigations with a Hoechst sorting reagent indicating that 
all cells in one cultivation flask were in the same maturation status. Jurkat cells were found to be 
PI-9-negative as suggested by published data [148], so they could be used as negative control. The 
PI-9 expression shown within K562 (CML cell line) is consistent with earlier findings whereas the 
absence of PI-9 in the AML cell lines HL-60 and U937 is controversial [82,148,155,156]. The latter 
might be related to differences in detection methods, cultivation conditions and the fact that PI-9 can 
be triggered by external stimuli (compare Table 10 and Table 14).  
It was found that the PI-9 expression level differed among the EGFR-positive and CD30-positive target 
cell lines (Table 6). The latter were chosen for further analysis (3.5) to compare cell lines which were 
initially derived from patients with the same cancer type (compare details in 4.3.2). Flow cytometric 
analysis indicated a heterogeneous expression of PI-9 among these cells (Figure 3B). This is in 
accordance to an earlier study (compare Table 11) showing that 6 out of 57 tested HL patients 
expressed the inhibitor [171]. In addition, PI-9 expression was also upregulated upon EBV infection, 
which is a main cause of B-type HL [72] and was recently even directly linked to EBV-positive cases of 
HL [172]. Other data, shown in Table 10 and Table 11, also indicate that PI-9 is expressed in a 
heterogeneous manner within the tumor cell population, leading to the survival of a small number of 
malignant cells surrounded by innate immune cells. PI-9 was expressed primarily in tumors 
containing many granzyme B-positive infiltrating CTLs and the high incidence of PI-9-positive tumor 
cells often predicted an unfavorable clinical outcome [173]. This suggest that PI-9-positive tumor 
cells are positively selected as they evade immunosurveillance, which is clinically relevant for the 
treatment of hematological disorders or solid tumors in which PI-9 expression is upregulated during 
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immunosurveillance or tumor therapy. Therefore the development of drugs that are effective against 
such resistant cells is highly advantageous [4]. 
Table 10: Overview of PI-9 expression in different carcinomas / melanomas. 
Cancer type Detection Hallmarks Ref. 
Lung cancer  In vitro (cell lines) 
In vivo (primary cancer 
cells) 
PI-9 highly expressed in lung cancer cell lines 
PI-9 expression was increased in primary lung cancer 
cells and significantly correlated with cancer stage 
(dependent on granzyme B expression of CTLs) 
[170] 
Prostate cancer In vitro (cell lines → 
qPCR and flow 
cytometry) 
In vivo (prostate tumor 
tissue → qPCR and 
immunohistochemistry) 
PI-9 expression in cell lines PC3 and DU-145 
 
 
PI-9 expression is up-regulated in pre-cancerous 
states, which is dysregulated in later stages whereas 
it remains in some tumors (pilot study) 
[169] 
Non-small cell 
lung carcinoma 
cells (NSCLCs) 
and tissues 
In vitro (cell lines → RT-
PCR and western blot 
analysis) 
In vivo (lung tissue 
samples from biopsies → 
RT-PCR) 
Strong PI-9 expression in 6 and low in 4 of 10 cell 
lines on mRNA level correlating with detection on 
protein level 
PI-9 mRNA and protein expression in all of 150 
patients at variable levels in NSCLC cells and tumors,  
the less differentiated lung adenocarcinomas 
showed significantly higher expression of PI-9 mRNA 
as compared to the well-differentiated tumors 
[174] 
Breast cancer In vitro (cell line MCF-7 
→ western blot and qRT-
PCR) 
In vivo (MCF-7 xenograft 
mouse model) 
PI-9 expression is induced by estrogens and depends 
on an interplay between estrogens, estrogen 
receptor and EGF/EGFR 
Induction of PI-9 by the estrogen ‘genistein’ 
[77] 
 
 
[175] 
Stage III and IV 
melanoma 
In vitro (cell lines → 
western blot of cell 
lysates) 
In vivo (paraffin 
embedded tissue of 
patients → 
immunohistochemistry) 
PI-9 expression in 6 of 14 melanoma cell lines 
 
 
PI-9 expression in 21 of 26 cases of primary 
melanoma and in 22 of 28 metastases 
After categorizing in respect to percentage of PI-9 
expressing tumor cells (+ if > 50 % of cells expressed 
PI-9, −if < 50 % of cells expressed PI-9) 15 of 26 
primary tumors and 12 of 28 metastases were + 
PI-9 expression in melanoma metastases correlates 
with poor clinical outcome following active specific 
immunotherapy (ASI) of stage III and IV melanoma 
patients 
[176] 
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Table 10: Cont. 
Cancer type Detection Hallmarks Ref. 
Nasopharyngeal 
carcinoma 
In vivo (formalin-fixed, 
paraffin-embedded 
tumor biopsies → 
immunohistochemistry) 
PI-9 expression in 3 of 43 cases 
Presence of many tumor infiltrating activate CTLs 
within patient biopsies is related to bad clinical 
outcome 
[177] 
Melanoma, 
breast, 
cervical and 
colon carcinoma 
In vitro (cell lines → PCR) 
 
In vivo (primary colon 
carcinoma cells → PCR) 
PI-9 expression in a subset of determined tumor 
lines (e.g. MCF-7, SK-BR3)  
PI-9 expression in 2 of 4 primary surgical specimens 
[80] 
 
Strategies to optimize the efficacy of granzyme B-based CFPs on primarily PI-9-positive cells include 
either the downregulation of PI-9 expression/ activity in target cells or the generation of granzyme B 
variants that are insensitive to PI-9 (3.5). The former may be achieved by RNA interference (RNAi) or 
antisense technology to knock down PI-9 gene expression. The successful use of siRNA to inhibit the 
expression of PI-9 has been described in stem cells [69] and in breast cancer [77]. However, interest 
in development of siRNA-based therapies has declined following the Phase III failure of Bevasiranib, 
which targeted the expression of vascular endothelial growth factor (VEGF) for the treatment of age-
related wet macular degeneration [178]. In alternative approaches, the NFκB inhibitor pyrrolidin 
dithiocarbamate (PTDC) has been used to suppress PI-9 gene expression in PBMCs cultivated in vitro 
[72], whereas the serine protease granzyme M (found in the cytotoxic granules of NK cells) can 
inhibit PI-9 at the protein level [56]. Hence, the genetic fusion of granzyme M to a specific binding 
domain facilitating cellular uptake could lead to the inactivation of endogenous PI-9 so the co-
administration of granzymes M and B could potentially clear the way for granzyme B-based therapy 
(further discussed in 4.6.2) [4]. 
Those strategies, however, are indirect approaches which require the administration of granzyme B 
in combination with a separate therapeutic modality. In contrast, as primarily intended in this study, 
granzyme B can be modified in such a way that it retains its enzymatic activity but becomes 
insensitive to PI-9. In an analogous approach, a human tissue-type plasminogen activator was 
mutated at a few critical contact residues to achieve resistance against a complex mixture of 
endogenous serpins [37,179].  
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Table 11: Overview of PI-9 expression in different lymphomas. 
Cancer type Detection Hallmarks Ref. 
Classical 
Hodgkin 
lymphoma 
In vivo (lymph node 
sections → gene 
expression via 
microarrays) 
PI-9 expression determined in 6 EBV+ and 10 EBV- cases: 
EBV+ are PI-9+, EBV- are PI-9- 
[172] 
Leukemia  In vitro (cell lines → 
western blot analysis) 
Ex vivo (monocytes 
from peripheral blood) 
PI-9 expression in 4 of 6 cell lines 
 
PI-9 expression in 0 of 2 ALL cases, 3 of 4 AML cases, 2 
of 3 CLL cases  
[180] 
NK/ T cell 
lymphoma 
In vivo (deparaffinized 
tissue sections of 
patient biopsies → 
immunohisto-
chemistry) 
PI-9 expression in 26 of 39 cases 
PI-9 expression level was heterogeneous from case to 
case with clusters of negative cells suggesting the 
emergence of PI-9 down-regulated subclones associated 
with aggressiveness and invasive potential 
High levels of PI-9 associated with favorable clinical 
outcome 
[181] 
Lymphomas In vitro (cell lines → 
flow cytometry) 
Ex vivo (isolation of 
monocytes from 
peripheral blood → 
flow cytometry) 
PI-9 expression in 10 of 18 lymphoma cell lines (e.g. 
K562) 
PI-9 expression in 9 of 14 primary lymphomas 
Using highly activated CL in vitro no inhibition of the 
perforin-dependent cytotoxic pathway has been 
observed. 
[148] 
ALCL 
(anaplastic 
large cell 
lymphoma) 
In vivo (biopsies of 
systemic ALCL patients 
→ immunohisto-
chemistry) 
PI-9 expression in 6 of 45 cases (percentages of PI-9+ 
cells ranged from 5 % to 75 %), primarily found in 
tumors harboring many Gb+ infiltrating CTLs 
High numbers of PI-9+ tumor cells predict resistance to 
chemotherapy-induced apoptosis and unfavorable 
outcome 
[173] 
Different non-
Hodgkin and 
Hodgkin 
lymphomas  
In vivo (formalin-fixed, 
paraffin-embedded 
tumor biopsies → 
immunohisto-
chemistry) 
Sub-division into 5 categories depending on percentage 
of PI-9+ cells 
PI-9 expression in neoplastic cells in 36 of 92 cases of T-
cell lymphoma, 20 of 75 of B-cell lymphoma and 6 of 57 
of Hodgkin lymphoma (expression varied between 5 and 
100 %) 
For further differentiation of PI-9 expression and 
lymphoma type see reference. 
[171] 
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4.3 GENERATION AND IDENTIFICATION OF A PI-9 INDEPENDENT GRANZYME B 
VARIANT 
4.3.1 Evaluation of in silico findings and comparison with in vitro enzymatic activity 
As described in the previous chapter, a granzyme B variant that can kill both PI-9-positive and PI-9-
negative tumor cells will provide a significant therapeutic advantage, particularly for the treatment of 
relapsing tumors. Since the underlying reaction is typical for the interaction between proteases and 
serpins the necessary structural hallmarks could be predicted in silico using a structurally related 
Michaelis complex formed between a rat trypsin and M. sexta serpin B1 (3.2).  
Using state-of-art molecular modeling techniques key residues at the interface of the two proteins 
which might decrease their affinity could be identified (3.2). Among wild-type granzyme B residues 
involved in complexing, only residues not located in its active site were considered so the catalytic 
activity was not expected to be affected. First results were generated using computational alanine 
scanning mutagenesis, a convenient and fast strategy to investigate the determinants of protein 
complex interactions [182]. However, hydration at the protein/ protein interface is not included in 
these calculations even though water molecules may play a very important role for complex stability 
[183]. Another disadvantage is that only alanine mutations can be simulated and the flexibility 
properties of the complex are omitted. Therefore, molecular dynamics simulations of wild-type and 
mutated complexes were performed in water solution which on the one hand demands a greater 
computational cost but on the other hand allows the qualitative assessment of the effect of all 
proposed mutations. Those mutations were decided considering the charge of the original amino 
acid, arginine, so in the end, including one double mutant, seven new granzyme B mutants were 
investigated (R28A, R28E, R28K, R28A/R201A, R201A, R201E, R201K) [149]. 
In vitro the corresponding mutations were introduced into the wild-type sequence of granzyme B via 
site-directed mutagenesis. The protein was produced via the established secretory expression in 
HEK293T cells [137,138,184] allowing natural glycosylation patterns within granzyme B which 
harbors two N-glycosylation sites [185]. These sites were not affected by the mutations. No 
differences in production rates were observed compared to the wild-type protein and all variants 
could successfully be cleaved by enterokinase (3.3).  
To test the remaining in vitro proteolytic activity after site-directed mutagenesis and challenge with 
PI-9, the inhibitor had to be recombinantly produced since pure protein was not commercially 
available. Bacterial expression turned out to be the most efficient method to obtain sufficient 
amounts of protein (3.4). The identity of the protein was confirmed by mass spectrometric analysis 
(data not shown). The successful complex formation of the produced protein could be verified after 
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incubation with recombinant granzyme B-based CFPs by detection of a SDS-stable complex on 
western blots by different antibodies (Figure 6). Because only the upper band disappeared after 
incubation with granzyme B (3.4), it could be concluded that the lower band might be the earlier 
described inactive variant of PI-9 lacking the RCL which resulted in the small decrease in molecular 
weight compared with intact PI-9 [56]. The same samples were used in a colorimetric granzyme B 
substrate assay and the inhibition of enzymatic activity by complex formation between wild-type 
granzyme B and the produced recombinant PI-9 could be directly confirmed. This assay was 
consequently used as the read-out system to identify the most promising PI-9-insensitive granzyme B 
mutants. Here, it was found that the in silico calculations were highly consistent with the in vitro 
results: GbR201A-, GbR201K- and GbR28K-based fusion proteins (to H22(scFv)) in the absence of PI-9 
feature catalytic activity similar to that of wild-type granzyme B indicating that the active site was not 
affected. In the presence of PI-9, GbR201K-H22(scFv) retains almost its entire catalytic activity 
whereas GbR28K-H22(scFv) and GbR201A-H22(scFv) kept three quarter or half of their enzymatic 
potential, respectively. The measured Km values (~ 104 µM) for GbR201K-H22(scFv) was almost 
identical to the one determined for the wild-type fusion protein (3.6.1) and consistent with published 
data for recombinant granzyme B [83,86].  
The PI-9 insensitivity of the recently described granzyme B variant K27A by Sun et al. [86] could not 
be reproduced neither during in silico nor in vitro experiments. The reason might be that this earlier 
structural in silico prediction was based on a complex with a modeled truncated PI-9 version 
consisting of only 12 residues (334–345) of the RCL. The latter is a solvent exposed stretch of amino 
acids representing the primary site of interaction with human granzyme B. Subsequently, different H-
bonds and salt bridges have been considered by Sun et al. resulting in different predictions. 
Inconsistencies seen in the in vitro assays could be explained by a different expression system for 
human granzyme B and PI-9 (P. pastoris with Sun et al.) leading to differences in glycosylation 
patterns [186], which can influence complex formation. Differences in protein quality used in this 
thesis and in the previous study could also have an effect.  
With the combination of the applied in silico and in vitro techniques it was possible to pre-select 
three out of eight generated granzyme B mutants, which retained their enzymatic activity even after 
incubation with recombinant PI-9. 
4.3.2 Selection of the optimal granzyme B mutant 
The above described results give a first insight into the functionality of the newly generated mutants. 
The three most promising variants (R28K, R201A, R201K) were further tested in vitro according to 
their binding activity and affinity to target cells, stability and cytotoxic as well as apoptotic efficacy. 
K27A was used as a comparative control. A sufficient evaluation of their PI-9 sensitivity required PI-9-
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negative as well as PI-9-positive cells. CD30-positive cell lines were used based on reasons described 
in detail earlier (4.2). To target those cells Ki4(scFv)-based fusion proteins were generated whose 
potential had been confirmed previously in combination with ETA’ whereby IC50 values of 43 - 85 pM 
were determined [112]. CD30-targeting murine Ki4(scFv) is an outstanding anti-CD30 single chain as 
it does not bind soluble CD30 receptor [187]. This is important since it has been reported that CD30 
ectodomain shedding occurs at high incidences [108], which could lead to an off-target capturing of 
the CFP. The H22(scFv)-based fusion proteins which were used during the above discussed in vitro 
characterization (4.3.1) were also employed during the evaluation of the mutants on PI-9-negative 
cells as a reference in comparative assays. 
It was found that both wild-type and mutants specifically bound to the target cells and did not exhibit 
unspecific binding to CD30- or CD64-negative control cell lines, respectively (Figure 10). Kd for the 
wild-type and the R201K mutated variant were also in the same nM range on the respective cell lines 
(3.6.2) and correlated to the affinity of 3*10-9 M published for Ki4(scFv) alone [187] and 10-8 to 
10-10 M reported for H22(scFv) [188]. This excluded a steric hindrance of antibody fragment binding 
by the mutated granzyme B fusions. Also a negative influence of the mutations on apoptosis inducing 
potential (Figure 13) as well as the cytotoxic activity could be excluded, since the observed IC50 values 
were comparable to the respective values determined with the wild-type protein (Figure 12). 
Compared to other published granzyme B-based CFPs (Table 9), the determined IC50 values exceed 
the average.  
The next step was to compare the ability of the generated mutants to kill PI-9 expressing cells and 
eventually select the most promising one. For this goal, different strategies were considered: either 
direct delivery of granzyme B and its variants into the cells or indirect delivery based on specific 
targeting of tumor antigens by genetic fusion to tumor specific ligands. Since the former approach 
was not successful (compare (3.5, 1)), strategies involving indirect, receptor-mediated delivery of the 
protein into the cells were pursued instead. Here, the modification of originally PI-9-negative cell 
lines to express PI-9 was first intended to exclude any cell-based differences (other than the 
expression of PI-9) which occur when different types of naturally PI-9-positive or -negative cell lines 
are used. The resistance of the cell lines used towards transfection with pMS-PI9-IV, however, limited 
this approach. Since HEK293T cells successfully produced cytosolic PI-9 after transfection with 
pMS-PI9-IV, it could be excluded that the reasons for the transfection difficulties were based on the 
chosen plasmid DNA, but rather were due to the cells themselves. It has been reported that certain 
cell lines are intrinsically easier to transfect than others, although the exact reason for these 
differences is currently unknown. Additionally, even clonal variability in DNA uptake has been 
reported in certain mouse cells [189]. 
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An alternative solution was to use cell lines equal in antigen-expression, but different in PI-9 
expression. As described in 4.2, CD30-positive cell lines belong to this category which also showed 
differences in sensitivity towards Gb-Ki4(scFv), whereby a limited apoptotic effect was observed on 
PI-9-positive L428 cell line whereas successful cell death induction was seen on PI-9-negative L540cy 
cells (Figure 7B). Limited internalization due to differences in receptor expression (Table 7) could be 
excluded as a reason for variations in cytotoxicity since complete internalization could be verified 
with the help of Ki4(scFv)-SNAP-BG-647 (Figure 11) and similar Kd values were measured for all cell 
lines used (Table 7).  
Based on these findings, an adequate cell-based test system could be set up for the further 
evaluation of the generated mutants and selection of the most promising variant. As suggested by 
the previous substrate assay (4.3.1), the wild-type and the already published mutant GbK27A were 
only effective in PI-9-negative cells (Figure 14). GbR201K-Ki4(scFv) was the most effective as it was 
able to significantly reduce the viability of both PI-9-positive (L428, L1236, K562) and PI-9-negative 
(L540cy) cell lines. These results were verified in an assay based on caspase 3/7 (Figure 15), which is a 
strong indicator for apoptosis induction, especially in case of granzyme B induced cell death (1.3.1). 
The cytotoxic effects triggered by GbR201K-Ki4(scFv) in L428 and L1236 were rather low compared to 
those in L540cy. The addition of endosomolytic agents like chloroquine led to improved effects in 
previous studies [160], but did not increase cytotoxicity here; neither did the increase in protein 
concentrations. However, the observed differences can be explained by the published, lower 
sensitivity of L428 and L1236 to apoptosis induction [97]. As described in 1.5, one of the signaling 
pathways characteristic for HL involves NFκB. In these previous studies L428 and L1236 were much 
more resistant to apoptosis induction by the anti-CD30 antibody 5F11 than L540 due to the 
expression of this anti-apoptotic protein leading to induced resistance to CD30-mediated cell death 
in HL cells. These effects can be explained by the defective NFκB inhibitor IκBα in L428 or the instable 
inhibitor in L1236 cells causing constitutively active NFκB, and thereby apoptosis resistance [190-
192]. In one study it was shown that NFκB could be down-regulated through the proteasome 
inhibitor bortezomib after CD30-mediated NFκB activation with the human CD30 antibody 5F11 [97]. 
The same protocol was adapted in this thesis as well. However, here, the addition of bortezomib did 
not improve cytotoxicity. Nevertheless, even the currently observed low cytotoxic effects can have 
high medical impact, especially if they lead to the elimination of treatment resistant cells responsible 
for the minimal residual disease which are potentially related to PI-9 expression (4.2). On the other 
hand the CD30-based system applied here has to be regarded as a model system to select the most 
promising granzyme B mutant and this was successfully accomplished.  
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In summary, based on a computational model of the complex between granzyme B and its inhibitor 
PI-9, seven new granzyme B variants were generated and their in silico predicted potential was 
successfully confirmed during comparative in vitro studies with the wild-type protein and an earlier 
suggested mutant. Finally, the variant GbR201K was selected as the most promising and was used for 
further evaluation as fusion to CD30-targeting Ki4(scFv) in vivo (4.4) as well as CD64-targeting 
H22(scFv) ex vivo on patient derived leukemic cells (4.5). 
 
4.4 EFFICACY OF THE GBR201K MUTANT IN VIVO 
To confirm the differences between the in vitro performance of wild-type and mutant granzyme B 
R201K, comparative studies on the biological activity were done employing the above used CD30-
positive cell lines L540cy (PI-9-negative) and L428 (PI-9-positive).  
First, the serum stability of GbR201K-based CFPs was compared to that of the wild-type, and no 
influence of the point-mutations on stability was observed (Figure 16 and Table 8). Murine serum 
itself was found to already be very cytotoxic towards the target cells. Therefore a proper 
discrimination between cell death induced by the fusion proteins or the serum was unfeasible. The 
isolation of the protein from the serum via IMAC was not done as then the protein concentration 
would be depending on His6-tag binding efficacy and not just serum stability. Alternatively, residual 
binding activity of the constructs to the target cells was used as measure for serum stability, whereby 
the detection of full length CFP was ensured by the employment of both His6-tag and granzyme B-
specific antibodies. Via this method, stability for at least 10 h was observed for both constructs. The 
half life of biopharmaceuticals strongly depends on their composition and the intended application 
and varies highly ranging from minutes to days [193]. The stability measured here is lower than the 
one published for the ETA’-based construct Ki4(scFv)-ETA’ which retained 85% to 90% of initial 
binding activity for at least 24 h [112]. However, according to Kampmeier et al. a 10 h stability should 
suffice for our application. In their study the tumor-specific SNAP-based signal was strongest after 
this time point in a subcutaneous mouse tumor model [194].  
Two different xenograft mouse models were established in this study, one based on the PI-9-positive 
L428 cells and one on PI-9-negative L540cy cells. So far in vivo studies for HL have been strongly 
restricted to a single cell line, L540cy, that achieves a sufficient tumor take rate in subcutaneous and 
disseminated mouse models [140]. However, tumor take rate related problems for L540cy have been 
experienced before in this group (Dr. rer. nat. Theo Thepen, personal communication). Therefore, it 
was decided to focus on a subcutaneous tumor model that is easier to monitor and faster to evaluate 
than a disseminated one. Via resuspension of the cells in Matrigel™, which leads to a fixed 
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accumulation of the cells and has been described to be advantageous to establish difficult tumor 
models [195], a high tumor take rate could be achieved (3.8.2). Because of the observed 
encapsulation and limited vascularization (Figure 17B) the connection of the tumor to the 
bloodstream was tested by quantitative analysis of soluble tumor-derived CD30 receptor in blood 
samples of tumor-bearing mice (3.8.2). The direct correlation observed between tumor size and 
CD30 concentration in blood suggested that intravenous application of the CFP could be successful. 
In addition, the localization of the fluorescent signal after injection of Ki4(scFv)-SNAP-BG-747 into 
L540cy tumor-bearing mice (Figure 17A) verified the specific delivery and the continuous CD30 
receptor expression on the tumors themselves in vivo. The latter was also confirmed by staining of 
tissue sections prepared from both L540cy and L428 tumors after treatment with the Ki4(scFv)-
derived constructs (Figure 18C and Figure 19C). Following, the usability of the established tumor 
model was completely demonstrated. The translocation of the construct to the low vascularized 
tumors was possibly supported by extravascular transport playing an important role within tumor 
tissue [196]. Several studies in the past have changed the understanding of the interstitial-lymphatic 
continuum of tumors from a passive to a more active one, so the delivery of tumor therapeutics is 
possible [197]. To optimize transport conditions in future animal experiments, the intravascular 
transport could be improved by the addition of dopamine, which supports the distribution and 
normalization of dysfunctional blood vessels in tumors and has significantly increased the 
concentration of anticancer drugs in tumor tissues in previous studies [198].  
As mentioned, no tumor mouse model was available for PI-9-positive L428 cells. Such a model was, 
however, necessary for the evaluation of the novel granzyme B mutant. Via Kat2 expression by these 
slowly and transiently growing cells in vivo the monitoring of tumor growth became possible via 
optical imaging (Figure 17C). The direct correlation between caliper measurements and tumor size 
determined by the imaging technique was proven recently confirming the reliability of the imaging 
measurements [150]. Hence, a novel HL tumor model based on the cell line L428 was established in 
this work.  
Since no difference in cytotoxic activity between Gb-Ki4(scFv) and its mutant GbR201K-Ki4(scFv) was 
detected on PI-9-negative cells in vitro, only the mutant was used to confirm its effectiveness on PI-9-
negative cells in vivo. Up-regulation of PI-9 in L540cy as an immune escape mechanism could be 
excluded by cell lysis and subsequent western blots of L540cy tumor-derived cells using PI-9-specific 
antibodies (data not shown). To treat L428 tumors both constructs were used, to confirm differential 
influence of endogenous PI-9 on the biological activity of wild-type and mutant granzyme B. To 
exclude unspecific effects by granzyme B itself, instead of using a buffer control, the non-binding 
control GbR201K-H22(scFv) was chosen. The obtained results clearly demonstrated that only the 
mutant was able to kill the PI-9-negative tumor cells as well as the PI-9-positive ones in vivo so this 
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variant has the potential to replace the wild-type in the future, since this only kills PI-9-negative cells 
(Figure 18B and Figure 19B). With this, the results of the previously obtained in vitro analyses could 
be confirmed after the establishment of appropriate tumor mouse models. 
In this study 50 µg of CFP per treatment day and injection was applied which was well tolerated by 
the mice. In a previous study by Gehrmann et al. much higher injected concentrations of 20 µg 
human granzyme B per gram body weight have been reported without inducing adverse side-effects, 
meaning that after injection of active granzyme B the investigated organs exhibited no 
pathophysiological changes and individual organs exhibited normal tissue architecture, with no 
evidence of infarcts or internal bleeding [199]. Therefore it seems that active human granzyme B at 
doses to efficiently reduce tumor size, does not induce detectable histological or morphological 
changes in normal organs. However, those conclusions have to be regarded with care since in our 
case immune suppressed mice were used and also species-dependent substrate specificities have to 
be considered which can distort the results. Those species-dependent substrate specificities leading 
to lacking cell death induction of granzyme B in foreign species have been described by others in 
vitro [200]. In addition the same could be shown and published in the time course of this work as 
well ex vivo (data not shown) when the cytotoxic efficacy of CD64-specific human CFPs and ETA’-
based IT was tested on murine and human derived macrophages [201]. In that study, Gb-H22(scFv) 
only killed human derived macrophages, leaving the murine derived cells unaffected. These data 
suggest that human granzyme B is not able to cause any side-effects in mice since it cannot even kill 
target cells after specific delivery. Therefore, the estimation of maximum tolerated doses (MTDs) of 
human granzyme B in humans becomes a challenge because the results from other species might be 
misleading. Possible side-effects in humans could be expected from unspecific binding to cells or 
tissue, due to the high positive surface charge of granzyme B [202], which can mediate electrostatic 
interactions with the negatively-charged heparin sulfate proteoglycans found on the surface of 
almost all cells. Also its potentially excessive extracellular activity, which is important for tissue 
remodeling during an immune response, can cause pathophysiological tissue destruction [203]. It 
seems that the only choice for a predictive pre-clinical model system will be primates due to their 
close relationship to humans. Corresponding studies have not yet been reported and neither has the 
efficacy of human granzyme B been tested in any primate cells. Another important fact regarding the 
in vivo experiments described here is that we use subcutaneous tumor models. These models are 
artificial because it does not reflect the biology of HL in humans (1.5). However, the focus here was 
on the differences in cell death induction by the wild-type versus the mutant and not on the disease 
itself. Therefore this model was sufficient for our studies. In summary, the exclusive biological 
activity of the novel granzyme B mutant R201K on PI-9-positive as well as PI-9-negative cells in 
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contrast to the wild-type protein could successfully be demonstrated in vivo based on the newly 
established xenograft tumor models. 
 
4.5 EX VIVO DETERMINATIONS ON PRIMARY LEUKEMIC CELLS 
Before biopharmaceuticals are approved for clinical studies, their in vitro and in vivo efficacy has to 
be tested extensively. These experimental data are based either on animal models or on cell-based 
assays. While animal models are commonly used for toxicity and metabolism studies, their 
extrapolation to humans is restricted. Furthermore, they are both expensive and have low-
throughput which usually limits their use to the late stages of preclinical testing. Cell-based assays 
are continuously being improved to help reverse the increasing trend of costly late-stage drug 
failures. These improvements are of interest to the pharmaceutical industry. Use of standard well 
established cell lines has the benefit of phenotypic stability and homogeneity, unlimited life span and 
ease of culture. However, they cannot mimic the complexity and heterogeneity of e. g. tumor cells 
and for some diseases appropriate cell lines are not even available. As a consequence, ex vivo 
models, comprising primary cells, are coming more and more into focus because they are thought to 
simulate more closely the actual cells. With the help of ex vivo models, the molecular mechanisms 
underlying tumor behavior can be elucidated and the potential of new anticancer treatment 
candidates evaluated. In addition to the great value for the characterization of new drugs in general, 
another advantage of ex vivo determinations is that individual patients can be studied enabling 
predictions on effectiveness of new drug candidates prior to clinical application [204]. These aspects 
are especially valuable in context of personalized medicine. However, primary cells are variable and 
often can only be cultured for a few passages before they reach senescence or undergo undesirable 
phenotypic changes. In addition, the availability of patient material is often very limited and the 
heterogeneity due to differences in patients’ treatment history restricts the comparison between 
different experiments. As a consequence, established cell lines have their value in providing first 
indication into the functionality of new drug candidates yielding reproducible data with standardized 
methods. Those results, however, should always be confirmed using appropriate primary cell 
material to approach the complex clinical situation and the real diverse hallmarks of the disease.  
4.5.1 CMML and AMML primary cells as target for CD64-specific fusion proteins 
Based on the above rationale, the potential of wild-type granzyme B and its most promising mutant 
was evaluated ex vivo in addition to in vitro and in vivo studies. For this purpose the CD64-specific 
constructs Gb-H22(scFv) and its mutant GbR201K-H22(scFv), whose in vitro efficacy has extensively 
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been tested during the time-course of this work (3.6.4 and 3.6.5), were applied and their efficacy was 
compared to the established IT H22(scFv)-ETA’. As target, the leukemic rare diseases CMML as well 
as AMML (1.6) have been chosen, since specific therapeutics against CMML and AMML represent 
unmet medical need for the patients. Research of corresponding targeted therapeutics is restricted 
by the lack of frequent and specific genetic aberrations known until now in this disease and the lack 
of mouse and in vitro models of the chronic disease. Thus, studies with primary cells, as performed 
within this thesis, are the only available system to test new immunotherapeutics.  
The hematological malignancy leukemia is especially suitable for immunotherapeutic treatment with 
CFPs because the circulating cancer cells are easily accessible and incomplete tumor penetration due 
to the absence of vascularization is not a limiting factor [205]. Numerous studies have been 
described in literature dealing with immunotherapeutics against primary leukemic cells, e.g. via IL-3 
[206], IL-4 [207] or CD33 [208,209]. Examples have been introduced in 1.2.1 and 1.6.  
Before cytotoxic assays on those primary cells were performed it was first evaluated, if CD64 is a 
valuable target to treat CMML and AMML patients, since this tumor marker has not been described 
for these diseases so far (1.6). Primary monocytes were isolated from fresh peripheral blood of 
largely newly diagnosed patients (university hospital, Aachen) (2.1.8). The high affinity receptor CD64 
is generally a promising candidate target in leukemia therapy. It is superior to most of the other 
investigated targets due to its characteristics of efficiently internalizing fused ligands as well as its 
restricted expression pattern, leaving normal, non-activated CD64-expressing cells unaffected (see 
below and 1.6). The potential of CD64-targeting H22(scFv)-ETA’ as well as the ability of Gb-H22(scFv) 
to specifically kill primary AML cells has been shown before [129,138]. The advantage of the latter is 
that its cytotoxic efficacy is based on a human effector molecule preventing expected immunogenic 
responses provoked by the non-human cell-death inducing agents and thereby allowing multiple 
treatment cycles.  
During phenotyping of the primary cells for CD64, CD56, CD14 and CD33 receptor expression (3.9.2), 
a clear over-expression of CD64 cells was found on the CMML cells, enabling specific binding of 
H22(scFv)-derived constructs (Figure 22A). The expression of CD64 has been discussed before in 
context of CMML, where a decrease of this marker has been described [115,210]. However, 
published data are based on immunohistochemical staining of bone marrow which is different to our 
results based on flow cytometric analyses of monocytic cells. The detected overexpression of CD64 
on the primary AMML cells was in accordance to published data [114]. Through double staining of 
patient derived cells, significant co-expression of CD64 and CD56 as well as co-expression of the 
malignant cell markers CD33 and CD14 with CD64, respectively, was observed via flow cytometry and 
confocal microscopy (Figure 21). The finding that the same cells express CD64 in parallel to the 
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already known tumor markers confirmed the assumption that CD64 is a promising target to eliminate 
malignant cells in CMML and AMML patients. In addition, this knowledge is valuable for the 
verification of the specific cell death described in the following section. 
To evaluate if Gb-H22(scFv) and GbR201K-H22(scFv) are actually stable in CMML and AMML patient-
derived serum, which is important for their potential clinical application, their serum stability was 
determined (Table 8). The stability of the IT H22(scFv)-ETA’ has been evaluated before, whereby after 
24 h 77 % of the original binding ability was retained after incubation in mouse serum [211]. This is 
10 % more than determined for the CFPs after 24 h in patient serum and corresponds to the 
determined stability of the CFPs after 6 h. Since H22(scFv) internalizes very fast and its affinity is very 
high (Kd = 2.1 nM (3.6.2)) [132], this was sufficient (see also 1.6 and 4.4).  
4.5.2 Specific cytotoxic efficacy of CD64-specific fusion proteins on primary CMML and 
AMML cells 
As indicated above, the characterization of CFPs using primary cells has some drawbacks (4.5). Firstly, 
patients have a different clinical history and samples of patients whose treatment has not started yet 
are obtainable just once. Secondly, in the present case it has to be taken into account that CMML 
and AMML are rare diseases limiting the number of available patients and that the cell number 
within their blood samples is irregular. These facts excluded a reproduction of the obtained results 
using the cells from the individual patient or direct comparison of the investigations. For these 
reasons, as many evaluation techniques as possible were used to obtain as much information as 
possible and to increase reliability and elucidate specificity.  
The standard XTT and Annexin V measurements after treatment with the H22(scFv)-based constructs 
confirmed cell death of up to 50 % even though the results differ slightly; with the XTT-based data 
showing higher toxic effects than observed during flow cytometry (Figure 23). This difference might 
be due to the fact that classical cell proliferation assays do not discriminate between apoptotic and 
necrotic cells as is the case for apoptosis assays. Hence, necrotic cells and very small cell fragments 
could skew flow cytometric measurements. Additionally, dose-depending viability assays showed a 
typical sigmoidal course despite the fact that still high overall viability remained (around 50 %). The 
measured cytotoxic impact and especially the high overall remaining viability after incubation of the 
primary cells with the CFPs were in contrast to the results obtained using homogeneous cell lines. 
This is probably due to the heterogeneous nature of the primary cell population since it contains a 
variable proportion of CD64-positive target cells together with many others; and the applied 
measurement techniques are influenced by those non-target cells. This phenomenon was also 
described previously in cytotoxicity studies conducted on primary AML cells [208,209,212]. The 
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enrichment of those cells, e. g. by magnetic cell sorting using CD64-specific antibodies, would have 
occupied the receptors and interfered with the binding and internalization of the fusion protein.  
It was observed that the percentage of dead cells did not correlate with the initially detected 
proportion of CD64 cells within the cell population. This discrepancy is due to the fact that the 
amount of the CD64 receptors is not related to the sensitivity of the cells. It is rather their activation 
state, influenced by mediators like IFNγ as used in the current tests (1.6). Thus, if the CD64-
expressing cells are not activated, they are not affected by the immunotherapeutic. This is also 
important for later clinical studies with CD64-specific CFPs since thereby it can be avoided that 
healthy CD64-positive cells are also killed [213]. Controls using the antibody alone and also the 
inactive granzyme B variant GbS184A-H22(scFv) [214] confirmed that cell death was induced by the 
effector domain and not just by receptor binding and internalization. Therefore, the proof-of-concept 
of the immunotherapeutics tested here could successfully be demonstrated. 
Determinations regarding the specificity of primary cell death were performed by four different 
approaches. First, using a competitive viability assay the antigen-specificity of cell death could be 
confirmed (3.6.4). Hence, it could be concluded that even in a mixture of different cells only the 
target cells would be specifically targeted. Second, efficient CD64-depending internalization into 
primary cells was shown by confocal microscopy (Figure 22B). Third, non-specific effects by 
granzyme B were excluded by incubation of the cells with the non-binding control Gb-Ki4(scFv). 
Fourth, based on co-staining experiments of the heterogeneous cell population (4.5.1), the selective 
reduction of the target cells was determined via flow cytometry using specific antibodies. The parallel 
staining with Annexin V and a target cell-specific antibody to specifically determine apoptosis of the 
targeted cells was only possible in one case (Figure 26A), likely due to the loss of receptor expression 
by apoptotic cells. Thus, many apoptotic cells would have been omitted during evaluation of the 
data. The same was seen during preliminary in vitro assays as well, where co-staining with Annexin V 
and CD56 of the CD56/CD64-positive cells and subsequent gating of CD56-positive cells prior to 
Annexin V-based evaluation significantly differed from the results obtained without prior gating (data 
not shown). As an alternative the position of the CD64-positive target cell population in FSC/ SSC 
dotplot has been identified so that the decrease of this population could be estimated after 
treatment of the cells (3.9.5). Because the obtained results correlated reproducibly with the results 
from viability and apoptosis assays (Figure 23 and Figure 25), this method was verified to be a 
reliable measure for specific cell death as was proposed earlier [212]. Another measure for specific 
cell death was the reduction of the target population identified and stained with an adequate 
antibody (shown for CD14-staining in Figure 26B) which has been chosen according to phenotyping 
(Figure 21). Since the incidence of blocking by the H22(scFv)-based constructs was observed on HL60 
in pre-tests, the use of CD64-specific antibodies was denied. In summary, the results obtained here 
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provide clear evidence that CMML and AMML cells can both be selectively killed by granzyme B-
based CFPs.  
4.5.3 The role of PI-9 and the potential of the determined cytolytic fusion proteins for 
personalized medicine 
To correlate the cytotoxic effects of the new PI-9 resistant granzyme B variant GbR201K-H22(scFv) on 
primary cells with the expression of the inhibitor, endogenous PI-9 levels were investigated 
immediately after isolation from peripheral blood and also after cultivation for different time 
intervals by western blotting. The reason for the observed upregulation of PI-9 in cell culture after 
day one is not known (Figure 20), but has been observed before in the AML cell line U937 [180]. 
Since the expression of PI-9 in lymphocytes and monocytes of PBMCs derived from normal blood has 
been described before [72] and was determined here as well (data not shown), it could not be 
explicitly concluded if the detected PI-9 expression is an escape mechanism in CMML and AMML to 
protect against CTL attack, or the usual PI-9 level in PBMCs. The previously found mild up-regulation 
of PI-9 by IFNγ in primary monocytes after in vitro cultivation could not be corroborated here (Figure 
20B), however this might be due to the applied different detection method based on flow cytometry 
[72]. Nevertheless, the detection of PI-9 within the target cells potentially diminishes the efficacy of 
wild-type granzyme B based immunotherapy. Therefore these cells also represented a potential ex 
vivo test system to evaluate the new granzyme B mutant R201K, especially in comparison with the 
granzyme M-based construct Gm-H22(scFv) which will further be elucidated in 4.6.1. Indeed a 
correlation between PI-9 expression and cytotoxic efficacy of the mutant was observed. In 
comparison to wild-type Gb-H22(scFv) a significantly higher cytotoxic activity of GbR201K-H22(scFv) 
was observed against cells with a distinct PI-9 expression. As observed during the in vitro studies on 
cell lines, no difference between the effect of the mutant and its wild-type occurred in cells not 
expressing the granzyme B inhibitor. However, to state that PI-9 expression is a hallmark of CMML or 
AMML in vivo, further investigations are required involving a higher number of patients and a more 
sensitive and in particular more quantitative detection method such as qPCR. The PI-9 expression 
level might then be an important marker for patient stratification in terms of personalized therapies 
(see below).  
Unexpectedly and in contrast to results obtained on cell lines, lower cytotoxic effects by 
H22(scFv)-ETA’ were observed, which acts independently of PI-9, compared to Gb-H22(scFv) and 
GbR201K-H22(scFv) ex vivo, even though the bacterial toxin-based IT has been proven to be highly 
effective before in preclinical in vitro and in vivo studies [211]. The reason might be that, as described 
previously for the similarly operating DT [215], cells were rather resistant to ETA’ (1.2.1) due to the 
cells’ lack in proliferation ex vivo. This is especially characteristic for CMML, where even in vivo cells 
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exhibit low cell cycle activity. In addition, this finding and also the fact that compared to wild-type 
Gb-H22(scFv) the other two CFPs GbR201K-H22(scFv) and Gm-H22(scFv) were partly more effective, 
might indicate that ex vivo studies can be used as a predictive screening method to determine 
optimal sensitivity of malignant cells from specific patients. This is one of the long-term aims in 
personalized medicine: providing the correct drug to the right patient with the appropriate dose. 
Over the past decade, the proof of this concept has been reported for imatinib, a competitive 
tyrosine-kinase inhibitor, which has dramatically improved the prognosis of CML patients with BCR–
ABL translocation (‘breakpoint cluster region’-‘Abelson’, chromosomal defect in Philadelphia 
chromosome) [216]. 
In summary, three major conclusions can be drawn from the here presented data: First, due to the 
co-expression with several CMML specific markers like CD56, CD33 and CD14, CD64 is a potential 
specific target for the treatment of CMML. Second, the applied CD64-targeting CFPs kill the target 
cells in a selective manner whereby the PI-9 independent granzyme B mutant R201K is as active as its 
wild-type on PI-9-negative cells but is superior if the target cells have up-regulated the inhibitor. 
Third, the applied CFPs are superior in cell death-induction compared to the bacterial based IT 
H22(scFv)-ETA’. 
 
4.6 APPLICATION OF GRANZYME M AS AN ALTERNATIVE EFFECTOR MOLECULE IN 
CYTOLYTIC FUSION PROTEINS 
As described earlier (1.2.2), research on targeted immunotherapy focuses more and more on human 
effector molecules fulfilling the cell-death inducing function instead of bacterial or plant toxins. 
Proteins of the granzyme family are most promising candidates for immunotherapeutic approaches 
and the successful application of granzyme B fusion proteins in immunotherapeutic approaches has 
been discussed and investigated extensively in this study. Depending on treatment history and 
developed, specific anti-apoptotic responses (1.4), it will be advantageous for individualized medicine 
to extend the portfolio of highly efficient human effector molecules for immunotherapeutic 
approaches. Hence, an alternative serine proteinase, granzyme M, was evaluated in this study for its 
use as effector molecule in human CFPs. The cytotoxic potential of granzyme M has already been 
confirmed independently by several groups (1.3.2) [49-55]. Its ability to kill tumor cells has previously 
been described in vivo, whereby it was demonstrated that adoptively transferred NK cells from 
granzyme M deficient mice were unable to inhibit tumor growth compared to wild-type NK cells [48]. 
In addition, the prospective of granzyme M is especially supported by the fact that it induces 
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apoptosis via distinct pathways compared to granzyme B and that it is not inhibited by PI-9, but 
instead is able to inactivate the inhibitor (1.3.2).  
Here, granzyme M was fused to two different well-established cancer cell-targeting antibody 
fragments, H22(scFv) and Ki4(scFv). All constructs were successfully expressed secretory in 
mammalian HEK293T cells to ensure correct post-translational modification, in contrast to other 
groups which used yeast as an expression system. After purification higher band at 150 kDa was 
observed during SDS-PAGE and western blot analysis (Figure 27B). Such a band was detected for the 
granzyme B constructs as well, but since it was much weaker, it was not further investigated. In this 
case, mass spectrometric analysis (performed in context of a master thesis) identified an additional 
protein apart from granzyme M within this band, called α-2-macroglobulin precursor [217]. This is a 
plasma protein, which is synthesized mainly in the liver, but also locally by macrophages, fibroblasts, 
and adrenocortical cells; it is also a component of the medium supplement FCS and of human serum. 
After secretory expression in HEK293T cells cultivated in synthetic, complete serum-free medium 
(Panserin293S, PAN Biotech GmbH) this band disappeared in the purified sample (data not shown), 
which confirmed the assumption that granzyme M complexes with α-2-macroglobulin from FCS. The 
major function of α-2-macroglobulin is the inhibition of proteinases. It does not inactivate the 
proteinase, but hinders the access of large substrates to its active site. This is accomplished via 
cleavage of a so called ‘bait’ region in the structure of α-2-macroglobulin, located near the middle of 
the polypeptide chain, which triggers a conformational change and consequent entrapment of the 
proteinase [218]. An inhibition, however, was not observed in this study, as the constructs were still 
highly enzymatically active as well as cytotoxic towards the target cells even if, according to the SDS-
PAGE, the complete fusion protein was trapped (only higher band visible and only weak band at 
expected height). It could be the fact that the complex, whose half life has been described to be only 
a few minutes [219], disintegrates before granzyme M is internalized into the targeted cells. This 
suggests an advantage for later use in humans, as by complexing the granzyme M-based 
immunotherapeutic with the human serum component α-2-macroglobulin, its serum stability could 
potentially be increased as the plasma protein acts as a carrier after i. v. injection of the 
immunotherapeutic. This, however, has to be further investigated to exclude unspecific binding, 
internalization, and killing of non-target cells as the α-2-macroglobulin receptor is expressed in many 
tissues and cells, especially in fibroblasts and hepatocytes [219].  
4.6.1 Efficacy of granzyme M based CFPs  
All generated and purified constructs were enzymatically active after purification as proved by 
cleavage of recombinant PI-9 and a synthetic substrate (Figure 28) and bound specifically to their 
respective target cells (Figure 29). Subsequently a cell-specific cytotoxic activity could be attested for 
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all constructs, whereas control cell lines remained unaffected (Figure 30 and Figure 31). To evaluate 
the potential of granzyme M-based CFPs their cytotoxic effects were compared with the equivalent 
constructs based on granzyme B. Thereby, it could be demonstrated that Gm-H22(scFv) triggers 
comparable cytotoxic and apoptotic effects as Gb-H22(scFv) (Figure 12 and Figure 30A,C) in a specific 
manner (Figure 30B). The same was true when granzyme M was fused to the epidermal growth 
factor receptor (EGFR)-specific antibody 425(scFv), which has previously been fused to ETA' and the 
efficacy of this construct has been demonstrated in vitro and in vivo [150,220]. Again Gm-425(scFv) 
was as cytotoxic active as Gb-425(scFv) during viability as well as in apoptosis assays using the EGFR-
positive, PI-9-negative cell line A431 (data not shown). These results indicated that granzyme M has 
indeed high potential as a novel effector molecule in CFPs.  
Differences were observed for CD30-specific constructs. Here, 100x lower cytotoxic efficacy, was 
observed for Gm-Ki4(scFv), which was in correlation with repeatedly observed lower apoptotic 
effects during Annexin V/ PI assays (3.10.4). During later studies in context of a Master thesis, 
however, the performance of both constructs was comparable, so the differences detected here 
might be due to the protein preparation used. The observations on L540cy were independent of PI-9. 
In presence of PI-9, Gm-Ki4(scFv) was advantageous regarding cell death induction compared to wild-
type Gb-Ki4(scFv) (Figure 31). Comparisons with GbR201K-Ki4(scFv) were not performed here due to 
time restrictions. Even though the detected effects were low (compare explanations in 4.3.2), it still 
suggested that granzyme M could be active despite of the ability of the target cells to express PI-9.  
To further evaluate these findings, the cytotoxic potential of the CD64-targeting CFPs based on 
granzyme M, granzyme B as well as granzyme B R201K, was comparatively tested on PI-9-positive 
primary leukemic cells ex vivo (4.5.2). Hereby, due to a limited availability of patient material and the 
delayed production of Gm-H22(scFv), only the last three patients could be considered, of which only 
one was PI-9-positive. The obstacles which have to be overcome when working with primary cells 
have already been discussed earlier (4.5). As shown for granzyme B constructs, Gm-H22(scFv) was 
also able to bind CD64-positive AMML and CMML primary cells and selectively kill them (3.10.5). 
When comparing the effects induced by Gm-H22(scFv), Gb-H22(scFv) and GbR201K-H22(scFv) in the 
presence of PI-9, it became obvious that the two new constructs are both advantageous compared to 
the wild-type Gb-H22(scFv) (Figure 32). Hence, as indicated on CD30-positive cell lines, the 
insensitivity of granzyme M-based CFPs towards PI-9 could be confirmed.  
In summary, apart from the verified ability to specifically kill cancerous cells in vitro and ex vivo, 
granzyme M is obviously able to induce apoptosis in the presence of PI-9 to the same extent as the 
new granzyme B mutant, whereas no difference in cytotoxicity between the granzyme B-based and 
granzyme M-based constructs was seen in cells lacking PI-9. Consequently, granzyme M has the 
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potential to serve either as an alternative to granzyme B or to improve the therapeutic efficiency of 
wild-type granzyme B by combinatorial immunotherapeutic treatment of PI-9 positive tumor entities. 
These aspects are further discussed in the following section. 
4.6.2 Clinical potential of granzyme M as effector molecule in cytolytic fusion proteins 
Based on the above described findings, granzyme M can extent the palette of available human pro-
apoptotic compounds for CFPs, which can be of great importance in the context of immunotherapy 
and especially for personalized medicine. Hereby, most effective cytolytic moieties and also best 
binding ligands need to be selected during pre-tests to achieve optimal therapeutic outcome for the 
patient. Preliminary indications for this have already been reported here during ex vivo studies by the 
application of three different CFPs on primary patient material (Figure 32A,B). In addition, 
granzyme M cannot be just valuable as such but also in combination with other immunotherapeutics, 
especially granzyme B-based constructs. For the latter there are two rationales:  
First, combination therapy with both granzymes has significant potential as these enzymes trigger 
different apoptotic pathways. Details on granzyme B and granzyme M substrates have been 
introduced in 1.3. The differences reflect the sequence specificity of each enzyme, i.e. methionine or 
leucine for granzyme M [43] and aspartate or glutamate for granzyme B [34]. Hereby it is evident 
that granzyme M is unique among the granzyme family, due to its specific expression by NK cells, 
which may have phylogenetically evolved early to serve a specialized function in innate immunity 
[45]. Furthermore it has been suggested that there are still unidentified substrates, which, in the 
presence of the protease, transiently induce a functional active-site conformation and leads to even 
more pathways for granzyme M to induce cell death [221]. Taken together, a combination of 
granzyme B and granzyme M may increase the cytotoxicity by synergistic effects and reduce the 
likelihood that cells can evolve resistance, e. g. by overexpression of particular inhibitors. Hereby, it 
would be more effective to use different target receptors for each enzyme, to prevent competition 
or steric hindrance of cell surface binding sites. Such combinations have been tested during a Master 
thesis related to this work in vitro on L540cy cells, which express both HL-specific receptors CD30 and 
CD25. These can be targeted by the already evaluated ligands Ki4(scFv) and RFT5(scFv) [222] 
respectively. Results after combination treatment with Gm-Ki4(scFv) and GbR201K-RFT5n(scFv) or 
GbR201K-Ki4(scFv) and GbR201K-RFT5n(scFv) indeed suggest synergistic effects of granzyme B and 
granzyme M.  
Second, the described ability of granzyme M to cleave PI-9 [56] holds potential for a combination 
approach, since thereby it could prevent inhibition of granzyme B. The ability of the granzyme M 
constructs to directly cleave PI-9 was only demonstrated in vitro using recombinant PI-9 during this 
work (Figure 28A). Corresponding determinations should be done in the future by either incubating 
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native cell lysates of PI-9-positive cells with a granzyme M based CFP or by cell lysis and subsequent 
western blot analysis of those cells after treatment with a corresponding construct. In fact, the high 
potential of this approach is supported by the finding, that the interaction between PI-9 and 
granzyme M has a high stoichiometry of inhibition (SI) value of 63, which means that PI-9 is a much 
better substrate than inhibitor of granzyme B [56]. By cleaving PI-9, granzyme M could therefore 
clear the way for apoptosis induced by granzyme B. Hence, granzyme M could be useful, not only in a 
therapeutic context, especially against treatment-resistant cells on its own, but also in combination 
with granzyme B.  
In contrast to granzyme B, granzyme M has not been investigated as extensively, so in the future 
both promising, as well as adverse effects may be detected on its prospective role as 
immunotherapeutic. Known so far is e.g. that on the down side, as described for granzyme B, a 
specific endogenous inhibitor, called serpin B4, has recently been suggested to form a typical SDS-
stable serpin–protease complex with granzyme M in vitro and thereby inhibited NK cell-mediated cell 
death in Hela cells [223]. However, the affinity between the two proteins is of a second-order rate 
constant of 1.3 x 104 M-1 s-1 which is two orders of magnitude below that of granzyme B and PI-9 and, 
in general, below the range of biologically-relevant interactions. This rather weak inhibition might be 
overcome by CFP-related excessive delivery of the effector molecule to the cells. Furthermore, the in 
vivo expression of this inhibitor has not been reported and any potential escape mechanisms in 
tumors remain to be investigated. Other serpins present in plasma, like α1-antichymotrypsin and α1-
proteinase inhibitor, could also become a limiting factor for granzyme M activity in blood as 
suggested earlier [56]. Their inhibitory relevance has to be evaluated in the future in serum-stability 
assays, and respective modifications, as shown in this study for granzyme B, should be considered. 
Other modifications, also in accordance to granzyme B, might involve the cationic sites within 
granzyme M that may lead to off-target effects [221]. Hence, current literature on this topic should 
be monitored carefully, as in vivo studies should be pursued to further evaluate the potential of 
granzyme M in immunotherapeutic approaches. 
Concluding, with the novel granzyme B mutant, identified during in silico homology modeling, it was 
demonstrated on in vitro, in vivo as well as ex vivo level that residual therapy-resistant cancer cells 
can be killed, provided the resistance is due to PI-9 expression as an escape mechanism. Additionally, 
the cytotoxic potential and the PI-9 insensitivity of granzyme M-based fusion proteins was verified in 
vitro and ex vivo clearing the way for a potential combination treatment with both granzymes. 
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5 Outlook 
The presented data emphasize the great efficacy of granzyme B-based cytolytic fusion proteins (CFPs) 
in vitro, in vivo as well as ex vivo and especially verify the necessity and potential of directed 
modifications, here to pave the way for inhibitor-insensitive treatment. On this basis further 
investigations and optimizations are now ongoing in our group concerning the structure of the 
corresponding CFPs as well as their extended application.  
Structural modifications include the introduction of an additional modification to reduce the high 
positive surface charge of granzyme B (pI ~ 10) which is mainly caused by two major heparan-binding 
motifs and might result in off-target effects by intrinsic binding to heparin sulfate proteoglycans. In a 
previous study, the basic amino acid residues involved in heparan sulfate binding were substituted 
for alanine which did not interfere with ligand binding or enzyme activity and reduced the negative 
impact of extracellular matrix effects [224]. Hence, specific cytotoxicity of granzyme B could be 
increased by using this granzyme B variant. Furthermore, the improvement of endosomal release 
after receptor mediated endocytosis within the target cells by certain adapter sequences is now 
being investigated in-house (confidential) which suggest that the engineering of granzyme B-based 
CFPs by the insertion of functional adapter elements will improve their therapeutic potential. As an 
alternative, a pH-sensitive fusogenic peptide has been introduced recently which increased specific 
cytotoxicity compared with the construct lacking the peptide, and demonstrated enhanced cellular 
uptake and improved delivery of granzyme B to the cytosol of target cells [166]. In addition, another 
promising mutational site is presently evaluated in our group which was also suggested from in silico 
determinations to be promising to render granzyme B resistant to PI-9 inhibition. The potential of 
structure related modifications of the human molecules, however, introduce novel sequences with 
potential antigenicity in vivo which have to be evaluated carefully.  
Further structural related improvements which are required for translation into clinical application to 
reduce potential immunogenicity include either removal of the His6-tag after IMAC purification or 
applying alternative purification strategies like ion exchange chromatography independent of any 
tags. In addition, the applied murine Ki4(scFv) should either be humanized or replaced by the human 
CD30L, which has been shown promising results in combination with human RNase angiogenin 
before [187] to prevent HAMA response.  
Regarding the extended application of the CFPs, the economic and up-scaled production of active 
granzyme B and granzyme M has to be considered. Therefore the yeast Hansenula polymorpha is 
now under investigation as a potential alternative expression system. It harbors the additional 
advantage to become independent of expensive enterokinase processing of the granzymes by 
insertion of the mating factor α prepro-leader sequence allowing straightforward purification of 
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active granzyme from the culture supernatant based on local Kex2-protease activity in the trans-
Golgi compartment. Furthermore, expression of E. coli is presently explored to increase protein yield 
with lower expenses. 
The described ex vivo findings need to be verified on additional patient material and evaluated in 
terms of personalized medicine. Those investigations will be most valuable in combination with 
information on the previous treatment and anamnesis. To further evaluate CD64 as valuable 
potential therapeutic target also for CMML and AMML in the clinical it will now be investigated if 
CD64 is indeed over-expressed on bone marrow samples of AMML and CMML patients. A 
corresponding set-up for immunohistochemical determinations with H22 antibody fragments is 
already established.  
In addition, further in vivo experiments are planned with the described constructs which include the 
establishment of a disseminated tumor model using the AML cell line HL60. The same might be 
indicated for Hodgkin lymphoma since for this disease a disseminated model is less artificial than the 
subcutaneous tumor model applied in this study. Furthermore, the novel variant GbR201K is now 
used in combination with several other binders to kill target cells despite the presence of 
endogenous PI-9.  
The CFP-based treatment of tumor cells, even in presence of PI-9, was shown to be feasible using the 
new effector molecule granzyme M. Further combination experiments are planned to test the 
potential of granzyme M to clear the way for granzyme B activity by inactivation of PI-9 within the 
target cells. These studies will be performed as soon as an adequate PI-9-positive cell line with both 
receptors co-expressed becomes available. In addition, the potential of granzyme M-based CFPs has 
to be shown in vivo as well using the xenograft tumor models already established for the 
granzyme B-based constructs. For both constructs the species-dependent substrate-specificity has to 
be taken into account when these enzymes undergo further studies using other than xenograft 
tumor models or the in our groups well established mouse inflammation model [213], especially 
when proceeding towards clinical application. These specificities can significantly obscure e.g. 
immunogenic or unspecific effects, so special care has to be taken when planning pre-clinical studies.  
In accordance to granzyme B, novel variants for granzyme M independent of the plasma serpins α1-
antichymotrypsin, α1-proteinase inhibitor and the endogenous inhibitor serpin B4, if detected in vivo 
as well, can also be established. Additionally, a granzyme M variant, which does not bind to α-2-
macroglobulin anymore, is planned to prevent its entrapment in human serum.  
The here developed novel constructs may eventually be used in the clinic in combination with 
conventional treatment approaches helping to reduce the necessary dose of non-specific drugs, 
avoiding adverse effects and promoting long-term remission.  
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6 Summary 
Current cancer treatments often lack specificity and therefore also kill healthy cells, resulting in 
severe side effects. To improve the specificity of cancer treatment, recombinant chimeric proteins 
such as immunotoxins have been developed, consisting of a tumor-selective binding domain and a 
cytotoxic protein primarily of bacterial or plant origin. To circumvent immunogenic responses, recent 
studies have focused on the development of fully human cytolytic fusion proteins (CFPs), containing 
pro-apoptotic components of human origin. Most promising are enzymes from granule-associated 
immune defense. The best studied is the serine protease granzyme B. However, its anti-tumor 
efficacy is limited by irreversible inhibition by serpin B9 (PI-9) which is naturally co-expressed in the 
cytosol of cytotoxic immune cells to avoid auto-toxicity by misdirected granzyme B. Several tumors 
have been described to overexpress PI-9 as a mechanism for immune escape. As a very high number 
of PI-9-positive tumor cells predicts unfavorable clinical outcome, the specific killing of these often 
treatment-resistant cells may strongly increase therapeutic success and life span.  
In this study different cell lines were found to express PI-9, including CD30-positive HL cell lines or 
primary leukemic cells, which decreased the cytotoxic efficacy of granzyme B-based CFPs during 
former studies. The aim of this work was therefore to improve the therapeutic potential of 
granzyme B by the generation of PI-9 resistant mutants. Therefore the interacting amino acids 
between granzyme B and PI-9 were elucidated by in silico simulations based on the known crystal 
structure of granzyme B as well as a complex between rat trypsin and Manduca sexta serpin B1. Two 
corresponding amino acids, R28 and R201, were identified and exchanged to Ala, Lys or Glu 
respectively, by site-directed mutagenesis. The resulting eight mutants, including a double mutant 
(R28A-R201A) and a published mutant (K27A), were further tested in vitro with regard to an 
increased resistance against PI-9 inhibition. The new mutants were fused to H22(scFv) and Ki4(scFv) 
which bind CD64 (high-affinity receptor for IgG, over-expressed e. g. on AML cells) and CD30 (cell 
membrane protein of the tumor necrosis factor receptor family, over-expressed e. g. on HL cells) 
respectively. Proteins were expressed in HEK293T cells and purified via affinity chromatography from 
the supernatant. Three mutants were identified by enzymatic activity assays to be as active as the 
wild-type in absence of PI-9 and especially retained most of their proteolytic activity after challenge 
with recombinant PI-9. These mutants were comparable to the corresponding wild-type constructs in 
respect to binding affinity (between 1.5 and 5.7 nM), cytotoxic and apoptotic activity (IC50 between 
1.2 and 5.3 nM) as well as serum stability (6 - 10 h).  
The mutant R201K demonstrated the best cytotoxic activity against both CD30-expressing PI-9-
positive and -negative tumor cells in vitro. To evaluate the influence of the mutation on the biological 
activity appropriate xenograft tumor models were set up. For HL, only PI-9-negative L540cy cells are 
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currently established. In addition, a novel tumor model with the PI-9-expressing HL cell line L428 was 
established here based on optical in vivo imaging. In these proof-of-principle models, it could be 
verified in vivo that only the mutant is able to kill cells both in the presence and absence of the 
inhibitor, this in contrast to the wild-type which only killed PI-9-negative L540cy tumor cells in vivo.  
This is analogous to ex vivo studies with primary cells from patients with the rare diseases CMML and 
AMML. These cells were targeted via the CD64 receptor. The data additionally demonstrated that the 
new constructs perform even better than H22(scFv)-ETA’. The differences in apoptotic efficacy 
between the applied constructs suggest ex vivo studies to be a predictive screening method for 
personalized medicine to enable a patient-specific treatment selection.  
In addition, a novel human granzyme-based CFP with a pro-apoptotic moiety based on granzyme M is 
firstly described here. This serine protease is known to be able to specifically cleave and inactivate 
PI-9. It may be a valuable addition to the palette of human effector molecules, in particular for the 
development of personalized medicine in which the optimal cytolytic protein and targeting molecule 
combination can be selected on a per-patient basis. Different fusion constructs, comprising 
granzyme M targeting CD64- and CD30-positive cancer cell lines were generated, expressed and 
purified analogous to the granzyme B-based constructs. During in vitro and ex vivo studies 
granzyme M was proved to be a potent human anti-tumor agent (IC50 between 1.2 and 6.4 nM for 
Gm-H22(scFv)), even in presence of PI-9. CFPs combining granzyme B and granzyme M offer potential 
for improved therapeutic approaches by simultaneously triggering different apoptotic pathways to 
circumvent possible overexpression of inhibitors within the target cell or by potentiating granzyme B 
activity by inactivating PI-9.  
In summary, during this thesis two new effector molecules, granzyme M and a PI-9 resistant variant 
of granzyme B, granzyme B R201K, have successfully been generated, produced and evaluated in 
vitro, ex vivo and in parts also in vivo in regard to their cytotoxic potential and for use in 
immunotherapy to treat leukemic diseases or HL. These effector molecules, either individually or in 
combination, also bear clinical relevance for the treatment of solid tumors or other hematological 
disorders that potentially express PI-9 or selected PI-9-positive cells under immune surveillance or 
tumor therapy. 
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8 Appendix 
8.1 DNA AND AMINO ACID SEQUENCE OF GBR201K 
The wild-type DNA sequence triplet cga was exchanged by aag in the modified GbR201K (position 
601-603). 
atcatcgggg  gacatgaggc caagccccac  tcccgcccct  acatggcttt  tcttatgatc   60 
tgggatcaga  agtctctgaa  gaggtgcggt  ggcttcctga  tacgagacga  cttcgtgctg  120 
acagctgctc  actgttgggg  aagctccata  aatgtcacct  tgggggccca  caatatcaag 180 
gaacaggagc  cgacccagca  gtttatccct  gtgaaaagag  ccatccccca  tccagcctat  240 
aatcctaaga  acttctccaa  tgacatcatg  ctactgcagc  tggagagaaa  ggccaagcgg 300 
accagagctg  tgcagcccct  caggctacct  agcaacaagg  cccaggtgaa  gccagggcag 360 
acatgcagtg  tggccggctg  ggggcagacg  gcccccctgg  gaaaacactc  acacacacta  420 
caagaggtga  agatgacagt  gcaggaagat  cgaaagtgcg  aatctgactt  acgccattat  480 
tacgacagta  ccattgagtt  gtgcgtgggg  gacccagaga  ttaaaaagac  ttcctttaag   540 
ggggactctg  gaggccctct  tgtgtgtaac  aaggtggccc  agggcattgt  ctcctatgga  600 
aagaacaatg  gcatgcctcc  acgagcctgc  accaaagtct  caagctttgt  acactggata  660 
aagaaaacca  tgaaacgcta  c                                                  681 
In accordance to that, the modified GbR201K amino acid sequence comprises a lysine (K) at position 
201 instead of wild-type arginine (R). 
IIGGHVAKPH  SRPYMAYLMI  WDQKSLKRCG  GFLIRDDFVL  TAAHCWGSSI  NVTLGAHNIK  60 
EQEPTQQFIP  VKRAIPHPAY  NPKNFSNDIM  LLQLERKAKR  TRAVQPLRLP  SNKAQVKPGQ  120 
TCSVAGWGQT  APLGKHSHTL  QEVKMTVQED  RKCESDLRHY  YDSTIELCVG  DPEIKKTSFK  180 
GDSGGPLVCN  KVAQGIVSYG  KNNGMPPRAC TKVSSFVHWI  KKTMKRY   227 
 
8.2 SYNTHETIC DNA SEQUENCE OF GM-H22(SCFV) IN PMS VECTOR 
The sequence of Gm-H22(scFv) is shown exemplary for all granzyme M-based constructs generated 
in this study. The single chain sequences were exchanged accordingly via appropriate restriction 
sites. 
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